Daphnia galeata metabolite - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	Daphnia galeata metabolite	go back to main search page
Accession:	CHEBI:83038	browse the term
Definition:	A Daphnia metabolite produced by the species Daphnia galeata.
Synonyms:	related_synonym:	Daphnia galeata metabolites

show annotations for term's descendants Sort by:
Rat (886 ) Mouse (900 ) Human (898 ) Chinchilla (0 ) Bonobo (0 ) Dog (2 ) Squirrel (0 ) Pig (14 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (886)

(22R)-22-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 1, group H, member 3

increases expression

ISO

22(R)-hydroxycholesterol increases expression of NR1H3 mRNA in macrophages

RGD

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

(24S)-24-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression

ISO

24-hydroxycholesterol results in increased expression of ABCA1 mRNA; 24-hydroxycholesterol results in increased expression of ABCA1 protein

PMID:15148325 PMID:19126211

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily G member 1

increases expression

ISO

24-hydroxycholesterol results in increased expression of ABCG1 protein

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

amyloid beta precursor protein

multiple interactions
increases metabolic processing

ISO

24-hydroxycholesterol affects the metabolism of and results in increased activity of APP protein; 24-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein
24-hydroxycholesterol results in increased metabolism of APP protein

PMID:15148325 PMID:17532301 PMID:19126211

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

ISO

24-hydroxycholesterol results in increased expression of CCL2 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

CD36 molecule

increases expression
multiple interactions

ISO

24-hydroxycholesterol results in increased expression of CD36 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases abundance

ISO

CYP27A1 protein results in decreased abundance of 24-hydroxycholesterol

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 39, subfamily a, polypeptide 1

increases metabolic processing

ISO

CYP39A1 protein results in increased metabolism of 24-hydroxycholesterol

NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

ISO

[24-hydroxycholesterol co-treated with NR1H3 protein] results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 46, subfamily a, polypeptide 1

affects abundance
increases chemical synthesis
increases metabolic processing

ISO

CYP46A1 gene SNP affects the abundance of 24-hydroxycholesterol
CYP46A1 protein results in increased chemical synthesis of 24-hydroxycholesterol
CYP46A1 protein results in increased metabolism of 24-hydroxycholesterol

PMID:14640697 PMID:19286353

NCBI chr 6:127,247,543...127,274,765
Ensembl chr 6:127,243,315...127,274,760

G

cytochrome P450 family 7 subfamily A member 1

increases metabolic processing

ISO

CYP7A1 protein results in increased metabolism of 24-hydroxycholesterol

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

estrogen receptor 1

multiple interactions

ISO

24-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 24-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

ISO

24-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 24-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein]

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity

ISO

24-hydroxycholesterol results in decreased activity of HMGCR protein

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

integrin subunit beta 1

increases expression
multiple interactions

ISO

24-hydroxycholesterol results in increased expression of ITGB1 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:56,705,171...56,753,195

G

matrix metallopeptidase 9

increases expression
multiple interactions

ISO

24-hydroxycholesterol results in increased expression of MMP9 mRNA
Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

ISO

[24-hydroxycholesterol co-treated with NR1H3 protein] results in increased expression of CYP3A4 mRNA

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

prostaglandin E synthase

multiple interactions
increases expression

ISO

Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of PTGES mRNA]

NCBI chr 3:34,575,643...34,586,987

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

ISO

24-hydroxycholesterol results in increased expression of PTGS2 protein
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

toll-like receptor 4

multiple interactions
increases expression

ISO

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

(25R)-cholest-5-ene-3beta,26-diol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

ISO
EXP

Docosahexaenoic Acids inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]
27-hydroxycholesterol results in increased expression of ABCA1 mRNA; 27-hydroxycholesterol results in increased expression of ABCA1 protein
[Fingolimod Hydrochloride results in increased abundance of 27-hydroxycholesterol] which results in increased expression of ABCA1 mRNA

PMID:15148325 PMID:17088262 PMID:18356535 PMID:18841091 PMID:20056921 More...

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 1A

increases expression

ISO

27-hydroxycholesterol results in increased expression of ABCB1 mRNA

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of ABCC1 mRNA

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily G member 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of ABCG1 protein

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of ACTA2 protein
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

ISO

27-hydroxycholesterol results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]

PMID:33131013 PMID:33880675 PMID:38180513

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

alkaline phosphatase, placental

decreases activity

ISO

27-hydroxycholesterol results in decreased activity of ALPP protein

NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606

G

apolipoprotein A1

multiple interactions

ISO

27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein E

increases expression

EXP

27-hydroxycholesterol results in increased expression of APOE mRNA; 27-hydroxycholesterol results in increased expression of APOE protein

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

multiple interactions
decreases secretion
increases expression

ISO

27-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein
27-hydroxycholesterol results in decreased secretion of APP protein alternative form
27-hydroxycholesterol results in increased expression of APP protein alternative form

PMID:15148325 PMID:19126211 PMID:19158428

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

activity-regulated cytoskeleton-associated protein

decreases expression

EXP

27-hydroxycholesterol results in decreased expression of ARC protein

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

beta-secretase 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of BACE1 protein

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

catalase

multiple interactions

ISO

CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

ISO

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

increases expression
increases secretion

ISO

27-hydroxycholesterol results in increased expression of CCL3 mRNA
27-hydroxycholesterol results in increased secretion of CCL3 protein

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

increases secretion
increases expression

ISO

27-hydroxycholesterol results in increased secretion of CCL4 protein
27-hydroxycholesterol results in increased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

cellular communication network factor 5

multiple interactions
increases expression

ISO

Fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CCN5 mRNA]

NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636

G

CD36 molecule

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of CD36 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cadherin 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 5

multiple interactions
decreases expression

ISO

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]
27-hydroxycholesterol results in decreased expression of CDH5 mRNA; 27-hydroxycholesterol results in decreased expression of CDH5 protein

NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368

G

cadherin 6

decreases expression

ISO

27-hydroxycholesterol results in decreased expression of CDH6 mRNA

NCBI chr 2:62,079,139...62,225,298
Ensembl chr 2:62,079,137...62,225,228

G

carboxylesterase 1D

decreases activity
multiple interactions

ISO

27-hydroxycholesterol results in decreased activity of CES1 protein
27-hydroxycholesterol inhibits the reaction [CES1 protein results in increased metabolism of bioresmethrin]

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

catenin beta 1

multiple interactions
increases activity

ISO

27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol results in increased expression of and affects the localization of CTNNB1 protein; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]
27-hydroxycholesterol results in increased activity of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X-C motif chemokine ligand 12

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of CXCL12 mRNA
fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CXCL12 mRNA]

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases abundance
multiple interactions
increases chemical synthesis

ISO
EXP

CYP27A1 protein results in increased abundance of 27-hydroxycholesterol
[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol
[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol
CYP27A1 protein results in increased chemical synthesis of 27-hydroxycholesterol

PMID:8496670 PMID:9215552 PMID:9660774 PMID:11408283 PMID:11714861 More...

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450 family 7 subfamily A member 1

increases metabolic processing

ISO
EXP

CYP7A1 protein results in increased metabolism of 27-hydroxycholesterol

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

increases hydroxylation
increases metabolic processing
increases abundance

ISO

CYP7B1 protein results in increased hydroxylation of 27-hydroxycholesterol
CYP7B1 protein results in increased metabolism of 27-hydroxycholesterol
CYP7B1 gene mutant form results in increased abundance of 27-hydroxycholesterol

PMID:10588945 PMID:10748047

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

E2F transcription factor 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of E2F1 mRNA

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:143,049,478...143,075,361

G

erb-b2 receptor tyrosine kinase 4

decreases expression

ISO

27-hydroxycholesterol results in decreased expression of ERBB4 mRNA

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

endogenous retrovirus group FRD member 1, envelope

decreases expression
multiple interactions

ISO

27-hydroxycholesterol results in decreased expression of ERVFRD-1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in decreased expression of ERVFRD-1 protein]

NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264

G

estrogen receptor 1

multiple interactions
affects response to substance
increases degradation

ISO

27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR1 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol binds to and results in increased activity of ESR1 protein]; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; 27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased activity of ESR1 protein]
ESR1 protein affects the susceptibility to 27-hydroxycholesterol
ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]
27-hydroxycholesterol results in increased degradation of ESR1 protein

PMID:17872378 PMID:17873880

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions
affects response to substance

ISO

27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR2 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein]
ESR2 protein affects the susceptibility to 27-hydroxycholesterol
ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]

PMID:17872378 PMID:17873880

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919

G

glial cells missing transcription factor 1

decreases expression
multiple interactions

ISO

27-hydroxycholesterol results in decreased expression of GCM1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in decreased expression of GCM1 protein]

NCBI chr 8:78,925,687...78,938,924
Ensembl chr 8:78,925,687...78,938,924

G

glutamate ionotropic receptor NMDA type subunit 1

decreases expression

EXP

27-hydroxycholesterol results in decreased expression of GRIN1 protein

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutamate ionotropic receptor NMDA type subunit 2A

decreases phosphorylation

EXP

27-hydroxycholesterol results in decreased phosphorylation of GRIN2A protein

NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637

G

glycogen synthase kinase 3 beta

multiple interactions
increases phosphorylation

ISO

27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646

G

hypoxia inducible factor 1 subunit alpha

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of HIF1A protein
HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]

PMID:27856279 PMID:33880675

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity
decreases expression
multiple interactions

ISO
EXP

27-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 27-hydroxycholesterol results in decreased activity of HMGCR protein
27-hydroxycholesterol results in decreased expression of HMGCR mRNA; 27-hydroxycholesterol results in decreased expression of HMGCR protein
[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]

PMID:7749852 PMID:7751816 PMID:7788503 PMID:9059514 PMID:11408283 More...

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

heme oxygenase 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of HMOX1 mRNA; 27-hydroxycholesterol results in increased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 9

multiple interactions
increases expression

ISO

CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

intercellular adhesion molecule 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of ICAM1 mRNA

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 1 beta

multiple interactions

ISO

27-hydroxycholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases secretion
increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased secretion of IL6 protein
27-hydroxycholesterol results in increased expression of IL6 mRNA
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; stattic inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]

PMID:11851725 PMID:28739487

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit beta 1

multiple interactions
increases expression

ISO

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:56,705,171...56,753,195

G

lecithin cholesterol acyltransferase

increases metabolic processing

ISO

LCAT protein results in increased metabolism of 27-hydroxycholesterol

NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231

G

low density lipoprotein receptor

decreases activity
decreases expression

ISO
EXP

27-hydroxycholesterol results in decreased activity of LDLR protein
27-hydroxycholesterol results in decreased expression of LDLR mRNA; 27-hydroxycholesterol results in decreased expression of LDLR protein

PMID:8820113 PMID:28167099

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

lipase E, hormone sensitive type

multiple interactions

ISO

LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein]

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

ISO

27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein
U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

ISO

27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein
U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of MMP9 mRNA
Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

increases phosphorylation
multiple interactions

ISO

27-hydroxycholesterol results in increased phosphorylation of MTOR protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

MYC proto-oncogene, bHLH transcription factor

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of MYC protein
HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630

G

nitric oxide synthase 2

multiple interactions
decreases expression

ISO

27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

decreases expression
multiple interactions

ISO

27-hydroxycholesterol results in decreased expression of NOS3 mRNA
27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS3 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

NPC intracellular cholesterol transporter 1

affects abundance

ISO

NPC1 protein affects the abundance of 27-hydroxycholesterol

NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049

G

NAD(P)H quinone dehydrogenase 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of NQO1 mRNA; 27-hydroxycholesterol results in increased expression of NQO1 protein

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group H, member 3

increases expression

EXP

27-hydroxycholesterol results in increased expression of NR1H3 mRNA; 27-hydroxycholesterol results in increased expression of NR1H3 protein

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 5, group A, member 1

increases activity
multiple interactions

ISO

27-hydroxycholesterol results in increased activity of NR5A1 protein
27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]

PMID:9144161 PMID:9804848

NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328

G

platelet and endothelial cell adhesion molecule 1

decreases expression

ISO

27-hydroxycholesterol results in decreased expression of PECAM1 protein

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

progesterone receptor

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of PGR mRNA; 27-hydroxycholesterol results in increased expression of PGR protein
fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of PGR mRNA]

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions
increases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of PIK3R1 protein]

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

peroxisome proliferator-activated receptor gamma

increases expression

EXP

27-hydroxycholesterol results in increased expression of PPARG mRNA; 27-hydroxycholesterol results in increased expression of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

prostaglandin E synthase

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of PTGES mRNA
Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]

NCBI chr 3:34,575,643...34,586,987

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of PTGS2 protein
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

selectin E

increases expression

ISO

27-hydroxycholesterol results in increased expression of SELE mRNA

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

solute carrier family 16 member 1

decreases expression

ISO

27-hydroxycholesterol results in decreased expression of SLC16A1 protein

NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611

G

solute carrier family 16, member 4

decreases expression

ISO

27-hydroxycholesterol results in decreased expression of SLC16A4 protein

NCBI chr 2:194,911,075...194,933,162
Ensembl chr 2:194,911,236...194,933,117

G

sphingomyelin phosphodiesterase 2

decreases activity

ISO

27-hydroxycholesterol results in decreased activity of SMPD2 protein

NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441

G

synuclein alpha

increases expression

ISO

27-hydroxycholesterol results in increased expression of SNCA mRNA; 27-hydroxycholesterol results in increased expression of SNCA protein

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

SRC proto-oncogene, non-receptor tyrosine kinase

decreases activity

EXP

27-hydroxycholesterol results in decreased activity of SRC protein

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

sterol regulatory element binding transcription factor 1

decreases expression

EXP

27-hydroxycholesterol results in decreased expression of SREBF1 mRNA; 27-hydroxycholesterol results in decreased expression of SREBF1 protein

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

steroidogenic acute regulatory protein

multiple interactions
increases abundance
increases expression

ISO
EXP

27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]
STAR protein results in increased abundance of 27-hydroxycholesterol
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein]
27-hydroxycholesterol results in increased expression of STAR mRNA; 27-hydroxycholesterol results in increased expression of STAR protein

PMID:9804848 PMID:12368294 PMID:15863358 PMID:20083572 PMID:23362264

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 3

multiple interactions
increases phosphorylation

ISO

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]

PMID:27856279 PMID:28739487

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057

G

trefoil factor 1

multiple interactions
increases expression

ISO

27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of TFF1 mRNA]

PMID:17872378 PMID:27856279

NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,235,736...9,239,597

G

transforming growth factor, beta 1

multiple interactions

ISO

[TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 4

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of TLR4 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

vascular cell adhesion molecule 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of VCAM1 mRNA

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vascular endothelial growth factor A

multiple interactions
increases secretion
increases expression

ISO

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

multiple interactions
increases expression

ISO

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]
27-hydroxycholesterol results in increased expression of VIM mRNA; 27-hydroxycholesterol results in increased expression of VIM protein

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta

multiple interactions

ISO

27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]

NCBI chr14:77,696,332...77,705,715
Ensembl chr14:77,696,333...77,705,741

1,2,3-trilinoleoylglycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

decreases expression

ISO

trilinolein results in decreased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily G member 5

decreases expression

ISO

trilinolein results in decreased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

decreases expression

ISO

trilinolein results in decreased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

ISO

trilinolein results in decreased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

ISO

trilinolein results in increased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

microsomal triglyceride transfer protein

increases expression

ISO

trilinolein results in increased expression of MTTP mRNA

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

NPC1 like intracellular cholesterol transporter 1

decreases expression

ISO

trilinolein results in decreased expression of NPC1L1 mRNA

NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113

G

stearoyl-CoA desaturase

multiple interactions
decreases expression

ISO

Clofibrate inhibits the reaction [trilinolein results in decreased expression of SCD1 mRNA]

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ferrochelatase

affects abundance

ISO

FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine

NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348

1-octadecanoyl-2-[(9Z)-octadecenoyl]-sn-glycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions
decreases abundance

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol
LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

decreases abundance
multiple interactions

ISO

LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase G, endothelial type

increases hydrolysis

ISO

LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

1-palmitoyl-2-oleoyl-sn-glycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

decreases abundance

ISO

LIPC gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

decreases abundance

ISO

LIPG gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

1-stearoyl-2-arachidonoyl-sn-glycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

collagen type I alpha 1 chain

multiple interactions

ISO

1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

diacylglycerol lipase, alpha

increases metabolic processing

ISO

DAGLA protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol

NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232

G

diacylglycerol lipase, beta

increases metabolic processing

ISO

DAGLB protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol

NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154

G

diacylglycerol kinase epsilon

increases phosphorylation

ISO

DGKE protein results in increased phosphorylation of 1-stearoyl-2-arachidonoylglycerol

NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100

G

PPARG coactivator 1 alpha

increases expression

ISO

1-stearoyl-2-arachidonoylglycerol results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

transforming growth factor, beta 1

multiple interactions

ISO

1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

transient receptor potential cation channel, subfamily M, member 6

multiple interactions

ISO

TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium]

NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520

1-stearoyl-2-linoleoyl-sn-glycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

decreases abundance

ISO

LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

decreases abundance

ISO

LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

increases expression

ISO

13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

increases expression

ISO

13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAV1 mRNA

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

C-C motif chemokine ligand 2

multiple interactions

EXP

[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

early growth response 1

multiple interactions

EXP

[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766

G

peroxisome proliferator activated receptor alpha

increases expression

EXP

13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARA protein

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

increases expression

EXP

13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

decreases activity

EXP

14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased activity of ACE protein

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions

ISO

14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased expression of ACE2 protein]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

angiotensinogen

decreases expression
multiple interactions
increases cleavage

EXP
ISO

14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased expression of AGT protein modified form
[14,15-epoxy-5,8,11-eicosatrienoic acid analog results in increased cleavage of AGT protein modified form] which results in increased abundance of angiotensin I (1-7)
14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

AKT serine/threonine kinase 1

increases phosphorylation

ISO

14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

cytochrome P450, family 2, subfamily c, polypeptide 79

increases chemical synthesis

ISO

CYP2C8 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases chemical synthesis

ISO

Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

epoxide hydrolase 2

multiple interactions
increases abundance

ISO

[Arsenites results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid; [Mercuric Chloride results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid
EPHX2 gene mutant form results in increased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid

PMID:19896470 PMID:22680237 PMID:24472606

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

fibroblast growth factor 2

increases expression

ISO

14,15-epoxy-5,8,11-eicosatrienoic acid results in increased expression of FGF2 protein

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221

G

mitogen activated protein kinase 1

increases phosphorylation

ISO

14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation

ISO

14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

ribosomal protein S6 kinase B1

increases phosphorylation

ISO

14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of RPS6KB1 protein

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908

G

transforming growth factor, beta 1

decreases secretion
multiple interactions

ISO

TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid
12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily e, polypeptide 1

affects metabolic processing

EXP

CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 4, subfamily f, polypeptide 18

increases chemical synthesis

ISO

CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily e, polypeptide 1

affects metabolic processing

EXP

CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 4, subfamily f, polypeptide 18

increases chemical synthesis

ISO

CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940

2-arachidonoylglycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

abhydrolase domain containing 12, lysophospholipase

increases hydrolysis

ISO

ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate

NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564

G

abhydrolase domain containing 6, acylglycerol lipase

increases hydrolysis

ISO

ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate

NCBI chr15:16,859,740...16,907,094
Ensembl chr15:16,859,738...16,906,985

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

EXP

glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA
Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

apolipoprotein E

multiple interactions

ISO

[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

arrestin, beta 1

multiple interactions

ISO

glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]

NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:153,838,078...153,904,061

G

arrestin, beta 2

multiple interactions

ISO

[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

activating transcription factor 4

increases expression
multiple interactions

ISO

glyceryl 2-arachidonate results in increased expression of ATF4 mRNA
iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA]

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

BTG anti-proliferation factor 2

increases expression

ISO

glyceryl 2-arachidonate results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

caspase 3

affects expression

ISO

glyceryl 2-arachidonate affects the expression of CASP3 mRNA

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 2

increases expression

ISO

glyceryl 2-arachidonate results in increased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine receptor 1

increases expression

ISO

glyceryl 2-arachidonate results in increased expression of CCR1 mRNA

NCBI chr 8:123,556,286...123,561,841

G

CD36 molecule

increases expression

ISO

glyceryl 2-arachidonate results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

carboxylesterase 1D

increases hydrolysis
multiple interactions

ISO

CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate
[CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

carboxylesterase 2H

increases hydrolysis
multiple interactions

ISO

CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate
[CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

cannabinoid receptor 1

multiple interactions
increases expression

ISO
EXP

[CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of glyceryl 2-arachidonate; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]
glyceryl 2-arachidonate results in increased expression of CNR1 mRNA
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]
Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein]

PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 More...

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor 2

multiple interactions
affects response to substance

ISO

[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]
CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate

PMID:10617657 PMID:15115777 PMID:20124950 PMID:27194477 PMID:30102254 More...

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

cAMP responsive element binding protein 3-like 3

multiple interactions
increases expression

ISO

glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]

NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048

G

corticotropin releasing hormone

increases abundance

ISO

CRH protein results in increased abundance of glyceryl 2-arachidonate

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions
increases expression

ISO

CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]

PMID:23894352 PMID:28095641

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions
increases expression

ISO

CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]

PMID:23894352 PMID:28095641

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

increases expression
multiple interactions

ISO

glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

cytochrome P450 family 8 subfamily B member 1

increases expression
multiple interactions

ISO

glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]

PMID:23894352 PMID:28095641

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

diacylglycerol lipase, alpha

multiple interactions

ISO

1-((fluoro(methyl)phosphoryl)oxy)-3-isopropoxypropan-2-yl oleate inhibits the reaction [DAGLA protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate]

NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

ISO

glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein
iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein]

PMID:29441458 PMID:32357311

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

epidermal growth factor

affects expression

ISO

glyceryl 2-arachidonate affects the expression of EGF mRNA; glyceryl 2-arachidonate affects the expression of EGF protein

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions
increases phosphorylation

ISO

GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

estrogen-related receptor gamma

increases abundance

ISO

ESRRG protein results in increased abundance of glyceryl 2-arachidonate

NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397

G

fatty acid binding protein 1

affects abundance
multiple interactions

ISO

FABP1 protein affects the abundance of glyceryl 2-arachidonate
FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fibroblast growth factor 1

affects expression

ISO

glyceryl 2-arachidonate affects the expression of FGF1 mRNA

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

fragile X messenger ribonucleoprotein 1

multiple interactions

ISO

[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate

NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050

G

FYN proto-oncogene, Src family tyrosine kinase

multiple interactions

EXP

FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr20:44,322,635...44,514,498
Ensembl chr20:42,766,369...42,959,911

G

glial cell derived neurotrophic factor

affects expression

ISO

glyceryl 2-arachidonate affects the expression of GDNF mRNA; glyceryl 2-arachidonate affects the expression of GDNF protein

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

G protein-coupled receptor kinase 2

multiple interactions

ISO

[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]

NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582

G

hypocretin neuropeptide precursor

increases chemical synthesis
multiple interactions

ISO

HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate
1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate]

NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210

G

heat shock protein family A (Hsp70) member 5

increases expression

ISO

glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891

G

intercellular adhesion molecule 1

increases expression

ISO

glyceryl 2-arachidonate results in increased expression of ICAM1 mRNA

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 1 beta

decreases expression
multiple interactions

ISO

glyceryl 2-arachidonate results in decreased expression of IL1B mRNA
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]

PMID:16364651 PMID:30611738

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

multiple interactions

ISO

glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 6

decreases expression
multiple interactions

ISO

glyceryl 2-arachidonate results in decreased expression of IL6 mRNA
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]

PMID:16364651 PMID:30611738

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

EXP

glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

ISO

INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

leptin

multiple interactions

ISO

[Dietary Fats co-treated with LEP protein] results in increased chemical synthesis of glyceryl 2-arachidonate

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

mitogen activated protein kinase kinase 1

multiple interactions

EXP

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

multiple interactions

EXP

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

ISO
EXP

CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein
glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12657697 PMID:31917333

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

ISO
EXP

CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein
glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12657697 PMID:31917333

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

monoglyceride lipase

multiple interactions
affects abundance
increases degradation
increases abundance
increases hydrolysis

EXP
ISO

[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate]
MGLL protein affects the abundance of glyceryl 2-arachidonate
MGLL protein results in increased degradation of glyceryl 2-arachidonate
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; [MJN110 results in decreased activity of MGLL protein] which results in decreased hydrolysis of and results in increased abundance of glyceryl 2-arachidonate
MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate

PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 More...

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

myeloperoxidase

multiple interactions

ISO

glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

ISO

GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein]

PMID:29441458 PMID:32357311

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

peroxisome proliferator activated receptor alpha

affects localization
multiple interactions

EXP

glyceryl 2-arachidonate affects the localization of PPARA protein
[palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

affects binding
multiple interactions
increases expression

ISO

glyceryl 2-arachidonate metabolite binds to PPARG protein
glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]
T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA]

PMID:21511917 PMID:26209559

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

prostaglandin-endoperoxide synthase 1

multiple interactions

EXP

[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

increases metabolic processing
multiple interactions

ISO

PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]
glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate]

PMID:18297109 PMID:21511917 PMID:26209559

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

tumor necrosis factor

decreases expression
multiple interactions

ISO
EXP

glyceryl 2-arachidonate results in decreased expression of TNF mRNA
glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein]
glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]

PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions
affects response to substance

EXP
ISO

glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein
TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate

PMID:18550765 PMID:21949157

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

YY1 transcription factor

increases expression

ISO

glyceryl 2-arachidonate results in increased expression of YY1 mRNA

NCBI chr 6:127,706,739...127,736,499
Ensembl chr 6:127,707,596...127,732,747

2-oleoylglycerol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

fatty acid binding protein 1

affects abundance

ISO

FABP1 protein affects the abundance of 2-oleoylglycerol

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

monoglyceride lipase

increases degradation
multiple interactions

EXP

MGLL protein results in increased degradation of 2-oleoylglycerol
Nitroglycerin promotes the reaction [MGLL protein results in increased degradation of 2-oleoylglycerol]

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

ISO

20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

clock circadian regulator

affects abundance

ISO

CLOCK protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr14:32,262,747...32,346,872
Ensembl chr14:31,908,566...31,990,400

G

collagen type I alpha 1 chain

multiple interactions
increases expression

ISO

20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein]
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

cytochrome P450, family 4, subfamily a, polypeptide 1

multiple interactions
increases chemical synthesis

EXP

20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]]
CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

PMID:11124159 PMID:12388396

NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464

G

cytochrome P450, family 4, subfamily a, polypeptide 2

increases expression

EXP

20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of CYP4A2 mRNA

NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165

G

cytochrome P450, family 4, subfamily f, polypeptide 18

increases chemical synthesis

ISO

CYP4F3 protein alternative form results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940

G

nuclear factor of activated T-cells 4

multiple interactions
increases localization

ISO
EXP

Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]

NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610

G

proopiomelanocortin

multiple interactions
increases abundance

EXP

HET0016 inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid]
POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

PMID:18067589 PMID:19458537

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

SMAD family member 3

multiple interactions
increases phosphorylation

ISO

20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

transforming growth factor, beta 1

multiple interactions
increases expression

ISO

20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein]
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

ISO

UGT1A1 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A5

increases glucuronidation

ISO

UGT1A4 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 2 member B7

increases glucuronidation

ISO

UGT2B7 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

20-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

ISO

[NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450 family 7 subfamily A member 1

increases metabolic processing

EXP
ISO

CYP7A1 protein results in increased metabolism of 20-hydroxycholesterol

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

hydroxysteroid (17-beta) dehydrogenase 10

multiple interactions

ISO

[20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein

NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488

G

melanocortin 2 receptor

multiple interactions

ISO

[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]

NCBI chr18:62,001,980...62,015,567
Ensembl chr18:62,004,948...62,015,488

G

nuclear receptor subfamily 5, group A, member 1

multiple interactions

ISO

[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA

NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328

25-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression
multiple interactions

ISO
EXP

25-hydroxycholesterol results in increased expression of ABCA1 mRNA
[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA; [25-hydroxycholesterol co-treated with alitretinoin] results in increased expression of ABCA1 protein; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]
[Cholesterol co-treated with 25-hydroxycholesterol] results in decreased expression of ABCA1 mRNA

PMID:12595494 PMID:16023994 PMID:17526932 PMID:19260826

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily G member 1

increases expression

ISO

25-hydroxycholesterol results in increased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

EXP

25-hydroxycholesterol results in increased expression of ACTA2 mRNA
15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of ACTA2 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of ACTA2 mRNA]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

adiponectin receptor 1

multiple interactions
decreases expression

ISO

[25-hydroxycholesterol co-treated with alitretinoin] results in decreased expression of ADIPOR1 mRNA
25-hydroxycholesterol results in decreased expression of ADIPOR1 mRNA

NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241

G

AKT serine/threonine kinase 1

decreases phosphorylation

ISO

25-hydroxycholesterol results in decreased phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

BCL2 associated X, apoptosis regulator

increases expression

ISO

25-hydroxycholesterol results in increased expression of BAX protein

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

ISO

25-hydroxycholesterol results in decreased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases activity

ISO
EXP

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases activity
multiple interactions

EXP

25-hydroxycholesterol results in increased activity of CASP8 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity
multiple interactions

EXP

25-hydroxycholesterol results in increased activity of CASP9 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]

Ensembl chr 5:154,109,046...154,126,626

G

cyclin-dependent kinase inhibitor 1B

increases expression

EXP

25-hydroxycholesterol results in increased expression of CDKN1B mRNA

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:167,760,181...167,764,982

G

calponin 1

multiple interactions
increases expression

EXP

15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of CNN1 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of CNN1 mRNA]

NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions
increases chemical synthesis

ISO

[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 25-hydroxycholesterol
CYP27A1 protein results in increased chemical synthesis of 25-hydroxycholesterol

PMID:8078928 PMID:17890683

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450 family 7 subfamily A member 1

increases metabolic processing

ISO
EXP

CYP7A1 protein results in increased metabolism of 25-hydroxycholesterol

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

increases metabolic processing
increases abundance

ISO

CYP7B1 protein results in increased metabolism of 25-hydroxycholesterol
CYP7B1 gene mutant form results in increased abundance of 25-hydroxycholesterol

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

estrogen receptor 1

multiple interactions

ISO

25-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 25-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

ISO

25-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 25-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein]

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919

G

fatty acid desaturase 1

multiple interactions
decreases expression

ISO

25-hydroxycholesterol inhibits the reaction [beta-hydroxy simvastatin acid results in increased expression of FADS1 mRNA]
25-hydroxycholesterol results in decreased expression of FADS1 mRNA

NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734

G

Fas cell surface death receptor

increases expression

ISO

25-hydroxycholesterol results in increased expression of FAS mRNA

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591

G

four and a half LIM domains 1

multiple interactions
increases expression

EXP

15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Brefeldin A inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Cycloheximide promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Dactinomycin promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Genistein inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]

NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928

G

ferritin heavy chain 1

decreases expression

ISO

25-hydroxycholesterol results in decreased expression of FTH1 protein

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

glutathione peroxidase 4

decreases expression

ISO

25-hydroxycholesterol results in decreased expression of GPX4 protein

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
decreases expression
decreases activity

ISO
EXP

[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein; [25-hydroxycholesterol co-treated with Mevalonic Acid] results in increased ubiquitination of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [25-hydroxycholesterol results in decreased activity of HMGCR protein]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [25-hydroxycholesterol results in decreased activity of HMGCR protein]
25-hydroxycholesterol results in decreased expression of HMGCR protein
25-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 25-hydroxycholesterol results in decreased activity of HMGCR protein
25-hydroxycholesterol results in decreased expression of HMGCR mRNA; 25-hydroxycholesterol results in decreased expression of HMGCR protein

PMID:7749852 PMID:7751816 PMID:9059514 PMID:12477733 PMID:18024962 More...

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

interleukin 1 beta

multiple interactions
increases secretion
increases expression

ISO

25-hydroxycholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
25-hydroxycholesterol results in increased secretion of IL1B protein
25-hydroxycholesterol results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases secretion
multiple interactions

ISO
EXP

25-hydroxycholesterol results in increased secretion of IL6 protein
25-hydroxycholesterol inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]
25-hydroxycholesterol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

PMID:11851725 PMID:27052460

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit alpha

increases expression

EXP

25-hydroxycholesterol results in increased expression of INHA mRNA; 25-hydroxycholesterol results in increased expression of INHA protein

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

inhibin subunit beta A

increases expression
decreases expression

EXP

25-hydroxycholesterol results in increased expression of INHBA mRNA
25-hydroxycholesterol results in decreased expression of INHBA protein

NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982

G

inhibin subunit beta B

increases expression

EXP

25-hydroxycholesterol results in increased expression of INHBB mRNA; 25-hydroxycholesterol results in increased expression of INHBB protein

NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832

G

insulin induced gene 1

decreases expression

ISO

25-hydroxycholesterol results in decreased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

lysosomal-associated membrane protein 1

increases expression

ISO

25-hydroxycholesterol results in increased expression of LAMP1 protein

NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883

G

low density lipoprotein receptor

decreases expression
multiple interactions

ISO

25-hydroxycholesterol results in decreased expression of LDLR mRNA; 25-hydroxycholesterol results in decreased expression of LDLR protein
25-hydroxycholesterol inhibits the reaction [[Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein] which results in increased expression of LDLR mRNA]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased expression of LDLR mRNA]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; LDLR gene mutant form results in increased susceptibility to [25-hydroxycholesterol co-treated with Cholesterol]

PMID:12477733 PMID:19260826 PMID:22153697 PMID:27447558

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

lipoprotein lipase

decreases expression
decreases activity

ISO

25-hydroxycholesterol results in decreased expression of LPL mRNA
25-hydroxycholesterol results in decreased activity of LPL protein

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

microtubule-associated protein 1 light chain 3 beta

increases lipidation

ISO

25-hydroxycholesterol results in increased lipidation of MAP1LC3B protein

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

membrane associated ring-CH-type finger 6

increases stability

ISO

25-hydroxycholesterol results in increased stability of MARCHF6 protein

NCBI chr 2:84,166,570...84,243,817
Ensembl chr 2:82,455,689...82,532,910

G

nuclear receptor coactivator 4

increases expression

ISO

25-hydroxycholesterol results in increased expression of NCOA4 protein

NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641
Ensembl chr16:7,366,542...7,409,641

G

nitric oxide synthase 2

increases expression

ISO

25-hydroxycholesterol results in increased expression of NOS2 mRNA

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

decreases expression

ISO

25-hydroxycholesterol results in decreased expression of NOS3 mRNA

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

nuclear receptor subfamily 1, group H, member 3

increases activity
multiple interactions

ISO

25-hydroxycholesterol results in increased activity of NR1H3 protein
[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA; [25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; SULT2B1 protein inhibits the reaction [25-hydroxycholesterol results in increased activity of NR1H3 protein]

PMID:9603267 PMID:12595494 PMID:27052460

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 5, group A, member 1

increases activity
multiple interactions

ISO

25-hydroxycholesterol results in increased activity of NR5A1 protein
25-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]

PMID:9144161 PMID:9804848

NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328

G

poly (ADP-ribose) polymerase 1

increases cleavage

ISO

25-hydroxycholesterol results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

[Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

[9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

RAR-related orphan receptor A

affects binding

ISO

25-hydroxycholesterol binds to RORA protein

NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931

G

RAR-related orphan receptor C

affects binding
multiple interactions

ISO

25-hydroxycholesterol binds to RORC protein
bisphenol A analog inhibits the reaction [25-hydroxycholesterol binds to RORC protein]; T0901317 inhibits the reaction [25-hydroxycholesterol binds to RORC protein]

PMID:22659100 PMID:31195007

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

stearoyl-CoA desaturase

decreases expression

ISO

25-hydroxycholesterol results in decreased expression of SCD protein

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

solute carrier family 7 member 11

decreases expression

ISO

25-hydroxycholesterol results in decreased expression of SLC7A11 protein

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

sterol regulatory element binding transcription factor 1

increases expression
multiple interactions

ISO

25-hydroxycholesterol results in increased expression of SREBF1 protein
[25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF1 protein

PMID:19260826 PMID:27324795

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

sterol regulatory element binding transcription factor 2

decreases activity
multiple interactions

ISO

25-hydroxycholesterol results in decreased activity of SREBF2 protein
25-hydroxycholesterol inhibits the reaction [[Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein] which results in increased expression of LDLR mRNA]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased expression of SREBF2 protein modified form]; [25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF2 protein; Clozapine inhibits the reaction [25-hydroxycholesterol results in decreased activity of SREBF2 protein]

PMID:17052361 PMID:22153697 PMID:27324795

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

steroidogenic acute regulatory protein

multiple interactions

ISO

25-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 3

multiple interactions

EXP

25-hydroxycholesterol inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057

G

sulfotransferase family 2B member 1

multiple interactions

ISO

SULT2B1 protein inhibits the reaction [25-hydroxycholesterol results in increased activity of NR1H3 protein]
SULT2B1 protein inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased abundance of 25-hydroxycholesterol]

NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295

G

TNF superfamily member 15

increases expression

ISO

25-hydroxycholesterol results in increased expression of TNFSF15 mRNA

NCBI chr 5:77,134,885...77,156,171
Ensembl chr 5:77,139,878...77,156,228

G

tumor protein p53

increases expression

ISO

25-hydroxycholesterol results in increased expression of TP53 protein

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

vascular cell adhesion molecule 1

increases expression

ISO

25-hydroxycholesterol results in increased expression of VCAM1 mRNA

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

26-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression
multiple interactions

ISO
EXP

27-hydroxycholesterol results in increased expression of ABCA1 mRNA; 27-hydroxycholesterol results in increased expression of ABCA1 protein
Docosahexaenoic Acids inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]
[Fingolimod Hydrochloride results in increased abundance of 27-hydroxycholesterol] which results in increased expression of ABCA1 mRNA

PMID:15148325 PMID:17088262 PMID:18356535 PMID:18841091 PMID:20056921 More...

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 1A

increases expression

ISO

27-hydroxycholesterol results in increased expression of ABCB1 mRNA

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of ABCC1 mRNA

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily G member 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of ABCG1 protein

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

ISO

Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]

PMID:33131013 PMID:33880675 PMID:38180513

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

alkaline phosphatase, placental

decreases activity

ISO

27-hydroxycholesterol results in decreased activity of ALPP protein

NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606

G

apolipoprotein A1

multiple interactions

ISO

27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein E

increases expression

EXP

27-hydroxycholesterol results in increased expression of APOE mRNA; 27-hydroxycholesterol results in increased expression of APOE protein

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

multiple interactions
increases expression
decreases secretion

ISO

27-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein
27-hydroxycholesterol results in increased expression of APP protein alternative form
27-hydroxycholesterol results in decreased secretion of APP protein alternative form

PMID:15148325 PMID:19126211 PMID:19158428

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

activity-regulated cytoskeleton-associated protein

decreases expression

EXP

27-hydroxycholesterol results in decreased expression of ARC protein

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

beta-secretase 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of BACE1 protein

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

catalase

multiple interactions

ISO

CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of CCL2 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

increases expression
increases secretion

ISO

27-hydroxycholesterol results in increased expression of CCL3 mRNA
27-hydroxycholesterol results in increased secretion of CCL3 protein

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

increases secretion
increases expression

ISO

27-hydroxycholesterol results in increased secretion of CCL4 protein
27-hydroxycholesterol results in increased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

cellular communication network factor 5

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of CCN5 mRNA
Fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CCN5 mRNA]

NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636

G

CD36 molecule

multiple interactions
increases expression

ISO

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cadherin 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 5

decreases expression
multiple interactions

ISO

27-hydroxycholesterol results in decreased expression of CDH5 mRNA; 27-hydroxycholesterol results in decreased expression of CDH5 protein
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]

NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368

G

cadherin 6

decreases expression

ISO

27-hydroxycholesterol results in decreased expression of CDH6 mRNA

NCBI chr 2:62,079,139...62,225,298
Ensembl chr 2:62,079,137...62,225,228

G

carboxylesterase 1D

multiple interactions
decreases activity

ISO

27-hydroxycholesterol inhibits the reaction [CES1 protein results in increased metabolism of bioresmethrin]
27-hydroxycholesterol results in decreased activity of CES1 protein

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

catenin beta 1

multiple interactions
increases activity

ISO

27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol results in increased expression of and affects the localization of CTNNB1 protein; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]
27-hydroxycholesterol results in increased activity of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X-C motif chemokine ligand 12

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of CXCL12 mRNA
fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CXCL12 mRNA]

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases abundance
increases chemical synthesis
multiple interactions

ISO
EXP

CYP27A1 protein results in increased abundance of 27-hydroxycholesterol
CYP27A1 protein results in increased chemical synthesis of 27-hydroxycholesterol
[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol
[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol

PMID:8496670 PMID:9215552 PMID:9660774 PMID:11408283 PMID:11714861 More...

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450 family 7 subfamily A member 1

increases metabolic processing

ISO
EXP

CYP7A1 protein results in increased metabolism of 27-hydroxycholesterol

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

increases abundance
increases metabolic processing
increases hydroxylation

ISO

CYP7B1 gene mutant form results in increased abundance of 27-hydroxycholesterol
CYP7B1 protein results in increased metabolism of 27-hydroxycholesterol
CYP7B1 protein results in increased hydroxylation of 27-hydroxycholesterol

PMID:10588945 PMID:10748047

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

E2F transcription factor 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of E2F1 mRNA

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:143,049,478...143,075,361

G

erb-b2 receptor tyrosine kinase 4

decreases expression

ISO

27-hydroxycholesterol results in decreased expression of ERBB4 mRNA

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

endogenous retrovirus group FRD member 1, envelope

multiple interactions
decreases expression

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in decreased expression of ERVFRD-1 protein]

NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264

G

estrogen receptor 1

multiple interactions
affects response to substance
increases degradation

ISO

27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR1 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol binds to and results in increased activity of ESR1 protein]; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; 27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased activity of ESR1 protein]
ESR1 protein affects the susceptibility to 27-hydroxycholesterol
ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]
27-hydroxycholesterol results in increased degradation of ESR1 protein

PMID:17872378 PMID:17873880

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions
affects response to substance

ISO

27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR2 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein]
ESR2 protein affects the susceptibility to 27-hydroxycholesterol
ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]

PMID:17872378 PMID:17873880

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919

G

glial cells missing transcription factor 1

decreases expression
multiple interactions

ISO

27-hydroxycholesterol results in decreased expression of GCM1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in decreased expression of GCM1 protein]

NCBI chr 8:78,925,687...78,938,924
Ensembl chr 8:78,925,687...78,938,924

G

glutamate ionotropic receptor NMDA type subunit 1

decreases expression

EXP

27-hydroxycholesterol results in decreased expression of GRIN1 protein

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutamate ionotropic receptor NMDA type subunit 2A

decreases phosphorylation

EXP

27-hydroxycholesterol results in decreased phosphorylation of GRIN2A protein

NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637

G

glycogen synthase kinase 3 beta

increases phosphorylation
multiple interactions

ISO

27-hydroxycholesterol results in increased phosphorylation of GSK3B protein
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646

G

hypoxia inducible factor 1 subunit alpha

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of HIF1A protein
HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]

PMID:27856279 PMID:33880675

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
decreases expression
decreases activity

ISO
EXP

[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]
27-hydroxycholesterol results in decreased expression of HMGCR mRNA; 27-hydroxycholesterol results in decreased expression of HMGCR protein
27-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 27-hydroxycholesterol results in decreased activity of HMGCR protein

PMID:7749852 PMID:7751816 PMID:7788503 PMID:9059514 PMID:11408283 More...

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

heme oxygenase 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of HMOX1 mRNA; 27-hydroxycholesterol results in increased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 9

multiple interactions
increases expression

ISO

CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

intercellular adhesion molecule 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of ICAM1 mRNA

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 1 beta

multiple interactions

ISO

27-hydroxycholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases secretion
multiple interactions
increases expression

ISO

27-hydroxycholesterol results in increased secretion of IL6 protein
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; stattic inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]

PMID:11851725 PMID:28739487

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit beta 1

multiple interactions
increases expression

ISO

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:56,705,171...56,753,195

G

lecithin cholesterol acyltransferase

increases metabolic processing

ISO

LCAT protein results in increased metabolism of 27-hydroxycholesterol

NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231

G

low density lipoprotein receptor

decreases activity
decreases expression

ISO
EXP

27-hydroxycholesterol results in decreased activity of LDLR protein
27-hydroxycholesterol results in decreased expression of LDLR mRNA; 27-hydroxycholesterol results in decreased expression of LDLR protein

PMID:8820113 PMID:28167099

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

lipase E, hormone sensitive type

multiple interactions

ISO

LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein]

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

ISO

U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

ISO

27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein
U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

multiple interactions
increases expression

ISO

Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

increases phosphorylation
multiple interactions

ISO

27-hydroxycholesterol results in increased phosphorylation of MTOR protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

MYC proto-oncogene, bHLH transcription factor

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of MYC protein
HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630

G

nitric oxide synthase 2

multiple interactions
decreases expression

ISO

27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions
decreases expression

ISO

27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS3 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

NPC intracellular cholesterol transporter 1

affects abundance

ISO

NPC1 protein affects the abundance of 27-hydroxycholesterol

NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049

G

NAD(P)H quinone dehydrogenase 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of NQO1 mRNA; 27-hydroxycholesterol results in increased expression of NQO1 protein

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group H, member 3

increases expression

EXP

27-hydroxycholesterol results in increased expression of NR1H3 mRNA; 27-hydroxycholesterol results in increased expression of NR1H3 protein

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 5, group A, member 1

increases activity
multiple interactions

ISO

27-hydroxycholesterol results in increased activity of NR5A1 protein
27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]

PMID:9144161 PMID:9804848

NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328

G

platelet and endothelial cell adhesion molecule 1

decreases expression

ISO

27-hydroxycholesterol results in decreased expression of PECAM1 protein

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

progesterone receptor

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of PGR mRNA; 27-hydroxycholesterol results in increased expression of PGR protein
fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of PGR mRNA]

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions
increases phosphorylation

ISO

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of PIK3R1 protein]

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

peroxisome proliferator-activated receptor gamma

increases expression

EXP

27-hydroxycholesterol results in increased expression of PPARG mRNA; 27-hydroxycholesterol results in increased expression of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

prostaglandin E synthase

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of PTGES mRNA
Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]

NCBI chr 3:34,575,643...34,586,987

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of PTGS2 protein
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

selectin E

increases expression

ISO

27-hydroxycholesterol results in increased expression of SELE mRNA

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

solute carrier family 16 member 1

decreases expression

ISO

27-hydroxycholesterol results in decreased expression of SLC16A1 protein

NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611

G

solute carrier family 16, member 4

decreases expression

ISO

27-hydroxycholesterol results in decreased expression of SLC16A4 protein

NCBI chr 2:194,911,075...194,933,162
Ensembl chr 2:194,911,236...194,933,117

G

sphingomyelin phosphodiesterase 2

decreases activity

ISO

27-hydroxycholesterol results in decreased activity of SMPD2 protein

NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441

G

synuclein alpha

increases expression

ISO

27-hydroxycholesterol results in increased expression of SNCA mRNA; 27-hydroxycholesterol results in increased expression of SNCA protein

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

SRC proto-oncogene, non-receptor tyrosine kinase

decreases activity

EXP

27-hydroxycholesterol results in decreased activity of SRC protein

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

sterol regulatory element binding transcription factor 1

decreases expression

EXP

27-hydroxycholesterol results in decreased expression of SREBF1 mRNA; 27-hydroxycholesterol results in decreased expression of SREBF1 protein

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

steroidogenic acute regulatory protein

multiple interactions
increases expression
increases abundance

ISO
EXP

27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein]
27-hydroxycholesterol results in increased expression of STAR mRNA; 27-hydroxycholesterol results in increased expression of STAR protein
STAR protein results in increased abundance of 27-hydroxycholesterol
27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein]

PMID:9804848 PMID:12368294 PMID:15863358 PMID:20083572 PMID:23362264

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 3

increases phosphorylation
multiple interactions

ISO

27-hydroxycholesterol results in increased phosphorylation of STAT3 protein
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]

PMID:27856279 PMID:28739487

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057

G

trefoil factor 1

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of TFF1 mRNA
27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of TFF1 mRNA]

PMID:17872378 PMID:27856279

NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,235,736...9,239,597

G

transforming growth factor, beta 1

multiple interactions

ISO

[TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 4

multiple interactions
increases expression

ISO

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

vascular cell adhesion molecule 1

increases expression

ISO

27-hydroxycholesterol results in increased expression of VCAM1 mRNA

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vascular endothelial growth factor A

increases secretion
multiple interactions
increases expression

ISO

27-hydroxycholesterol results in increased secretion of VEGFA protein
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

increases expression
multiple interactions

ISO

27-hydroxycholesterol results in increased expression of VIM mRNA; 27-hydroxycholesterol results in increased expression of VIM protein
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta

multiple interactions

ISO

27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]

NCBI chr14:77,696,332...77,705,715
Ensembl chr14:77,696,333...77,705,741

3beta-hydroxycholest-5-en-26-oic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases chemical synthesis
multiple interactions

ISO

CYP27A1 protein results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid
[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid

PMID:8078928 PMID:9215552 PMID:9660774 PMID:14622972

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

nuclear receptor coactivator 2

multiple interactions

ISO

3-hydroxy-5-cholestenoic acid affects the reaction [NR1H3 protein binds to NCOA2 protein]

NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:5,835,706...6,067,451

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

ISO

3-hydroxy-5-cholestenoic acid affects the reaction [NR1H3 protein binds to NCOA2 protein]; 3-hydroxy-5-cholestenoic acid binds to and results in increased activity of NR1H3 protein

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

4beta-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases chemical synthesis

ISO

[CYP3A4 protein results in increased oxidation of Cholesterol] which results in increased chemical synthesis of cholest-5-ene-3,4-diol
CYP3A4 protein results in increased chemical synthesis of cholest-5-ene-3,4-diol

PMID:11514559 PMID:19954708

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases chemical synthesis

ISO

Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 5,6-epoxy-8,11,14-eicosatrienoic acid]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

epoxide hydrolase 2

increases abundance

ISO

EPHX2 gene mutant form results in increased abundance of 5,6-epoxy-8,11,14-eicosatrienoic acid

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

5,6alpha-epoxy-5alpha-cholestan-3beta-ol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

epidermal growth factor receptor

increases phosphorylation

EXP

cholesterol alpha-oxide results in increased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

epoxide hydrolase 1

increases metabolic processing
multiple interactions

ISO

EPHX1 protein results in increased metabolism of cholesterol alpha-oxide
disparlure promotes the reaction [EPHX1 protein results in increased metabolism of cholesterol alpha-oxide]; Lanosterol analog inhibits the reaction [EPHX1 protein results in increased metabolism of cholesterol alpha-oxide]

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

epoxide hydrolase 2

multiple interactions

ISO

cholesterol alpha-oxide inhibits the reaction [EPHX2 protein results in increased metabolism of stilbene oxide analog]

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

EXP

RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

EXP

cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein
RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 2

increases expression

EXP

cholesterol alpha-oxide results in increased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases expression

EXP

cholesterol alpha-oxide results in increased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

increases phosphorylation
multiple interactions

EXP

cholesterol alpha-oxide results in increased phosphorylation of MTOR protein
RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

7-ketocholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily D member 1

decreases expression
multiple interactions

ISO

7-ketocholesterol results in decreased expression of ABCD1 mRNA
alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD1 mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD1 mRNA]

NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115

G

ATP binding cassette subfamily D member 3

decreases expression
multiple interactions

ISO

7-ketocholesterol results in decreased expression of ABCD3 mRNA
alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD3 mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD3 mRNA]

NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020

G

ATP binding cassette subfamily G member 5

multiple interactions
decreases expression

ISO

[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with Oligomycins] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ABCG5 mRNA
7-ketocholesterol results in decreased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

multiple interactions

ISO

[7-ketocholesterol co-treated with Oligomycins] results in decreased expression of ABCG8 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA acetyltransferase 1

multiple interactions

ISO

[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ACAT1 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ACAT1 mRNA

NCBI chr 8:62,876,003...62,905,080
Ensembl chr 8:53,979,813...54,008,855

G

acyl-CoA oxidase 1

decreases expression

ISO

7-ketocholesterol results in decreased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

aryl hydrocarbon receptor

multiple interactions
affects binding

ISO
EXP

7-ketocholesterol inhibits the reaction [AHR protein binds to CYP1A1 enhancer]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA]
7-ketocholesterol binds to AHR protein

PMID:11042205 PMID:16480812

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

multiple interactions

EXP

7-ketocholesterol results in decreased phosphorylation of and results in decreased activity of AKT1 protein; alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased phosphorylation of and results in decreased activity of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

EXP

7-ketocholesterol results in increased expression of BAX protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

EXP

Acetylcysteine inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 11

affects localization

ISO

7-ketocholesterol affects the localization of BCL2L11 protein

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:115,366,646...115,404,068

G

BH3 interacting domain death agonist

decreases expression
multiple interactions

EXP

7-ketocholesterol results in decreased expression of BID protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

caspase 1

multiple interactions
affects localization
increases activity

ISO

Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; methyl-beta-cyclodextrin inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; tempol inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; Verapamil inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases activity
increases cleavage
multiple interactions

ISO
EXP

7-ketocholesterol results in increased activity of CASP3 protein
7-ketocholesterol results in increased cleavage of CASP3 protein
alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in increased cleavage of CASP3 protein]; argan oil inhibits the reaction [7-ketocholesterol results in increased cleavage of CASP3 protein]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; beta-Tocopherol affects the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Serotonin inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]

PMID:12450566 PMID:16934673 PMID:24650663 PMID:25845326 PMID:29065513

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases activity
multiple interactions

ISO

7-ketocholesterol results in increased activity of CASP7 protein
Serotonin inhibits the reaction [7-ketocholesterol results in increased activity of CASP7 protein]

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

multiple interactions
increases activity

EXP

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases activity

EXP

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]

Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

ISO

7-ketocholesterol results in increased expression of CCL2 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

multiple interactions
increases expression

ISO

resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

increases expression
multiple interactions

ISO

7-ketocholesterol results in increased expression of CCL4 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL4 protein]

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

multiple interactions
increases expression

ISO

resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL5 protein]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

CD38 molecule

multiple interactions

ISO

CD38 gene mutant form promotes the reaction [7-ketocholesterol results in increased expression of MAP1LC3B protein]

NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986

G

colony stimulating factor 2

increases expression
multiple interactions

ISO

7-ketocholesterol results in increased expression of CSF2 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CSF2 protein]

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 3

increases expression
multiple interactions

ISO

7-ketocholesterol results in increased expression of CSF3 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CSF3 protein]

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

C-X-C motif chemokine ligand 10

increases expression

ISO

7-ketocholesterol results in increased expression of CXCL10 protein

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

cytochrome b-245 beta chain

affects localization
multiple interactions

ISO

7-ketocholesterol affects the localization of CYBB protein
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CYBB protein]; Amitriptyline inhibits the reaction [7-ketocholesterol analog affects the localization of CYBB protein]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases expression

ISO
EXP

7-ketocholesterol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [AHR protein binds to CYP1A1 enhancer]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
7-ketocholesterol inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 mRNA]; 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
7-ketocholesterol results in decreased expression of CYP1A1 protein

PMID:11042205 PMID:18708364

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases metabolic processing

ISO

CYP27A1 protein results in increased metabolism of 7-ketocholesterol

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450 family 7 subfamily A member 1

decreases activity

EXP

7-ketocholesterol results in decreased activity of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

epidermal growth factor receptor

increases phosphorylation

EXP

7-ketocholesterol results in increased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity
increases expression
multiple interactions

ISO

7-ketocholesterol results in decreased activity of HMGCR protein
7-ketocholesterol results in increased expression of HMGCR mRNA
[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of HMGCR mRNA; [7-ketocholesterol co-treated with Oligomycins] results in decreased expression of HMGCR mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of HMGCR mRNA

PMID:7751816 PMID:23454145

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

hydroxysteroid (17-beta) dehydrogenase 4

decreases expression

ISO

7-ketocholesterol results in decreased expression of HSD17B4 mRNA

NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952

G

intercellular adhesion molecule 1

increases expression

ISO

7-ketocholesterol results in increased expression of ICAM1 mRNA; 7-ketocholesterol results in increased expression of ICAM1 protein

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 10

decreases expression
multiple interactions
increases expression

ISO

7-ketocholesterol results in decreased expression of IL10 mRNA
resveratrol promotes the reaction [7-ketocholesterol results in increased expression of IL10 protein]

PMID:24727230 PMID:24895526

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

increases expression
multiple interactions

ISO

7-ketocholesterol results in increased expression of IL1B protein
Amitriptyline inhibits the reaction [7-ketocholesterol results in increased expression of IL1B protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

multiple interactions

ISO

[resveratrol co-treated with 7-ketocholesterol] results in increased expression of IL1RN protein

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 6

increases expression
multiple interactions

ISO

7-ketocholesterol results in increased expression of IL6 protein
7-ketocholesterol results in decreased degradation of and results in increased expression of IL6 mRNA; pyrazolanthrone inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]; resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]

PMID:18515973 PMID:24895526

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

kininogen 1

multiple interactions

ISO

[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ACAT1 mRNA; [7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of HMGCR mRNA

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

microtubule-associated protein 1 light chain 3 beta

increases expression
multiple interactions

ISO

7-ketocholesterol results in increased expression of MAP1LC3B protein
CD38 gene mutant form promotes the reaction [7-ketocholesterol results in increased expression of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

ISO
EXP

U 0126 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein]
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein]

PMID:15955068 PMID:20466046

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

ISO
EXP

7-ketocholesterol results in increased phosphorylation of MAPK3 protein
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein]
U 0126 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein]

PMID:15955068 PMID:20466046

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 2

increases expression
multiple interactions

EXP
ISO

7-ketocholesterol results in increased expression of MMP2 mRNA
7-ketocholesterol results in increased expression of MMP2 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of MMP2 protein]

PMID:20466046 PMID:24895526

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases expression
multiple interactions

EXP
ISO

7-ketocholesterol results in increased expression of MMP9 mRNA
7-ketocholesterol results in increased expression of MMP9 protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of MMP9 protein]

PMID:20466046 PMID:24895526

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

increases phosphorylation
multiple interactions

EXP

7-ketocholesterol results in increased phosphorylation of MTOR protein
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

nuclear factor kappa B subunit 1

increases expression
multiple interactions

ISO
EXP

7-ketocholesterol results in increased expression of NFKB1 protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]

PMID:24895526 PMID:25845326

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

increases phosphorylation
multiple interactions

EXP

7-ketocholesterol results in increased phosphorylation of NFKBIA protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of NFKBIA protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of NFKBIA protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of NFKBIA protein]

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941

G

NLR family, pyrin domain containing 3

multiple interactions
affects localization

ISO

Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

increases expression

ISO

7-ketocholesterol results in increased expression of NOS2 mRNA

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPC1 like intracellular cholesterol transporter 1

decreases expression

ISO

7-ketocholesterol results in decreased expression of NPC1L1

NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

EXP

7-ketocholesterol results in increased cleavage of PARP1 protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

paraoxonase 1

multiple interactions

ISO

7-ketocholesterol inhibits the reaction [Methylcholanthrene results in increased expression of PON1 mRNA]; 7-ketocholesterol inhibits the reaction [Quercetin results in increased expression of PON1 mRNA]; 7-ketocholesterol inhibits the reaction [resveratrol results in increased expression of PON1 mRNA]

PMID:15169886 PMID:15458977

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

paraoxonase 2

increases activity
increases expression

ISO

7-ketocholesterol results in increased activity of PON2 protein
7-ketocholesterol results in increased expression of PON2 mRNA

NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248

G

paraoxonase 3

multiple interactions

ISO

7-ketocholesterol inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]

NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855

G

peroxisome proliferator activated receptor alpha

decreases expression
multiple interactions

ISO

7-ketocholesterol results in decreased expression of PPARA mRNA
alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of PPARA mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of PPARA mRNA]

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein tyrosine kinase 2 beta

multiple interactions

ISO

7-ketocholesterol results in increased phosphorylation of and results in increased activity of PTK2B protein

NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282

G

PYD and CARD domain containing

affects localization
multiple interactions

ISO

7-ketocholesterol affects the localization of PYCARD protein
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of PYCARD protein]

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

EXP
ISO

7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein]
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of RELA protein]

PMID:24895526 PMID:25845326

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

sphingomyelin phosphodiesterase 1

multiple interactions

ISO

SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased expression of IL1B protein]

NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794

G

transglutaminase 2

multiple interactions

ISO

7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TGM2 mRNA]

NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:146,772,687...146,801,981

G

tumor necrosis factor

multiple interactions
increases expression

ISO

resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases expression
multiple interactions

EXP

7-ketocholesterol results in increased expression of TP53 protein
Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

vascular cell adhesion molecule 1

increases expression

ISO

7-ketocholesterol results in increased expression of VCAM1 mRNA; 7-ketocholesterol results in increased expression of VCAM1 protein

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vascular endothelial growth factor A

increases expression
multiple interactions

ISO

7-ketocholesterol results in increased expression of VEGFA protein
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

7alpha-hydroxycholesterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase domain 17

decreases activity

EXP

cholest-5-en-3 beta,7 alpha-diol results in decreased activity of ADAM17 protein

NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639

G

amyloid beta precursor protein

increases chemical synthesis
decreases secretion

EXP

APP protein results in increased chemical synthesis of cholest-5-en-3 beta,7 alpha-diol
cholest-5-en-3 beta,7 alpha-diol results in decreased secretion of APP protein

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

caspase 3

multiple interactions
increases activity

ISO

alpha-Tocopherol inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased activity of CASP3 protein]; beta-Tocopherol affects the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased activity of CASP3 protein]

PMID:12450566 PMID:16934673

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

ISO

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

increases secretion
increases expression

ISO

cholest-5-en-3 beta,7 alpha-diol results in increased secretion of CCL3 protein
cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL3 mRNA

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

increases expression
increases secretion

ISO

cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL4 mRNA
cholest-5-en-3 beta,7 alpha-diol results in increased secretion of CCL4 protein

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

CD36 molecule

increases expression
multiple interactions

ISO

cholest-5-en-3 beta,7 alpha-diol results in increased expression of CD36 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cytochrome P450, family 46, subfamily a, polypeptide 1

increases hydroxylation

ISO

CYP46A1 protein results in increased hydroxylation of cholest-5-en-3 beta,7 alpha-diol

NCBI chr 6:127,247,543...127,274,765
Ensembl chr 6:127,243,315...127,274,760

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

EXP

[Uranyl Nitrate results in decreased activity of CYP7A1 protein] which results in decreased chemical synthesis of cholest-5-en-3 beta,7 alpha-diol

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity

EXP

cholest-5-en-3 beta,7 alpha-diol results in decreased activity of HMGCR protein

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

hydroxysteroid (17-beta) dehydrogenase 10

multiple interactions

ISO

[cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein

NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488

G

integrin subunit beta 1

increases expression
multiple interactions

ISO

cholest-5-en-3 beta,7 alpha-diol results in increased expression of ITGB1 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:56,705,171...56,753,195

G

lipoprotein lipase

decreases activity
decreases expression

ISO

cholest-5-en-3 beta,7 alpha-diol results in decreased activity of LPL protein
cholest-5-en-3 beta,7 alpha-diol results in decreased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

mitogen activated protein kinase 1

increases activity

ISO

cholest-5-en-3 beta,7 alpha-diol results in increased activity of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases activity

ISO

cholest-5-en-3 beta,7 alpha-diol results in increased activity of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

multiple interactions
increases expression

ISO

Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

prostaglandin E synthase

increases expression
multiple interactions

ISO

cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGES mRNA
Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGES mRNA]

NCBI chr 3:34,575,643...34,586,987

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

ISO

[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein
cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

toll-like receptor 4

increases expression
multiple interactions

ISO

cholest-5-en-3 beta,7 alpha-diol results in increased expression of TLR4 mRNA
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases chemical synthesis

ISO

Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

epoxide hydrolase 1

affects hydrolysis

ISO

EPHX1 protein affects the hydrolysis of 8,9-epoxyeicosatrienoic acid

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

epoxide hydrolase 2

increases abundance

ISO

EPHX2 gene mutant form results in increased abundance of 8,9-epoxyeicosatrienoic acid

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

9,10,13-TriHOME

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

epoxide hydrolase 3

multiple interactions

ISO

[EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] results in decreased abundance of [9,10,13-trihydroxy-11-octadecenoic acid binds to Ceramides]; [EPHX3 gene mutant form results in decreased hydrolysis of Epoxy Compounds] which results in decreased chemical synthesis of 9,10,13-trihydroxy-11-octadecenoic acid

NCBI chr 7:11,206,812...11,212,122
Ensembl chr 7:11,206,812...11,212,122

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions

EXP

arachidonyltrifluoromethane inhibits the reaction [AGT protein results in increased abundance of Epoprostenol]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]

NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827

G

interleukin 1 beta

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

insulin 1

multiple interactions

EXP

arachidonyltrifluoromethane inhibits the reaction [BL 11282 promotes the reaction [Glucose results in increased secretion of INS1 protein]]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

increases secretion
multiple interactions

ISO

arachidonyltrifluoromethane results in increased secretion of INS protein
arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

leptin

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

mitogen activated protein kinase 1

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

neuregulin 1

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

phospholipase A2 group 4A

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PLA2G4A protein]
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA]

PMID:18938131 PMID:19063610 PMID:19162293

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:61,877,813...62,022,266

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PTGS2 protein]; arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]]

PMID:18938131 PMID:19063610 PMID:19162293

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

S100 calcium binding protein A11

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Oxaliplatin]

NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044

G

suppressor of cytokine signaling 3

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA]

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

superoxide dismutase 2

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2]

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189

G

tumor necrosis factor

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular endothelial growth factor A

multiple interactions

ISO

arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]
arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]]

PMID:19063610 PMID:19162293

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases export

ISO

ABCB1 protein results in increased export of anandamide

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily G member 2

multiple interactions
decreases expression

ISO

8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]
anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein

PMID:30610963 PMID:34756920

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409

G

acyl-CoA oxidase 1

multiple interactions

ISO

anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ACOX1 mRNA]

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

1-acylglycerol-3-phosphate O-acyltransferase 2

multiple interactions

ISO

anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of AGPAT2 mRNA]

NCBI chr 3:29,814,924...29,826,569
Ensembl chr 3:9,416,843...9,428,371

G

amyloid beta precursor protein

decreases response to substance
decreases metabolic processing
decreases abundance

EXP
ISO

anandamide results in decreased susceptibility to APP protein
APP protein results in decreased metabolism of anandamide
APP protein results in decreased abundance of anandamide

PMID:22233683 PMID:26976670

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arrestin, beta 2

multiple interactions

ISO

anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

bradykinin receptor B1

multiple interactions
decreases activity

ISO

AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

caspase 3

increases cleavage
multiple interactions

ISO

anandamide results in increased cleavage of CASP3 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

CD36 molecule

increases expression

ISO

anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

glycoprotein hormones, alpha polypeptide

decreases expression

ISO

anandamide results in decreased expression of CGA mRNA

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

cannabinoid receptor 1

affects activity
increases response to substance
decreases expression
affects binding
increases activity
multiple interactions

ISO
EXP

anandamide affects the activity of CNR1 protein
CNR1 protein results in increased susceptibility to anandamide
anandamide results in decreased expression of CNR1 protein
anandamide binds to CNR1 protein
anandamide results in increased activity of CNR1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1]
[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of anandamide; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]

PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 More...

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor 2

affects activity
affects binding
multiple interactions

ISO
EXP

anandamide affects the activity of CNR2 protein
anandamide binds to CNR2 protein
anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]

PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 PMID:30102254

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

cAMP responsive element binding protein 1

multiple interactions
decreases phosphorylation

ISO

anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]
anandamide results in decreased phosphorylation of CREB1 protein

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816

G

corticotropin releasing hormone

decreases abundance

ISO

CRH protein results in decreased abundance of anandamide

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

cytochrome P450, family 2, subfamily j, polypeptide 4

multiple interactions
increases metabolic processing

ISO

cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

DNA-damage inducible transcript 3

increases expression
multiple interactions

ISO

anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein
4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]

PMID:21949157 PMID:26513129 PMID:29441458

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation
multiple interactions

ISO

anandamide results in increased phosphorylation of EIF2S1 protein
4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

endogenous retrovirus group FRD member 1, envelope

decreases expression

ISO

anandamide results in decreased expression of ERVFRD-1 mRNA

NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264

G

coagulation factor III, tissue factor

multiple interactions
increases expression

ISO

anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]
anandamide results in increased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid amide hydrolase

increases degradation
increases response to substance
decreases metabolic processing
multiple interactions
affects expression

ISO
EXP

FAAH results in increased degradation of anandamide
FAAH gene mutant form results in increased susceptibility to anandamide
FAAH gene mutant form results in decreased metabolism of anandamide
FAAH protein results in increased degradation of anandamide
[Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; FAAH protein results in increased metabolism of and results in decreased activity of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]; Silybin inhibits the reaction [FAAH protein results in increased metabolism of and results in decreased activity of anandamide]
anandamide affects the expression of FAAH protein
[cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide]

PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 More...

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

fatty acid binding protein 1

multiple interactions
affects abundance
affects binding

EXP
ISO

11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein]
FABP1 protein affects the abundance of anandamide
FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]

PMID:29414765 PMID:30232874

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

EXP

anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein]
anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein

PMID:9748483 PMID:15601931 PMID:19515121

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

interferon gamma

multiple interactions

ISO

anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

increases expression

ISO

anandamide results in increased expression of IGF1 protein

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 12B

multiple interactions

ISO

[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 1 beta

multiple interactions

ISO

anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]
anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]

PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

ISO

anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

leptin

decreases abundance
multiple interactions
decreases activity
decreases transport

ISO

LEP protein results in decreased abundance of anandamide
Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide]
LEP protein results in decreased activity of anandamide
LEP protein results in decreased transport of anandamide

PMID:16154199 PMID:29967158

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

mitogen activated protein kinase kinase 1

multiple interactions

EXP

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

multiple interactions

EXP

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

ISO
EXP

anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
anandamide results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12657697 PMID:19477951 PMID:21179406

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

ISO
EXP

anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
anandamide results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12657697 PMID:19477951 PMID:21179406

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 1

increases expression

ISO

anandamide results in increased expression of MMP1 mRNA

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 3

increases expression

ISO

anandamide results in increased expression of MMP3 mRNA

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

multiple interactions
increases expression

ISO

N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nitric oxide synthase 2

multiple interactions

ISO

anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

PMID:11891798 PMID:15748152

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

poly (ADP-ribose) polymerase 1

increases cleavage

ISO

anandamide results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

anandamide binds to and results in increased activity of PPARA protein

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression
increases metabolic processing

EXP
ISO

[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide
anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein
PTGS2 results in increased metabolism of anandamide
[nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]

PMID:16330497 PMID:17245358 PMID:20702753

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

selectin P

multiple interactions
increases expression

ISO

anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein]
anandamide results in increased expression of SELP protein

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

TIMP metallopeptidase inhibitor 1

increases expression
multiple interactions

ISO

anandamide results in increased expression of TIMP1 mRNA
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions
increases abundance

EXP
ISO

anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]
TNF protein results in increased abundance of anandamide
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]

PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions
increases response to substance
increases activity
affects response to substance
affects binding

ISO
EXP

3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]
TRPV1 protein results in increased susceptibility to anandamide
anandamide results in increased activity of TRPV1 protein
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein]
anandamide binds to TRPV1 protein

PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 More...

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

vascular endothelial growth factor A

multiple interactions

ISO

anandamide results in decreased expression of and results in decreased secretion of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

arachidonic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases degradation

ISO

Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]
Arachidonic Acid results in increased degradation of ABCA1 protein

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions

ISO

Arachidonic Acid promotes the reaction [GW 4064 results in increased expression of ABCB11 mRNA]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily D member 3

decreases expression

ISO

Arachidonic Acid results in decreased expression of ABCD3 mRNA

NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020

G

ATP binding cassette subfamily G member 1

decreases expression

ISO

Arachidonic Acid results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

adenosine deaminase, RNA-specific, B1

decreases expression

ISO

Arachidonic Acid results in decreased expression of ADARB1 mRNA

NCBI chr20:11,222,569...11,350,854
Ensembl chr20:11,222,583...11,350,852

G

angiotensinogen

multiple interactions

ISO

Eicosapentaenoic Acid inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid]; Quinacrine inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aryl hydrocarbon receptor

multiple interactions

ISO

AHR affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [PLA2G4A protein results in increased secretion of Arachidonic Acid]]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

ISO

Arachidonic Acid results in increased phosphorylation of AKT1 protein
aristolochic acid I inhibits the reaction [Arachidonic Acid results in increased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

arachidonate 12-lipoxygenase, 12S type

affects response to substance
increases metabolic processing

ISO

ALOX12 protein affects the susceptibility to Arachidonic Acid
ALOX12 protein results in increased metabolism of Arachidonic Acid

PMID:17027136 PMID:19373248

NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

ISO

[TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid

NCBI chr10:53,863,060...53,874,938
Ensembl chr10:53,863,060...53,874,938

G

arachidonate 15-lipoxygenase

affects metabolic processing
multiple interactions
increases metabolic processing

ISO

ALOX15 protein affects the metabolism of Arachidonic Acid
[ALOX15 protein affects the metabolism of Arachidonic Acid] which affects the susceptibility to Acetylcholine; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,12,15-trihydroxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,14,15-trihydroxyeicosa-5,8,12-trienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-11,12-epoxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of Dinoprostone; ALOX15 protein results in increased metabolism of and affects the susceptibility to Arachidonic Acid
ALOX15 protein results in increased metabolism of Arachidonic Acid
[IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA

PMID:8305483 PMID:11861792 PMID:21193584 PMID:23872364

NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874

G

arachidonate 5-lipoxygenase

multiple interactions
increases metabolic processing

ISO

[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [Sorbitol co-treated with Calcimycin co-treated with Arachidonic Acid] affects the localization of ALOX5 protein; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which affects the abundance of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which results in decreased susceptibility to Arachidonic Acid; Arachidonic Acid inhibits the reaction [L 708714 binds to ALOX5 protein]; CJ 13610 inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]; zileuton inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]

PMID:7577949 PMID:7592874 PMID:9495842 PMID:10779545 PMID:11698504 More...

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

apolipoprotein A1

multiple interactions
decreases expression

ISO

Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]
Arachidonic Acid results in decreased expression of APOA1 mRNA

PMID:7983038 PMID:16118212

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein C1

decreases expression

ISO

Arachidonic Acid results in decreased expression of APOC1 mRNA

NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375

G

apolipoprotein E

multiple interactions
decreases response to substance

ISO

APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]
Aspirin inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; tempol inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

increases secretion
multiple interactions

ISO

APP protein modified form results in increased secretion of Arachidonic Acid
[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 3 (Gill blood group)

decreases expression

ISO

Arachidonic Acid results in decreased expression of AQP3 mRNA

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

Rho GDP dissociation inhibitor alpha

increases expression

ISO

Arachidonic Acid results in increased expression of ARHGDIA mRNA

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023

G

activating transcription factor 1

multiple interactions

ISO

Arachidonic Acid inhibits the reaction [Quercetin results in increased phosphorylation of ATF1 protein]

NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670

G

activating transcription factor 2

multiple interactions
increases phosphorylation

ISO

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of ATF2 protein]

NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:58,718,332...58,795,236

G

activating transcription factor 3

increases expression

ISO

Arachidonic Acid results in increased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:102,751,321...102,764,631

G

arginine vasopressin

increases abundance

EXP

AVP protein results in increased abundance of Arachidonic Acid

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

BCL2-associated agonist of cell death

multiple interactions

ISO

[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein]

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BARX homeobox 1

decreases expression

ISO

Arachidonic Acid results in decreased expression of BARX1 mRNA

NCBI chr17:15,990,412...15,993,887
Ensembl chr17:15,990,412...15,993,887

G

BCL2 associated X, apoptosis regulator

multiple interactions
affects localization

ISO

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]

PMID:19540902 PMID:19720122 PMID:30626086

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

ISO

Arachidonic Acid results in decreased expression of BCL2 protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein]

PMID:19540902 PMID:19620254 PMID:19720122

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions
decreases expression

ISO

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]

PMID:19540902 PMID:19620254 PMID:19720122 PMID:27916511 PMID:30626086

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

brain-derived neurotrophic factor

decreases expression

ISO

Arachidonic Acid results in decreased expression of BDNF mRNA

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

BH3 interacting domain death agonist

increases cleavage
multiple interactions

ISO

Arachidonic Acid results in increased cleavage of BID protein
FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein]

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

caspase 3

increases activity
multiple interactions
increases degradation

ISO

Arachidonic Acid results in increased activity of CASP3 protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased degradation of CASP3 protein alternative form]; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein]

PMID:16704987 PMID:19540902 PMID:19620254 PMID:19720122 PMID:23266427 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases activity

ISO

FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP8 protein]

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity

ISO

Arachidonic Acid results in increased activity of CASP9 protein

PMID:19540902 PMID:19720122

Ensembl chr 5:154,109,046...154,126,626

G

catalase

increases activity

EXP

Arachidonic Acid results in increased activity of CAT protein

PMID:7548195 PMID:16982041

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

CD40 molecule

multiple interactions

ISO

Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:153,790,449...153,805,534

G

carboxylesterase 1D

decreases activity
multiple interactions

ISO
EXP

Arachidonic Acid results in decreased activity of CES1 protein
[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]; gallocatechol inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]
[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]

PMID:19761868 PMID:21049984 PMID:37353134

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

carboxylesterase 2H

multiple interactions

ISO

[CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

cannabinoid receptor 2

multiple interactions

ISO

CNR2 protein affects the reaction [Arachidonic Acid results in increased expression of CXCL8 protein]

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

collagen type XVIII alpha 1 chain

decreases expression

ISO

Arachidonic Acid results in decreased expression of COL18A1 mRNA

NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593

G

carnitine palmitoyltransferase 1A

increases expression

ISO

Arachidonic Acid results in increased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element binding protein 1

increases phosphorylation
multiple interactions

EXP

Arachidonic Acid results in increased phosphorylation of CREB1 protein
Ketoconazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of CREB1 protein]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816

G

C-terminal Src kinase

increases activity
affects localization

ISO

Arachidonic Acid results in increased activity of CSK protein
Arachidonic Acid affects the localization of CSK protein

NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292

G

CTD small phosphatase like

decreases expression

ISO

Arachidonic Acid results in decreased expression of CTDSPL mRNA

NCBI chr 8:118,642,729...118,767,238
Ensembl chr 8:118,642,672...118,767,117

G

cytochrome c, somatic

affects localization

ISO

Arachidonic Acid affects the localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytoglobin

multiple interactions

EXP

CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]

NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442

G

cytochrome P450, family 1, subfamily a, polypeptide 1

affects metabolic processing
multiple interactions

ISO

CYP1A1 protein affects the metabolism of Arachidonic Acid
Arachidonic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

PMID:15258110 PMID:19063610

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases metabolic processing
decreases activity

ISO

CYP1A2 protein results in increased metabolism of Arachidonic Acid
Arachidonic Acid results in decreased activity of CYP1A2 protein

PMID:12675279 PMID:16978661

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

affects metabolic processing

ISO

CYP1B1 protein affects the metabolism of Arachidonic Acid

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 24, subfamily a, polypeptide 1

decreases expression

ISO

Arachidonic Acid results in decreased expression of CYP24A1 mRNA

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases metabolic processing

ISO

CYP2B6 protein results in increased metabolism of Arachidonic Acid

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity
increases metabolic processing
multiple interactions

ISO

Arachidonic Acid results in decreased activity of CYP2C19 protein
CYP2C19 protein results in increased metabolism of Arachidonic Acid
CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]

PMID:12675279 PMID:16978661 PMID:18004210

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 79

increases metabolic processing

ISO

CYP2C8 protein results in increased metabolism of Arachidonic Acid

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases metabolic processing

ISO

CYP2D6 protein results in increased metabolism of Arachidonic Acid

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
affects hydroxylation
increases response to substance
decreases activity

ISO
EXP

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; Cadmium Chloride affects the reaction [CYP2E1 protein results in increased susceptibility to Arachidonic Acid]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; CYP2E1 results in increased susceptibility to [Arachidonic Acid co-treated with Zinc Sulfate]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Arachidonic Acid]
CYP2E1 protein affects the hydroxylation of Arachidonic Acid
Arachidonic Acid results in decreased activity of CYP2E1 protein

PMID:12086689 PMID:12566070 PMID:15205388 PMID:16978661 PMID:17034788 More...

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily j, polypeptide 4

multiple interactions

ISO

Arachidonic Acid inhibits the reaction [CYP2J2 protein results in decreased methylation of Astemizole]

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases metabolic processing
decreases activity

ISO

Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Arachidonic Acid]
Arachidonic Acid results in decreased activity of CYP3A4 protein

PMID:12675279 PMID:16978661

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 4, subfamily f, polypeptide 18

multiple interactions
increases hydroxylation

ISO

rubiarbonone C inhibits the reaction [CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid]

NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940

G

dopachrome tautomerase

decreases expression

ISO

Arachidonic Acid results in decreased expression of DCT mRNA

NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836

G

DNA-damage-inducible transcript 4

increases expression

ISO

Arachidonic Acid results in increased expression of DDIT4 mRNA

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

DEAD-box helicase 24

decreases expression

ISO

Arachidonic Acid results in decreased expression of DDX24 mRNA

NCBI chr 6:122,564,767...122,582,032
Ensembl chr 6:122,564,767...122,581,927

G

desmin

increases expression

EXP

Arachidonic Acid results in increased expression of DES mRNA

NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699

G

7-dehydrocholesterol reductase

decreases expression

ISO

Arachidonic Acid results in decreased expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

EBP, cholestenol delta-isomerase

decreases expression

ISO

Arachidonic Acid results in decreased expression of EBP mRNA

NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826

G

epidermal growth factor receptor

multiple interactions

EXP

5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [Arachidonic Acid results in increased phosphorylation of and results in increased activity of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

increases expression

ISO

Arachidonic Acid results in increased expression of EGR1 mRNA

PMID:8764118 PMID:16704987

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766

G

eukaryotic translation initiation factor 4E binding protein 3

multiple interactions

ISO

Arachidonic Acid promotes the reaction [Quercetin results in decreased phosphorylation of EIF4EBP3 protein]

NCBI chr18:28,263,089...28,268,033
Ensembl chr18:28,162,311...28,268,024

G

epoxide hydrolase 2

increases metabolic processing

ISO

EPHX2 protein results in increased metabolism of Arachidonic Acid

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

ergosterol biosynthesis 28 homolog

decreases expression

ISO

Arachidonic Acid results in decreased expression of ERG28 mRNA

NCBI chr 6:105,474,112...105,483,078
Ensembl chr 6:105,474,113...105,483,078

G

coagulation factor III, tissue factor

increases expression

ISO

Arachidonic Acid results in increased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fatty acid amide hydrolase

multiple interactions
increases chemical synthesis

EXP

Nitroglycerin promotes the reaction [FAAH protein results in increased chemical synthesis of Arachidonic Acid]

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

Fas associated via death domain

multiple interactions

ISO

FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP8 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein]

NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653

G

fatty acid desaturase 1

multiple interactions

ISO

[geraniol results in decreased activity of FADS1 protein] which results in decreased chemical synthesis of Arachidonic Acid

NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734

G

fatty acid desaturase 2

decreases expression

ISO

Arachidonic Acid results in decreased expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

Fas cell surface death receptor

multiple interactions
increases expression

ISO

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]
Arachidonic Acid results in increased expression of FAS mRNA; Arachidonic Acid results in increased expression of FAS protein

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions
increases expression

ISO

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]
Arachidonic Acid results in increased expression of FASLG mRNA; Arachidonic Acid results in increased expression of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

decreases expression

ISO

Arachidonic Acid results in decreased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor receptor 3

decreases expression

ISO

Arachidonic Acid results in decreased expression of FGFR3 mRNA

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression
decreases phosphorylation

ISO

[Arachidonic Acid co-treated with Quercetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of FOS protein; Arachidonic Acid inhibits the reaction [Quercetin results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]
Arachidonic Acid results in decreased phosphorylation of FOS protein

PMID:8764118 PMID:10864209 PMID:15878913 PMID:16704987 PMID:19720122 More...

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

increases expression

ISO

Arachidonic Acid results in increased expression of FOSL1 mRNA

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

growth associated protein 43

increases phosphorylation

ISO

Arachidonic Acid results in increased phosphorylation of GAP43 protein

NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045

G

glutamate-cysteine ligase, catalytic subunit

increases expression
increases activity

ISO

Arachidonic Acid results in increased expression of GCLC mRNA
Arachidonic Acid results in increased activity of GCLC protein

PMID:16704987 PMID:17092368

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression

ISO
EXP

Arachidonic Acid results in increased expression of GCLM mRNA
Arachidonic Acid metabolite results in increased expression of GCLM mRNA

PMID:16704987 PMID:27012417

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glutaredoxin

affects response to substance

ISO

GLRX protein affects the susceptibility to Arachidonic Acid

NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680

G

glucosamine-6-phosphate deaminase 1

decreases expression

ISO

Arachidonic Acid results in decreased expression of GNPDA1 mRNA

NCBI chr18:30,165,435...30,177,462
Ensembl chr18:30,165,427...30,177,486

G

glutamic--pyruvic transaminase

multiple interactions

ISO

Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

ISO

[Iodoacetates results in decreased activity of GPX1 protein] which affects the metabolism of Arachidonic Acid

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 4

multiple interactions

ISO

[Iodoacetates results in decreased activity of GPX4 protein] which affects the metabolism of Arachidonic Acid; Arachidonic Acid promotes the reaction [Sodium Selenite results in increased expression of and results in increased activity of GPX4 protein]

PMID:11115402 PMID:14642406

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glycogen synthase kinase 3 beta

multiple interactions

ISO

[SB 216763 results in decreased activity of GSK3B protein] results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases expression

ISO

Arachidonic Acid results in decreased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

heme oxygenase 1

increases expression
multiple interactions
decreases response to substance

ISO
EXP

Arachidonic Acid results in increased expression of HMOX1 mRNA
Arachidonic Acid metabolite results in increased expression of HMOX1 mRNA; Arachidonic Acid metabolite results in increased expression of HMOX1 protein
NFE2L2 gene mutant form inhibits the reaction [Arachidonic Acid metabolite results in increased expression of HMOX1 protein]
HMOX1 protein results in decreased susceptibility to Arachidonic Acid

PMID:15036350 PMID:16704987 PMID:17092368 PMID:27012417

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heparan sulfate 2-O-sulfotransferase 1

decreases expression

ISO

Arachidonic Acid results in decreased expression of HS2ST1 mRNA

NCBI chr 2:233,508,018...233,641,769
Ensembl chr 2:233,508,021...233,641,769

G

heat shock protein 90 alpha family class B member 1

decreases expression

ISO

Arachidonic Acid results in decreased expression of HSP90AB1 mRNA

NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488

G

5-hydroxytryptamine receptor 1A

multiple interactions

ISO

Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

inhibitor of DNA binding 3

decreases expression

ISO

Arachidonic Acid results in decreased expression of ID3 mRNA

NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:148,372,762...148,374,349

G

isopentenyl-diphosphate delta isomerase 1

decreases expression

ISO

Arachidonic Acid results in decreased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

intraflagellar transport 25

decreases expression

ISO

Arachidonic Acid results in decreased expression of IFT25 mRNA

NCBI chr 5:122,035,588...122,062,421
Ensembl chr 5:122,035,581...122,062,421

G

insulin-like growth factor binding protein 7

decreases expression

ISO

Arachidonic Acid results in decreased expression of IGFBP7 mRNA

NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314

G

interleukin 12B

multiple interactions

ISO

Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 1 alpha

multiple interactions

ISO

[IL1A protein co-treated with Arachidonic Acid] results in increased abundance of Dinoprostone

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions

ISO

[Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

multiple interactions

ISO

[IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

increases secretion

ISO

Arachidonic Acid results in increased secretion of IL6 protein

PMID:20436887 PMID:21457203

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

ilvB acetolactate synthase like

decreases expression

ISO

Arachidonic Acid results in decreased expression of ILVBL mRNA

NCBI chr 7:11,039,870...11,049,924
Ensembl chr 7:11,039,871...11,049,924

G

insulin 2

increases secretion
multiple interactions

ISO

Arachidonic Acid results in increased secretion of INS protein
Arachidonic Acid promotes the reaction [Glucose results in increased secretion of INS protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]; phenidone promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

ISL LIM homeobox 1

decreases expression

ISO

Arachidonic Acid results in decreased expression of ISL1 mRNA

NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584

G

integrin subunit alpha 2b

increases expression
multiple interactions

ISO

Arachidonic Acid results in increased expression of ITGA2B protein
Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]]

NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168

G

integrin subunit alpha 6

increases expression

ISO

Arachidonic Acid results in increased expression of ITGA6 mRNA

NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428

G

integrin subunit beta 3

multiple interactions
increases expression

ISO

Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]

PMID:18413191 PMID:23249183

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

ISO

Arachidonic Acid results in increased expression of JUN mRNA
Arachidonic Acid results in increased expression of and results in increased phosphorylation of JUN protein; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein]

PMID:8764118 PMID:16704987 PMID:19720122

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

ISO

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Arachidonic Acid analog results in increased expression of JUNB mRNA]
Arachidonic Acid results in increased expression of JUNB mRNA

NCBI chr19:40,081,126...40,082,910
Ensembl chr19:23,176,294...23,178,035

G

potassium two pore domain channel subfamily K member 10

multiple interactions

ISO

Arachidonic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]

NCBI chr 6:117,690,052...117,826,120
Ensembl chr 6:117,694,222...117,825,695

G

potassium two pore domain channel subfamily K member 2

multiple interactions

ISO

Arachidonic Acid promotes the reaction [KCNK2 protein results in increased transport of Potassium]

NCBI chr13:100,766,101...100,963,435
Ensembl chr13:100,766,113...100,963,435

G

potassium two pore domain channel subfamily K member 4

multiple interactions

ISO

Arachidonic Acid promotes the reaction [KCNK4 protein results in increased transport of Potassium]

PMID:10767409 PMID:16075240

NCBI chr 1:204,117,941...204,129,494
Ensembl chr 1:204,114,572...204,125,925

G

KLF transcription factor 5

increases expression

ISO

Arachidonic Acid results in increased expression of KLF5 mRNA

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

KLF transcription factor 6

increases expression
multiple interactions

ISO

Arachidonic Acid results in increased expression of KLF6 mRNA; Arachidonic Acid results in increased expression of KLF6 mRNA alternative form; Arachidonic Acid results in increased expression of KLF6 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [Arachidonic Acid co-treated with Hydrogen Peroxide] results in increased expression of KLF6 protein; [Arachidonic Acid co-treated with SB 203580] results in decreased expression of KLF6 mRNA; [Arachidonic Acid co-treated with Vitamin K 3] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid inhibits the reaction [pyrazolanthrone results in decreased expression of KLF6 mRNA]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

kininogen 1

multiple interactions

ISO

Arachidonic Acid inhibits the reaction [GW 4064 results in increased expression of KNG1 mRNA]

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

keratin 18

multiple interactions

ISO

[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein

NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
Ensembl chr10:133,157,475...133,161,166

G

keratin 8

multiple interactions

ISO

[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein

NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728

G

lysosomal-associated membrane protein 2

decreases expression

ISO

Arachidonic Acid results in decreased expression of LAMP2 mRNA

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

low density lipoprotein receptor

multiple interactions
decreases response to substance

ISO

Aspirin inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; tempol inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]
LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid
Aspirin inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

leptin

multiple interactions

ISO

Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipase C, hepatic type

decreases abundance
multiple interactions

ISO

LIPC gene mutant form results in decreased abundance of Arachidonic Acid
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

decreases abundance
multiple interactions

ISO

LIPG gene mutant form results in decreased abundance of Arachidonic Acid
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

G

lecithin retinol acyltransferase

increases expression

EXP

Arachidonic Acid results in increased expression of LRAT mRNA

NCBI chr 2:170,562,148...170,571,212
Ensembl chr 2:168,266,877...168,273,619

G

lanosterol synthase

decreases expression

ISO

Arachidonic Acid results in decreased expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

leukotriene B4 receptor

affects response to substance

ISO

LTB4R1 protein affects the susceptibility to Arachidonic Acid

NCBI chr15:29,263,199...29,265,716

G

LUC7-like 3 pre-mRNA splicing factor

decreases expression

ISO

Arachidonic Acid results in decreased expression of LUC7L3 mRNA

NCBI chr10:79,240,050...79,276,555
Ensembl chr10:79,240,563...79,276,538

G

MAF bZIP transcription factor F

increases expression

ISO

Arachidonic Acid results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

mitogen activated protein kinase kinase 1

multiple interactions

ISO

FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase 1

increases phosphorylation
affects abundance
multiple interactions

ISO
EXP

Arachidonic Acid results in increased phosphorylation of MAPK1 protein
MAPK1 protein affects the abundance of Arachidonic Acid
[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK1 protein]

PMID:16216387 PMID:19464254

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions

ISO
EXP

MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]
MAPK14 protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid]

PMID:16120751 PMID:19540902

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
affects abundance
increases phosphorylation

ISO
EXP

[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK3 protein]
MAPK3 protein affects the abundance of Arachidonic Acid

PMID:16216387 PMID:19464254

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

ISO

MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981

G

microtubule-associated protein tau

increases phosphorylation
multiple interactions

ISO

Arachidonic Acid results in increased phosphorylation of MAPT protein
Ro 31-8220 inhibits the reaction [Arachidonic Acid results in increased phosphorylation of MAPT protein]

NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129

G

matrix metallopeptidase 13

increases secretion
multiple interactions
increases expression

ISO

Arachidonic Acid results in increased secretion of MMP13 protein
Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP13 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP13 protein]

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 2

multiple interactions
increases expression
increases secretion

ISO

Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP2 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases expression
multiple interactions
increases secretion

ISO

Arachidonic Acid results in increased expression of MMP9 mRNA
Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP9 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP9 protein]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

increases secretion
multiple interactions
increases expression

ISO

Arachidonic Acid results in increased secretion of MPO protein
5-((1,5-bis(4-methoxyphenyl)pyrazol-3-yl)dimethoxymethyl)-2-chlorobenzamide inhibits the reaction [Arachidonic Acid results in increased expression of MPO protein]

PMID:3111576 PMID:9831321

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

metallothionein 2

multiple interactions

ISO

Arachidonic Acid promotes the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

mechanistic target of rapamycin kinase

multiple interactions

ISO

[Quercetin co-treated with Arachidonic Acid] results in decreased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

neutrophil cytosolic factor 1

multiple interactions
increases localization

ISO

Adiponectin inhibits the reaction [Arachidonic Acid results in increased localization of NCF1 protein]; Arachidonic Acid affects the reaction [Zymosan analog affects the localization of NCF1 protein]

PMID:12101222 PMID:20832062

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

neutrophil cytosolic factor 2

multiple interactions

ISO

Arachidonic Acid affects the reaction [Zymosan analog affects the localization of NCF2 protein]

NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases expression

EXP

NFE2L2 gene mutant form inhibits the reaction [Arachidonic Acid metabolite results in increased expression of HMOX1 protein]
Arachidonic Acid metabolite results in increased expression of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nerve growth factor

multiple interactions

EXP

NGF protein inhibits the reaction [Arachidonic Acid results in increased expression of TFRC protein]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

NADPH oxidase 1

multiple interactions

ISO

Arachidonic Acid results in increased cleavage of and results in increased secretion of NOX1 protein; Cholesterol, LDL affects the reaction [Adiponectin inhibits the reaction [Arachidonic Acid results in increased cleavage of NOX1 protein]]

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

G

NAD(P)H quinone dehydrogenase 1

increases expression

EXP

Arachidonic Acid metabolite results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group H, member 4

affects binding
multiple interactions

ISO

Arachidonic Acid binds to NR1H4 protein
Arachidonic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 2, group F, member 1

decreases expression

ISO

Arachidonic Acid results in decreased expression of NR2F1 mRNA

NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123

G

nuclear receptor subfamily 4, group A, member 2

decreases expression

ISO

Arachidonic Acid results in decreased expression of NR4A2 mRNA

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions
decreases chemical synthesis

ISO

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in decreased abundance of Arachidonic Acid analog
NR5A2 gene mutant form results in decreased chemical synthesis of Arachidonic Acid

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

neurturin

decreases expression

ISO

Arachidonic Acid results in decreased expression of NRTN mRNA

NCBI chr 9:1,581,860...1,587,835
Ensembl chr 9:1,581,975...1,583,102

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

ISO

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased cleavage of PARP1 protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form]

PMID:10403056 PMID:19540902 PMID:21132278 PMID:30626086

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

phosphodiesterase 4D interacting protein

decreases expression

ISO

Arachidonic Acid results in decreased expression of PDE4DIP mRNA

NCBI chr 2:185,293,236...185,490,100
Ensembl chr 2:185,293,214...185,468,379

G

decaprenyl diphosphate synthase subunit 2

decreases expression

ISO

Arachidonic Acid results in decreased expression of PDSS2 mRNA

NCBI chr20:46,709,631...46,938,704
Ensembl chr20:46,709,649...46,938,708

G

pleckstrin homology-like domain, family A, member 1

increases expression

ISO

Arachidonic Acid results in increased expression of PHLDA1 mRNA

NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861

G

phospholipase A2 group 4A

multiple interactions
increases expression

ISO
EXP

AHR affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [PLA2G4A protein results in increased secretion of Arachidonic Acid]]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA]
PLA2G4A protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid]
Arachidonic Acid results in increased expression of PLA2G4A mRNA; Arachidonic Acid results in increased expression of PLA2G4A protein

PMID:15878913 PMID:16120751 PMID:19162293

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:61,877,813...62,022,266

G

phospholipase A2, group V

multiple interactions

ISO

PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Arachidonic Acid]

NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658

G

phospholipase A2 group VI

multiple interactions

EXP

PLA2G6 protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid]

NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114

G

phospholipase A2, activating protein

multiple interactions

ISO

PLAA protein promotes the reaction [Lipopolysaccharides results in increased abundance of Arachidonic Acid]

NCBI chr 5:109,428,600...109,460,373
Ensembl chr 5:109,428,265...109,460,282

G

perilipin 2

increases expression

ISO
EXP

Arachidonic Acid results in increased expression of PLIN2 mRNA
Arachidonic Acid results in increased expression of PLIN2 mRNA; Arachidonic Acid results in increased expression of PLIN2 protein

NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression

ISO

Arachidonic Acid results in increased expression of PMAIP1 mRNA

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

paraoxonase 1

multiple interactions
decreases activity

ISO

Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid]
Arachidonic Acid results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

increases expression
multiple interactions

ISO

Arachidonic Acid results in increased expression of PPARA mRNA; Arachidonic Acid results in increased expression of PPARA protein
Arachidonic Acid binds to and results in increased activity of PPARA protein

PMID:10403814 PMID:11172467 PMID:15491415

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor delta

increases expression

ISO

Arachidonic Acid results in increased expression of PPARD mRNA

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

peroxisome proliferator-activated receptor gamma

decreases expression
increases expression
multiple interactions

ISO
EXP

Arachidonic Acid results in decreased expression of PPARG mRNA; Arachidonic Acid results in decreased expression of PPARG protein
Arachidonic Acid results in increased expression of PPARG protein
Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA]

PMID:11172467 PMID:12604186 PMID:19063610

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1 catalytic subunit alpha

decreases expression

ISO

Arachidonic Acid results in decreased expression of PPP1CA mRNA

NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327

G

pre-mRNA splicing tri-snRNP complex factor PRPF4

decreases expression

ISO

Arachidonic Acid results in decreased expression of PRPF4 mRNA

NCBI chr 5:75,859,934...75,873,924
Ensembl chr 5:75,859,924...75,873,919

G

phosphoserine aminotransferase 1

increases expression

ISO

Arachidonic Acid results in increased expression of PSAT1 mRNA

NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682

G

platelet-activating factor receptor

multiple interactions

EXP

[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of PTAFR mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of PTAFR mRNA]

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 1

increases activity
increases response to substance
increases metabolic processing
multiple interactions

ISO

Arachidonic Acid results in increased activity of PTGS1 protein
PTGS1 results in increased susceptibility to Arachidonic Acid
PTGS1 protein alternative form results in increased metabolism of Arachidonic Acid; PTGS1 protein results in increased metabolism of Arachidonic Acid
[[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid]; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; DuP 697 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; Resveratrol inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; SC 560 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; valerylsalicylate inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]

PMID:15863457 PMID:16141368 PMID:19751497 PMID:20933508 PMID:21163909

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression
increases metabolic processing
increases response to substance
increases activity

ISO
EXP

[[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine; [lenabasum results in increased expression of PTGS2 mRNA] which results in increased secretion of Arachidonic Acid; [PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA; Arachidonic Acid inhibits the reaction [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone binds to and results in decreased activity of PTGS2 protein]; Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS2 protein]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; nimesulide inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]
Arachidonic Acid results in increased expression of PTGS2 protein
PTGS2 results in increased susceptibility to Arachidonic Acid
12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 2-methoxybenzoic acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid; [nimesulide results in decreased expression of PTGS2] which results in increased abundance of Arachidonic Acid; [PTGS2 protein results in increased abundance of prostaglandin G2] inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; Arachidonic Acid affects the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; Benzoic Acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; Eugenol inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid]; Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]
Arachidonic Acid results in increased expression of PTGS2 mRNA; Arachidonic Acid results in increased expression of PTGS2 protein

PMID:9013627 PMID:9146894 PMID:11112151 PMID:12538810 PMID:12757841 More...

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine phosphatase 4A1

increases expression

ISO

Arachidonic Acid results in increased expression of PTP4A1 mRNA

NCBI chr 9:33,214,201...33,245,046
Ensembl chr 9:33,214,208...33,221,964

G

Rap guanine nucleotide exchange factor 2

increases expression

ISO

Arachidonic Acid results in increased expression of RAPGEF2 mRNA

NCBI chr 2:164,207,513...164,322,157
Ensembl chr 2:164,207,513...164,244,247

G

resistin

decreases expression

ISO

Arachidonic Acid results in decreased expression of RETN mRNA

NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620

G

ribosomal protein S6 kinase B1

multiple interactions

ISO

Arachidonic Acid promotes the reaction [Quercetin results in decreased phosphorylation of RPS6KB1 protein]

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908

G

retinoid X receptor alpha

affects binding

ISO

Arachidonic Acid binds to RXRA protein

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

stearoyl-CoA desaturase

increases expression

ISO

Arachidonic Acid results in increased expression of SCD mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

selectin P

increases expression
multiple interactions

ISO

Arachidonic Acid results in increased expression of SELP protein
Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]

PMID:17543677 PMID:18413191 PMID:23249183

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

serpin family B member 2

increases expression

ISO

Arachidonic Acid results in increased expression of SERPINB2 mRNA

NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408

G

S-phase kinase associated protein 2

decreases expression

ISO

Arachidonic Acid results in decreased expression of SKP2 mRNA

NCBI chr 2:59,888,406...59,916,471
Ensembl chr 2:58,161,229...58,189,338

G

solute carrier family 4 member 2

increases expression

ISO

Arachidonic Acid results in increased expression of SLC4A2 mRNA

NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965

G

solute carrier family 7 member 11

increases expression

ISO

Arachidonic Acid results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

snail family transcriptional repressor 2

increases expression

ISO

Arachidonic Acid results in increased expression of SNAI2 mRNA

NCBI chr11:99,686,934...99,690,349
Ensembl chr11:86,181,909...86,186,200

G

suppressor of cytokine signaling 3

multiple interactions

ISO

Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA]

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

superoxide dismutase 1

decreases activity
increases activity
multiple interactions

EXP

Arachidonic Acid results in decreased activity of SOD1 protein
Arachidonic Acid results in increased activity of SOD1 protein
2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
increases activity
increases expression

ISO
EXP

[Arachidonic Acid results in increased abundance of Reactive Oxygen Species] which results in increased expression of SOD2; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Arachidonic Acid results in increased expression of and results in increased activity of SOD2 protein; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Dactinomycin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Phenols inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]
Arachidonic Acid results in increased activity of SOD2 protein
2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein]

PMID:12031898 PMID:16982041

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189

G

SRY-box transcription factor 9

decreases expression

ISO

Arachidonic Acid results in decreased expression of SOX9 mRNA

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

secreted protein acidic and cysteine rich

decreases expression

ISO

Arachidonic Acid results in decreased expression of SPARC mRNA

NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396

G

spastin

decreases expression

ISO

Arachidonic Acid results in decreased expression of SPAST mRNA

NCBI chr 6:21,055,349...21,106,586
Ensembl chr 6:21,055,349...21,107,954

G

sequestosome 1

increases expression

ISO

Arachidonic Acid results in increased expression of SQSTM1 mRNA

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

SLIT-ROBO Rho GTPase activating protein 2

decreases expression

ISO

Arachidonic Acid results in decreased expression of SRGAP2 mRNA

NCBI chr13:42,745,956...42,967,091
Ensembl chr13:42,745,947...42,967,058

G

sulfiredoxin 1

increases expression

EXP

Arachidonic Acid metabolite results in increased expression of SRXN1 mRNA

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

signal sequence receptor subunit 2

decreases expression

ISO

Arachidonic Acid results in decreased expression of SSR2 mRNA

NCBI chr 2:174,048,291...174,057,043
Ensembl chr 2:174,048,460...174,057,042

G

steroidogenic acute regulatory protein

increases expression
multiple interactions

EXP

Arachidonic Acid results in increased expression of STAR protein
Arachidonic Acid inhibits the reaction [Dimethoate results in decreased expression of STAR protein]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

stanniocalcin 2

increases expression

ISO

Arachidonic Acid results in increased expression of STC2 mRNA

NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973

G

serine/threonine kinase 11

multiple interactions

ISO

STK11 protein affects the reaction [resveratrol results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]]

NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315

G

transcription factor EB

decreases expression

ISO

Arachidonic Acid results in decreased expression of TFEB mRNA

NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714

G

transferrin receptor

multiple interactions
increases expression

EXP

NGF protein inhibits the reaction [Arachidonic Acid results in increased expression of TFRC protein]

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor, beta 1

multiple interactions

EXP

[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

thyroid hormone responsive

decreases expression
multiple interactions

ISO

Arachidonic Acid results in decreased expression of THRSP mRNA
Flurbiprofen inhibits the reaction [Arachidonic Acid results in decreased expression of THRSP mRNA]

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

TIMP metallopeptidase inhibitor 1

multiple interactions

EXP

[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

toll-like receptor 4

multiple interactions

EXP

[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of TLR4 mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of TLR4 mRNA]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions
increases abundance
increases secretion

ISO

Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased secretion of Arachidonic Acid]
TNF protein results in increased abundance of Arachidonic Acid
Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]; TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]]

PMID:1515551 PMID:10588948 PMID:15684433

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 12A

increases expression

ISO

Arachidonic Acid results in increased expression of TNFRSF12A mRNA

NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045

G

TNF receptor superfamily member 1A

multiple interactions

ISO

TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]]

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

tensin 3

decreases expression

ISO

Arachidonic Acid results in decreased expression of TNS3 mRNA

NCBI chr14:83,173,649...83,405,671
Ensembl chr14:83,173,649...83,405,998

G

DNA topoisomerase II alpha

decreases expression

ISO

Arachidonic Acid results in decreased expression of TOP2A mRNA

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:83,945,735...83,976,874

G

tumor protein p53

multiple interactions

ISO

[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Arachidonic Acid
[TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

transient receptor potential cation channel, subfamily A, member 1

increases activity
multiple interactions

ISO

Arachidonic Acid results in increased activity of TRPA1 protein
Ruthenium Red inhibits the reaction [Arachidonic Acid results in increased activity of TRPA1 protein]

NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570

G

transient receptor potential cation channel, subfamily C, member 4

multiple interactions

ISO

TRPC4 protein affects the reaction [Arachidonic Acid results in increased transport of Calcium]

NCBI chr 2:138,307,676...138,476,856
Ensembl chr 2:138,308,084...138,476,768

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

EXP

[Arachidonic Acid co-treated with Phorbol 12,13-Dibutyrate] results in increased activity of TRPV1 protein

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

transient receptor potential cation channel, subfamily V, member 4

increases activity

ISO

Arachidonic Acid results in increased activity of TRPV4 protein

NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

ISO

UGT1A1 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases glucuronidation

ISO

UGT1A3 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A5

increases glucuronidation

ISO

UGT1A4 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation

ISO

UGT1A9 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 2 member B7

increases glucuronidation

ISO

UGT2B7 protein results in increased glucuronidation of Arachidonic Acid

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

G

vascular endothelial growth factor A

multiple interactions
increases expression

ISO

[PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA
[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]
Arachidonic Acid results in increased expression of VEGFA mRNA

PMID:12821125 PMID:18388244 PMID:19464254

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta

increases expression

ISO

Arachidonic Acid results in increased expression of YWHAZ mRNA

NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668

G

zinc finger protein 36

increases expression

ISO

Arachidonic Acid results in increased expression of ZFP36 mRNA

NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564

arachidonoyl-CoA

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

arachidonyl-2'-chloroethylamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

agouti related neuropeptide

decreases expression

EXP

arachidonyl-2-chloroethylamide results in decreased expression of AGRP mRNA

NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584

G

AKT serine/threonine kinase 1

decreases phosphorylation

ISO

arachidonyl-2-chloroethylamide results in decreased phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

angiopoietin 1

multiple interactions

ISO

arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT1 protein]

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin 2

multiple interactions

ISO

arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT2 protein]

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804

G

arginine vasopressin

multiple interactions

EXP

arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

BCL2, apoptosis regulator

multiple interactions
increases expression

ISO

[Streptozocin co-treated with arachidonyl-2-chloroethylamide] results in increased expression of BCL2 protein
arachidonyl-2-chloroethylamide results in increased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

CART prepropeptide

decreases expression
multiple interactions

EXP

arachidonyl-2-chloroethylamide results in decreased expression of CARTPT mRNA
[arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA

NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713

G

caspase 3

multiple interactions

ISO

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

ISO

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]

Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 4

increases expression
multiple interactions

ISO

arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

CD86 molecule

increases expression
multiple interactions

ISO

arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cannabinoid receptor 1

multiple interactions

EXP
ISO

CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]

PMID:12734338 PMID:27455076 PMID:29033935

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

diacylglycerol lipase, alpha

multiple interactions
increases expression

ISO

ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]
arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA; arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein

NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232

G

diacylglycerol lipase, beta

increases expression
multiple interactions

ISO

arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]

NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154

G

DNA-damage inducible transcript 3

multiple interactions

ISO

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

dopamine receptor D2

decreases expression

EXP

arachidonyl-2-chloroethylamide results in decreased expression of DRD2 mRNA

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

estrogen-related receptor gamma

increases expression
multiple interactions

ISO
EXP

arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA; arachidonyl-2-chloroethylamide results in increased expression of ESRRG protein
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]

PMID:27455076 PMID:30019168 PMID:31912162

NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397

G

fibrinogen alpha chain

increases expression
multiple interactions

ISO

arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA
GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA]

NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528

G

fibrinogen beta chain

multiple interactions
increases expression

ISO

GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGB mRNA]

NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979

G

fibroblast growth factor 21

increases expression
increases secretion
multiple interactions

ISO
EXP

arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA
arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein
arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]
arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA; arachidonyl-2-chloroethylamide results in increased expression of FGF21 protein

NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454

G

fibrinogen gamma chain

increases expression
multiple interactions

ISO

arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA
GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA]

NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322

G

forkhead box O1

multiple interactions
decreases phosphorylation

ISO

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA]
arachidonyl-2-chloroethylamide results in decreased phosphorylation of FOXO1 protein

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

ISO

arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glutathione-disulfide reductase

multiple interactions

ISO

arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hypocretin neuropeptide precursor

increases expression

EXP

arachidonyl-2-chloroethylamide results in increased expression of HCRT mRNA

NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210

G

interleukin 6

increases expression
multiple interactions

ISO

arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

ISO

[arachidonyl-2-chloroethylamide co-treated with Glucose] results in increased secretion of INS1 protein; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]

PMID:26671069 PMID:26847930 PMID:30761839

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

ISO
EXP

AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]
arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein
arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

ISO
EXP

AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]
arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

myeloperoxidase

multiple interactions
increases activity

ISO

Acetylcysteine inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases expression

ISO

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nitric oxide synthase 2

multiple interactions
increases expression

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nuclear respiratory factor 1

multiple interactions
decreases expression

ISO

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]

NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328

G

oligodendrocyte transcription factor 2

increases expression

EXP

arachidonyl-2-chloroethylamide results in increased expression of OLIG2 protein

NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152

G

oxytocin/neurophysin I prepropeptide

multiple interactions

EXP

arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]

NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490

G

poly (ADP-ribose) polymerase 1

multiple interactions

ISO

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

ISO

arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

pro-melanin-concentrating hormone

multiple interactions
increases expression

EXP

arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA]
arachidonyl-2-chloroethylamide results in increased expression of PMCH mRNA

NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250

G

proopiomelanocortin

multiple interactions
decreases expression

EXP

arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]
arachidonyl-2-chloroethylamide results in decreased expression of POMC mRNA

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

PPARG coactivator 1 alpha

multiple interactions
decreases expression

ISO

FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
affects localization

ISO

AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ras homolog family member A

multiple interactions
increases activity

ISO

AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

transcription factor A, mitochondrial

decreases expression
multiple interactions

ISO

arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA]

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

tumor necrosis factor

increases expression
multiple interactions

ISO

arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA; arachidonyl-2-chloroethylamide results in increased expression of TNF protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

ISO

arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased phosphorylation of TRP53 protein]

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

vascular endothelial growth factor A

multiple interactions

ISO

AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor C

multiple interactions

ISO

AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]

NCBI chr16:44,445,293...44,560,887
Ensembl chr16:37,712,262...37,827,848

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

platelet-activating factor acetylhydrolase 1b, regulatory subunit 1

increases expression
multiple interactions

EXP

Castor Oil results in increased expression of PAFAH1B1 protein
isosorbide-5-mononitrate inhibits the reaction [Castor Oil results in increased expression of PAFAH1B1 protein]

PMID:1354728 PMID:2743081 PMID:8738301

NCBI chr10:60,031,441...60,090,259
Ensembl chr10:59,534,117...59,591,808

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetoacetyl-CoA synthetase

multiple interactions

EXP

Cholesterol results in decreased expression of and results in decreased activity of AACS protein

NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954

G

ATP binding cassette subfamily A member 1

increases export
affects expression
multiple interactions
affects export
increases transport

ISO
EXP

ABCA1 protein results in increased export of Cholesterol
cholesterol cotreated with 25-hydroxycholesterol decreases expression of abca1 mrna and protein in rat hepatoma cells; and increases expression of abca1 mRNA in rat fibroblasts
1-Butanol inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]]; 1-oleoyl-2-acetylglycerol inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; [HCAR2 protein results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [Resveratrol results in increased expression of ABCA1 protein] which results in increased secretion of Cholesterol; APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]; APOA1 protein promotes the reaction [ABCA1 protein results in increased export of Cholesterol]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; glycolaldehyde inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Glyoxal inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; mastoparan inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; MDCO-216 promotes the reaction [ABCA1 protein results in increased transport of Cholesterol]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]]
[[colestimide co-treated with Pravastatin] results in increased expression of ABCA1 protein] which results in decreased abundance of Cholesterol; [Cholesterol co-treated with 25-hydroxycholesterol] results in decreased expression of ABCA1 mRNA; Cholesterol inhibits the reaction [bisphenol A results in decreased expression of ABCA1 mRNA]
ABCA1 protein affects the export of Cholesterol
[[Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [[Plant Preparations co-treated with Cholesterol, Dietary] results in increased expression of ABCA1 mRNA] which results in increased secretion of Cholesterol; [Capsaicin results in increased expression of ABCA1 protein] which results in decreased uptake of Cholesterol; [Capsaicin results in increased expression of ABCA1 protein] which results in increased secretion of Cholesterol; [Cholesterol co-treated with Dietary Fats] results in increased expression of ABCA1 mRNA; [Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCA1 mRNA

CTD
RGD

PMID:14993927 PMID:15694933 PMID:15983222 PMID:16118212 PMID:17526932 More...

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

increases secretion

ISO

ABCB11 protein results in increased secretion of Cholesterol

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 4

affects export

ISO

ABCB4 protein affects the export of Cholesterol

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily G member 1

multiple interactions

ISO

[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol; HCAR2 protein inhibits the reaction [[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol]
[resveratrol results in increased expression of ABCG1 protein] which results in increased secretion of Cholesterol

PMID:20372816 PMID:21317532

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 2

increases activity
multiple interactions

ISO

Cholesterol results in increased activity of ABCG2 protein
Sulfasalazine promotes the reaction [Cholesterol results in increased activity of ABCG2 protein]

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 5

affects export
multiple interactions
increases expression
decreases expression
increases secretion

ISO
EXP

ABCG5 protein affects the export of Cholesterol
[Diosgenin results in increased expression of ABCG5 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol results in decreased expression of ABCG5 mRNA] which results in decreased secretion of Cholesterol
Cholesterol results in increased expression of ABCG5 mRNA
Cholesterol results in decreased expression of ABCG5 mRNA
[Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCG5 mRNA; Cholates promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol]; Diosgenin promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol]

PMID:12963437 PMID:15611112 PMID:15683829 PMID:15696852 PMID:18356535

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

increases secretion
multiple interactions
increases expression
decreases expression
affects export

ISO
EXP

ABCG8 protein results in increased secretion of Cholesterol
[Diosgenin results in increased expression of ABCG8 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol results in decreased expression of ABCG8 mRNA] which results in decreased secretion of Cholesterol
Cholesterol results in increased expression of ABCG8 mRNA
Cholesterol results in decreased expression of ABCG8 mRNA
[Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCG8 mRNA; Cholates promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol]; Diosgenin promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol]
ABCG8 protein affects the export of Cholesterol

PMID:12963437 PMID:15611112 PMID:15683829 PMID:15696852 PMID:18356535

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA carboxylase alpha

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACACA mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acyl-CoA dehydrogenase medium chain

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACADM mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACADM mRNA]

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

acetylcholinesterase

multiple interactions

ISO

[Copper co-treated with Cholesterol] results in increased activity of ACHE protein; Clioquinol inhibits the reaction [[Copper co-treated with Cholesterol] results in increased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

ATP citrate lyase

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACLY mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,412,049...85,463,320

G

acyl-CoA oxidase 1

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

actin alpha 2, smooth muscle

multiple interactions

ISO

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

advanced glycosylation end product-specific receptor

affects abundance

ISO

AGER protein affects the abundance of Cholesterol

NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078

G

angiotensinogen

multiple interactions
affects abundance
increases expression

ISO
EXP

Cholesterol inhibits the reaction [irbesartan results in increased expression of AGT protein]
[Puromycin Aminonucleoside co-treated with Cholesterol] results in increased expression of AGT mRNA; Hydralazine inhibits the reaction [AGT protein affects the abundance of Cholesterol]; Losartan inhibits the reaction [AGT protein affects the abundance of Cholesterol]
Cholesterol results in increased expression of AGT protein

PMID:12495295 PMID:19028402 PMID:19109942

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

increases expression
multiple interactions

ISO

Cholesterol results in increased expression of AGTR1 mRNA
Cholesterol inhibits the reaction [irbesartan results in increased expression of AGTR1 mRNA]

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

angiotensin II receptor, type 2

multiple interactions

EXP

[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 mRNA; [Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 protein; [Puromycin Aminonucleoside co-treated with Cholesterol] results in increased expression of AGTR2 mRNA; Rosiglitazone promotes the reaction [[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 mRNA]; Rosiglitazone promotes the reaction [[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 protein]

PMID:12495295 PMID:21269478

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

aryl hydrocarbon receptor

multiple interactions

ISO

[beta-Naphthoflavone results in increased activity of AHR protein] which results in decreased chemical synthesis of and results in decreased secretion of Cholesterol

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

multiple interactions

ISO
EXP

Cholesterol inhibits the reaction [irbesartan results in increased expression of AKT1 protein]
[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein]
Cholesterol results in increased expression of and results in increased phosphorylation of AKT1 protein

PMID:19028402 PMID:19672739 PMID:31877369

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

albumin

multiple interactions

EXP

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of ALB protein; [lard co-treated with Cholesterol] results in increased expression of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

annexin A2

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

apoptotic peptidase activating factor 1

multiple interactions
increases expression

EXP

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of APAF1 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of APAF1 mRNA]

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

apolipoprotein A1

multiple interactions
increases export
affects transport
decreases expression
increases secretion

ISO
EXP

1-oleoyl-2-acetylglycerol inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [Acrolein affects the metabolism of APOA1 protein] which results in decreased secretion of Cholesterol; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [pirinixic acid binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Acrolein inhibits the reaction [APOA1 protein affects the transport of Cholesterol]; APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]; APOA1 protein promotes the reaction [ABCA1 protein results in increased export of Cholesterol]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; CYP27A1 protein promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; Fingolimod Hydrochloride promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; isosilybin A promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; mastoparan inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; Resveratrol inhibits the reaction [APOA1 protein results in increased export of Cholesterol]
[Ethanol co-treated with APOA1 protein] results in decreased abundance of Cholesterol
APOA1 affects the transport of Cholesterol
Cholesterol results in decreased expression of APOA1 protein
2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; 27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; [Glutathione co-treated with Quercetin] promotes the reaction [APOA1 protein results in increased export of Cholesterol]; [T0901317 co-treated with APOA1 protein] results in increased secretion of Cholesterol; Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]; Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; PPARA affects the reaction [Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; Quercetin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; T0901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]

PMID:12531903 PMID:12595494 PMID:15983222 PMID:16037261 PMID:16115471 More...

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein B

increases expression
multiple interactions

EXP

Cholesterol results in increased expression of APOB protein
Selenium inhibits the reaction [Cholesterol results in increased expression of APOB protein]

PMID:16271152 PMID:16581047

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein E

affects response to substance
affects localization
multiple interactions
increases abundance
increases export

ISO
EXP

APOE protein affects the susceptibility to Cholesterol
Cholesterol affects the localization of APOE protein
Cholesterol promotes the reaction [APOE protein binds to CAV1 protein]
APOE gene mutant form results in increased abundance of Cholesterol
APOE protein results in increased export of Cholesterol
24-diamino-5-phenylthiazole inhibits the reaction [T0901317 promotes the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]]; [[Air Pollutants results in increased abundance of Particulate Matter] promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]] which affects the abundance of Cholesterol; [APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol; APOE gene mutant form promotes the reaction [Dietary Fats results in increased abundance of Cholesterol]; APOE inhibits the reaction [Cholesterol, Dietary results in increased abundance of Cholesterol]; Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol]; CAV1 protein affects the reaction [Cholesterol affects the localization of APOE protein]; Enalapril inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol affects the localization of APOE protein]; N-butyloxycarbonyl-methionyl-aspartyl-glycyl-cysteinyl-glutamyl-leucine inhibits the reaction [[[Air Pollutants results in increased abundance of Particulate Matter] promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]] which affects the abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; paricalcitol inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; T0901317 promotes the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]

PMID:11397713 PMID:12472773 PMID:16179587 PMID:21169230 PMID:21908651 More...

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

multiple interactions
increases oxidation

ISO
EXP

[Copper co-treated with Cholesterol] results in increased expression of APP mRNA
APP protein results in increased oxidation of Cholesterol

PMID:15591071 PMID:17134702

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 9

increases expression

ISO

Cholesterol results in increased expression of AQP9 mRNA

NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395

G

androgen receptor

multiple interactions

ISO

[2,4-Dichlorophenoxyacetic Acid co-treated with Glyphosate co-treated with lard co-treated with Cholesterol co-treated with Glucose co-treated with Sucrose co-treated with Fructose] results in decreased expression of AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

increases expression
multiple interactions

ISO

Cholesterol results in increased expression of AREG mRNA
CLEC4E protein promotes the reaction [Cholesterol results in increased expression of AREG mRNA]

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

ATPase copper transporting beta

increases abundance

EXP

ATP7B gene mutant form results in increased abundance of Cholesterol

NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636

G

BCL2 associated X, apoptosis regulator

decreases expression
multiple interactions

EXP
ISO

Cholesterol analog results in decreased expression of BAX mRNA
Cholesterol inhibits the reaction [Cadmium Chloride results in increased expression of BAX protein]

PMID:19477266 PMID:29486218

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

EXP
ISO

Cholesterol analog results in decreased expression of BCL2 mRNA
Cholesterol inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein]

PMID:19477266 PMID:29486218

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2-related protein A1

increases expression

EXP

Cholesterol analog results in increased expression of BCL2A1 mRNA

NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:89,716,914...89,724,998

G

Bcl2-like 1

multiple interactions

ISO

Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of BCL2L1 mRNA]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

brain-derived neurotrophic factor

multiple interactions

EXP

[Dietary Fats co-treated with Cholesterol] results in decreased expression of BDNF protein; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of BDNF protein]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

BCL2-interacting killer

increases expression

EXP

Cholesterol analog results in increased expression of BIK mRNA

NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296

G

similar to human chromosome 15 open reading frame 48

increases expression

ISO

Cholesterol results in increased expression of C15ORF48 mRNA

NCBI chr 3:109,719,952...109,723,505
Ensembl chr 3:109,719,897...109,724,006
Ensembl chr 3:109,719,897...109,724,006

G

caspase 1

increases expression
increases cleavage
multiple interactions
increases activity
affects localization

EXP
ISO

Cholesterol analog results in increased expression of CASP1 mRNA
Cholesterol results in increased cleavage of CASP1 protein
Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased activity of CASP1 protein]; tempol inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; Verapamil inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein]

PMID:19477266 PMID:25833014 PMID:28633109 PMID:33239236

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions
increases cleavage
increases activity
increases expression

ISO
EXP

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein; [Copper co-treated with Cholesterol] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein]; Cholesterol inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein modified form]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol results in increased activity of CASP3 protein]
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP3 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] inhibits the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in decreased activity of CASP3 protein
Cholesterol results in increased cleavage of CASP3 protein
Cholesterol analog results in increased expression of CASP3 mRNA
Cholesterol analog results in increased cleavage of CASP3 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP3 mRNA]

PMID:17134702 PMID:19477266 PMID:21872649 PMID:28275691 PMID:29486218 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 4

multiple interactions
increases expression

EXP

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP4 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP4 mRNA]

NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:2,598,876...2,635,092

G

caspase 8

multiple interactions
increases expression
increases activity

EXP

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased activity of CASP8 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP8 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP8 mRNA]; Cholesterol promotes the reaction [Hydrogen Peroxide results in increased expression of CASP8 protein]; Hydrogen Peroxide promotes the reaction [Cholesterol results in increased expression of CASP8 protein]
Cholesterol analog results in increased expression of CASP8 mRNA; Cholesterol results in increased expression of CASP8 protein

PMID:19477266 PMID:20946910

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases expression
increases activity

EXP
ISO

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased activity of CASP9 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP9 mRNA]
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP9 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP9 protein]

PMID:19477266 PMID:35385781

Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions
increases expression

EXP
ISO

[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein; lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol linoleate inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased activity of CAT protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of CAT mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased activity of CAT protein]; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in increased activity of CAT protein]
Cholesterol results in increased expression of CAT protein

PMID:16933029 PMID:29486218 PMID:35385781

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

increases transport
multiple interactions

ISO
EXP

CAV1 protein results in increased transport of Cholesterol
CAV1 protein affects the reaction [Cholesterol affects the localization of APOE protein]
Cholesterol promotes the reaction [APOE protein binds to CAV1 protein]

PMID:12640124 PMID:21169230

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

caveolin 3

affects import

ISO

CAV3 protein affects the import of Cholesterol

NCBI chr 4:145,582,168...145,598,142
Ensembl chr 4:145,582,060...145,598,137

G

C-C motif chemokine ligand 1

increases expression

ISO

Cholesterol results in increased expression of CCL1 mRNA

NCBI chr10:67,128,331...67,131,109
Ensembl chr10:67,128,331...67,131,159

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

ISO
EXP

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CCL2 mRNA; [Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of CCL2 protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of CCL2 mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of CCL2 protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CCL2 mRNA; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein]
Cholesterol results in increased expression of CCL2 mRNA; Cholesterol results in increased expression of CCL2 protein

PMID:19028402 PMID:22129739 PMID:25833014 PMID:26606054 PMID:33239236

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 4

multiple interactions
increases expression

ISO

CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CCL4 mRNA]

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 7

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CCL7 mRNA

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

CD36 molecule

multiple interactions

ISO

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein; [Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein]; Losartan promotes the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA]; Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA]

PMID:18302760 PMID:35622622

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

CD40 ligand

multiple interactions
increases expression

EXP

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CD40LG mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CD40LG mRNA]

NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306

G

cyclin-dependent kinase 4

multiple interactions

ISO

Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of CDK4 mRNA]

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 5 regulatory subunit 2

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CDK5R2 mRNA

NCBI chr 9:76,416,251...76,417,719
Ensembl chr 9:76,416,062...76,418,344

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CDKN1A mRNA

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

CCAAT/enhancer binding protein alpha

multiple interactions

ISO

[[artemisic acid results in decreased expression of CEBPA mRNA] which results in decreased expression of HMGCR mRNA] which results in decreased chemical synthesis of Cholesterol

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

carboxylesterase 1D

increases metabolic processing
increases abundance
increases expression

ISO
EXP

CES1 protein results in increased metabolism of Cholesterol
CES1 protein results in increased abundance of Cholesterol
Cholesterol results in increased expression of CES1 mRNA

PMID:8049197 PMID:11015575 PMID:12773168 PMID:15825828

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

C-type lectin domain family 4, member E

multiple interactions
increases response to substance

ISO

[Cholesterol co-treated with CLEC4E] results in increased expression of CXCL2 protein; [Cholesterol co-treated with CLEC4E] results in increased expression of TNF protein; Cholesterol binds to and results in increased activity of CLEC4E protein; CLEC4E protein inhibits the reaction [Cholesterol results in increased expression of TIMP3 mRNA]; CLEC4E protein promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of AREG mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CCL4 mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CLEC5A mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CSF1 mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of DCSTAMP mRNA]
CLEC4E protein results in increased susceptibility to Cholesterol

NCBI chr 4:156,606,927...156,612,911
Ensembl chr 4:156,607,614...156,612,767

G

C-type lectin domain containing 5A

increases expression
multiple interactions

ISO

Cholesterol results in increased expression of CLEC5A mRNA
CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CLEC5A mRNA]

NCBI chr 4:69,407,125...69,416,872
Ensembl chr 4:69,407,835...69,416,859

G

carnitine palmitoyltransferase 1A

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element binding protein 1

multiple interactions

EXP

[Dietary Fats co-treated with Cholesterol] results in decreased expression of CREB1 protein; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of CREB1 protein]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816

G

crystallin, beta B3

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CRYBB3 mRNA

NCBI chr12:43,557,103...43,562,120
Ensembl chr12:43,557,103...43,562,120

G

citrate synthase

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CS mRNA

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:758,345...791,421

G

colony stimulating factor 1

increases expression
multiple interactions

ISO

Cholesterol results in increased expression of CSF1 mRNA
CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CSF1 mRNA]

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

cystatin C

multiple interactions

EXP

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CST3 protein

NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822

G

cathepsin B

decreases activity

ISO

Cholesterol results in decreased activity of CTSB protein

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

C-X-C motif chemokine ligand 2

multiple interactions

ISO

[Cholesterol co-treated with CLEC4E] results in increased expression of CXCL2 protein

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 9

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CXCL9 mRNA

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

cytochrome b-245 beta chain

multiple interactions
affects localization

EXP
ISO

[Cholesterol co-treated with Particulate Matter] results in increased expression of CYBB protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CYBB mRNA; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of CYBB protein]
Cholesterol analog affects the localization of CYBB protein

PMID:26606054 PMID:28633109 PMID:30672636

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 11, subfamily a, polypeptide 1

affects metabolic processing
increases metabolic processing

ISO

CYP11A1 protein affects the metabolism of Cholesterol
CYP11A1 protein results in increased metabolism of Cholesterol

PMID:16054388 PMID:19900470

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 17, subfamily a, polypeptide 1

affects chemical synthesis

ISO

CYP17A1 protein affects the chemical synthesis of Cholesterol

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

ISO

Cholesterol results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases chemical synthesis
multiple interactions
increases secretion

ISO
EXP

CYP27A1 protein results in decreased chemical synthesis of Cholesterol
[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased chemical synthesis of Bile Acids and Salts] promotes the reaction [LDLR protein results in increased uptake of Cholesterol]; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 25-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; CYP27A1 protein promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; CYP27A1 protein results in increased hydroxylation of and results in decreased abundance of Cholesterol
[Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of CYP27A1 mRNA
CYP27A1 protein results in increased secretion of Cholesterol

PMID:8078928 PMID:8496670 PMID:9215552 PMID:9660774 PMID:11408283 More...

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily a, polypeptide 3

decreases activity

ISO

Cholesterol results in decreased activity of CYP2A4 protein

NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases activity

ISO

Cholesterol results in decreased activity of CYP2B10 protein

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity

ISO

Cholesterol results in decreased activity of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

ISO
EXP

[CYP3A4 protein results in increased oxidation of Cholesterol] which results in increased chemical synthesis of cholest-5-ene-3,4-diol; Cholesterol promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in decreased abundance of Cholesterol

PMID:11514559 PMID:19299527 PMID:34461081

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions

EXP

[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in decreased abundance of Cholesterol

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 46, subfamily a, polypeptide 1

multiple interactions
increases hydroxylation

ISO

CYP46A1 gene SNP affects the metabolism of and affects the abundance of Cholesterol
CYP46A1 protein results in increased hydroxylation of Cholesterol

PMID:14640697 PMID:19286353

NCBI chr 6:127,247,543...127,274,765
Ensembl chr 6:127,243,315...127,274,760

G

cytochrome P450 family 7 subfamily A member 1

affects metabolic processing
multiple interactions
increases metabolic processing
increases expression

ISO
EXP

CYP7A1 protein affects the metabolism of Cholesterol
CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of EIF4EBP1 protein]; CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of GSK3B protein]; CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6 protein]; CYP7A1 mRNA inhibits the reaction [Tretinoin results in increased abundance of Cholesterol]
CYP7A1 protein results in increased metabolism of Cholesterol
Cholesterol results in increased expression of CYP7A1 mRNA
turmeric extract promotes the reaction [Cholesterol results in increased expression of CYP7A1 mRNA]

PMID:1175606 PMID:7925343 PMID:11013305 PMID:15696852 PMID:21535835 More...

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

increases activity
increases expression

EXP

Cholesterol results in increased activity of CYP7B1 protein
Cholesterol results in increased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

EXP

cholesterol decreases expression of Cyp8b1 mRNA in liver

RGD

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

death associated protein kinase 1

multiple interactions
increases expression

EXP

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of DAPK1 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of DAPK1 mRNA]

NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991

G

dendrocyte expressed seven transmembrane protein

multiple interactions
increases expression

ISO

CLEC4E protein promotes the reaction [Cholesterol results in increased expression of DCSTAMP mRNA]

NCBI chr 7:70,807,455...70,822,067
Ensembl chr 7:70,807,581...70,822,078

G

DNA-damage inducible transcript 3

multiple interactions

ISO

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

diacylglycerol O-acyltransferase 1

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of DGAT1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of DGAT1 mRNA

NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:108,218,524...108,234,299

G

diacylglycerol O-acyltransferase 2

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA]

NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:153,454,080...153,484,428

G

24-dehydrocholesterol reductase

affects abundance
multiple interactions

ISO

DHCR24 protein affects the abundance of Cholesterol
[DHCR24 protein results in increased metabolism of Desmosterol] which results in increased abundance of Cholesterol

PMID:19260826 PMID:23042211

NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:121,344,575...121,371,137

G

7-dehydrocholesterol reductase

decreases abundance
multiple interactions
increases chemical synthesis
affects response to substance

ISO

DHCR7 mutant form results in decreased abundance of Cholesterol
Simvastatin promotes the reaction [DHCR7 results in increased chemical synthesis of Cholesterol]
DHCR7 mutant form affects the susceptibility to Cholesterol

PMID:15896653 PMID:16446309 PMID:19365639

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

iodothyronine deiodinase 1

affects expression
decreases expression
decreases activity

EXP

Cholesterol affects the expression of DIO1 mRNA
Cholesterol results in decreased expression of DIO1 mRNA
Cholesterol results in decreased activity of DIO1 protein

PMID:16271152 PMID:16874406

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 2

increases degradation

ISO

Cholesterol results in increased degradation of DIO2 protein

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

epidermal growth factor

multiple interactions

ISO

[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the abundance of Reactive Oxygen Species; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the expression of SOD2 mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased activity of CAT protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of CAT mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of MKI67 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of TP53 mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP3 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP9 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the abundance of Reactive Oxygen Species; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the abundance of Reactive Oxygen Species]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of CAT mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of MKI67 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of SOD2 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of TP53 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased activity of CAT protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased expression of MKI67 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] inhibits the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in decreased activity of CASP3 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of MKI67 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of TP53 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased susceptibility to Silver Compounds; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in decreased expression of MKI67 protein]; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in increased activity of CAT protein]; EGF protein affects the susceptibility to [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds]; EGF protein inhibits the reaction [[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the abundance of Reactive Oxygen Species]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of EGFR mRNA

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 2 subunit alpha

decreases abundance

ISO

EIF2S1 protein modified form results in decreased abundance of Cholesterol

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

eukaryotic translation initiation factor 4A1

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of EIF4A1 mRNA

NCBI chr10:54,384,345...54,389,855
Ensembl chr10:54,384,347...54,389,858

G

eukaryotic translation initiation factor 4E binding protein 1

increases phosphorylation
multiple interactions

ISO

Cholesterol results in increased phosphorylation of EIF4EBP1 protein
CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of EIF4EBP1 protein]

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

erythrocyte membrane protein band 4.1

multiple interactions

EXP

[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein; [Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein]

NCBI chr 5:144,110,010...144,264,037
Ensembl chr 5:144,111,906...144,237,821

G

endothelial cell-specific molecule 1

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ESM1 mRNA

NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804

G

fatty acid binding protein 1

multiple interactions

EXP

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of FABP1 protein

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

Fas associated via death domain

multiple interactions
increases expression

EXP

Cholesterol promotes the reaction [Hydrogen Peroxide results in increased expression of FADD protein]; Hydrogen Peroxide promotes the reaction [Cholesterol results in increased expression of FADD protein]

NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653

G

Fas cell surface death receptor

multiple interactions
increases expression

ISO
EXP

Cholesterol inhibits the reaction [FGF7 protein results in increased expression of FAS mRNA]
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of FAS mRNA
Cholesterol analog results in increased expression of FAS mRNA
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of FAS mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of FAS mRNA]

PMID:16162944 PMID:19477266 PMID:22129739

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

increases expression

EXP

Cholesterol analog results in increased expression of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

farnesyl diphosphate farnesyl transferase 1

increases chemical synthesis

ISO

FDFT1 protein results in increased chemical synthesis of Cholesterol

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

decreases expression

EXP

Cholesterol results in decreased expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

fibroblast growth factor 19

multiple interactions

ISO

[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol; Dasatinib inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; NR1H4 protein mutant form inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

fibroblast growth factor 7

multiple interactions

ISO
EXP

Cholesterol inhibits the reaction [FGF7 protein results in increased expression of FAS mRNA]; Cholesterol inhibits the reaction [FGF7 protein results in increased expression of SCD mRNA]
[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of FGF7 protein

PMID:16034455 PMID:16162944

NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929

G

fibroblast growth factor receptor 4

affects metabolic processing
decreases metabolic processing

ISO

FGFR4 protein affects the metabolism of Cholesterol
FGFR4 protein results in decreased metabolism of Cholesterol

PMID:11956156 PMID:15750181

NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242

G

Fms related receptor tyrosine kinase 1

increases expression

ISO

Cholesterol results in increased expression of FLT1 mRNA

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

growth arrest and DNA-damage-inducible, gamma

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

guanylate binding protein 2

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GBP2 mRNA

NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:231,332,284...231,348,571

G

guanylate binding protein 4

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GBP4 mRNA

NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879

G

guanylate binding protein family member 6

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GBP9 mRNA

NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062
Ensembl chr14:4,730,453...4,839,062

G

glutamate-cysteine ligase, catalytic subunit

increases expression

ISO

Cholesterol results in increased expression of GCLC protein

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

gap junction protein, beta 1

decreases abundance

ISO

GJB1 protein results in decreased abundance of Cholesterol

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

G protein subunit alpha i3

multiple interactions

ISO

Cholesterol inhibits the reaction [Progesterone results in decreased expression of GNAI3 protein]

NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742

G

GNAS complex locus

multiple interactions

ISO

Cholesterol inhibits the reaction [Progesterone results in increased expression of GNAS protein]

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

glycoprotein Ib platelet subunit alpha

increases expression

ISO

Cholesterol results in increased expression of GP1BA mRNA

NCBI chr10:55,352,938...55,355,804
Ensembl chr10:55,352,899...55,356,774

G

glycerol-3-phosphate acyltransferase, mitochondrial

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of GPAM mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of GPAM mRNA

NCBI chr 1:264,111,599...264,176,112
Ensembl chr 1:254,106,331...254,142,639

G

glutathione peroxidase 2

multiple interactions

EXP

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glycogen synthase kinase 3 beta

increases phosphorylation
multiple interactions

ISO
EXP

Cholesterol results in increased phosphorylation of GSK3B protein
[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein]
CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of GSK3B protein]

PMID:28275691 PMID:31877369

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646

G

general transcription factor 3C subunit 6

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GTF3C6 mRNA

NCBI chr20:43,656,400...43,668,382
Ensembl chr20:43,655,875...43,667,873

G

granzyme A

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GZMA mRNA

NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493

G

granzyme B

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GZMB mRNA

NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814

G

H2A.X variant histone

increases phosphorylation
multiple interactions

ISO

Cholesterol results in increased phosphorylation of H2AX protein
bisphenol A promotes the reaction [Cholesterol results in increased phosphorylation of H2AX protein]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased phosphorylation of H2AX protein]]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

2-hydroxyacyl-CoA lyase 1

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of HACL1 mRNA

NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027

G

hepatitis A virus cellular receptor 1

multiple interactions

EXP

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HAVCR1 mRNA

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

heparin-binding EGF-like growth factor

increases expression

ISO

Cholesterol results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

hydroxycarboxylic acid receptor 2

multiple interactions

ISO

[HCAR2 protein results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol

NCBI chr12:32,726,252...32,728,238
Ensembl chr12:32,726,184...32,728,504

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

EXP

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HIF1A mRNA

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases activity
decreases expression
multiple interactions

ISO
EXP

Cholesterol results in decreased activity of HMGCR protein
cholesterol decreases expression of Hmgcr mRNA in liver
[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA; [Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein; [turmeric extract co-treated with Cholesterol] results in decreased expression of HMGCR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Selenium promotes the reaction [Cholesterol results in decreased expression of HMGCR mRNA]
[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein; [[artemisic acid results in decreased expression of CEBPA mRNA] which results in decreased expression of HMGCR mRNA] which results in decreased chemical synthesis of Cholesterol; [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [artemisic acid results in decreased expression of HMGCR protein] which results in decreased chemical synthesis of Cholesterol; [Clozapine results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; [Haloperidol results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]

CTD
RGD

PMID:11408283 PMID:12477733 PMID:16027736 PMID:16581047 PMID:17516993 More...

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

heme oxygenase 1

multiple interactions
increases expression
decreases expression

EXP

[Cholesterol co-treated with Particulate Matter] results in increased expression of HMOX1 mRNA; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HMOX1 mRNA; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]; turmeric extract inhibits the reaction [Cholesterol results in decreased expression of HMOX1 mRNA]

PMID:21535835 PMID:26606054 PMID:30672636

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hepatocyte nuclear factor 4, alpha

multiple interactions

EXP

[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]

NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320

G

intercellular adhesion molecule 1

multiple interactions

EXP

[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein]

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

interferon-induced protein 44

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IFI44 mRNA

NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844

G

interferon-induced protein with tetratricopeptide repeats 3

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IFIT3 mRNA

NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307

G

interferon gamma

multiple interactions

EXP

[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

multiple interactions

EXP

[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of IGF1 protein

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 2 receptor

multiple interactions

EXP

[IGF2R protein alternative form results in increased susceptibility to Streptozocin] which results in increased abundance of Cholesterol

NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501

G

insulin-like growth factor binding protein 1

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

insulin-like growth factor binding protein 3

multiple interactions

EXP

[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of IGFBP3 protein

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

interleukin 10

multiple interactions

ISO

[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased secretion of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 18 binding protein

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IL18BP mRNA

NCBI chr 1:156,372,923...156,374,963
Ensembl chr 1:156,372,883...156,374,963

G

interleukin 1 beta

multiple interactions
increases expression

ISO
EXP

[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein; CLEC4E protein promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]
Cholesterol results in increased expression of IL1B protein
Cholesterol analog results in increased expression of IL1B protein
[Cholesterol co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of IL1B protein; Amitriptyline inhibits the reaction [Cholesterol analog results in increased expression of IL1B protein]; bisphenol A promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; Cholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]; Quercetin inhibits the reaction [Cholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]; SMPD1 protein affects the reaction [Cholesterol analog results in increased expression of IL1B protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein; [Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA; [Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of IL1B mRNA; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA]
Cholesterol results in increased expression of IL1B mRNA

PMID:22869926 PMID:25833014 PMID:26296894 PMID:26606054 PMID:28633109 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

increases expression

ISO

Cholesterol results in increased expression of IL1RN mRNA

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 6

multiple interactions
increases expression

ISO
EXP

[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of IL6 protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of IL6 mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of IL6 protein]
[Cholesterol co-treated with Particulate Matter] results in increased expression of IL6 mRNA; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein]
Cholesterol results in increased expression of IL6 mRNA; Cholesterol results in increased expression of IL6 protein

PMID:19028402 PMID:30672636 PMID:33239236

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit beta A

increases expression

ISO

Cholesterol results in increased expression of INHBA mRNA

NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982

G

insulin 1

multiple interactions

EXP

[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

ISO

[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Cholesterol analog

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

interferon regulatory factor 7

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IRF7 mRNA

NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832

G

insulin receptor substrate 1

affects abundance

ISO

IRS1 gene polymorphism affects the abundance of Cholesterol

NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122

G

ISG15 ubiquitin-like modifier

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ISG15 mRNA

NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435

G

integrin subunit alpha M

increases expression

ISO

Cholesterol increases expression of ITGAM protein on monocytes and granulocytes

RGD

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

potassium voltage-gated channel subfamily H member 2

decreases localization

EXP

Cholesterol results in decreased localization of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008

G

KIT ligand

increases expression

ISO

Cholesterol results in increased expression of KITLG mRNA

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

keratin 19

multiple interactions

ISO

Cholesterol inhibits the reaction [arachidonyl dopamine results in increased expression of KRT19 mRNA]

NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799

G

lysosomal-associated membrane protein 1

increases expression

ISO

Cholesterol results in increased expression of LAMP1 protein

NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883

G

lecithin cholesterol acyltransferase

increases acylation
multiple interactions

ISO
EXP

LCAT protein results in increased acylation of Cholesterol
[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]

PMID:4847537 PMID:30273964

NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231

G

lipocalin 2

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of LCN2 mRNA

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

low density lipoprotein receptor

increases uptake
affects abundance
increases response to substance
multiple interactions
decreases expression
decreases activity

ISO
EXP

LDLR protein results in increased uptake of Cholesterol
LDLR protein affects the abundance of Cholesterol
LDLR gene mutant form results in increased susceptibility to Cholesterol
(+)-JQ1 compound inhibits the reaction [LDLR gene mutant form results in increased susceptibility to Cholesterol]; [LDLR gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol; [Tobacco Smoke Pollution promotes the reaction [LDLR protein affects the susceptibility to Dietary Fats]] which results in increased abundance of Cholesterol; argatroban inhibits the reaction [[LDLR gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]; Chloroquine affects the reaction [SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]]; SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]
Cholesterol results in decreased expression of LDLR mRNA
[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA; [Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA; [turmeric extract co-treated with Cholesterol] results in increased expression of LDLR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Selenium inhibits the reaction [Cholesterol results in decreased activity of LDLR protein]; Selenium inhibits the reaction [Cholesterol results in decreased expression of LDLR mRNA]; turmeric extract inhibits the reaction [Cholesterol results in decreased expression of LDLR mRNA]
[CYP27A1 protein results in increased chemical synthesis of Bile Acids and Salts] promotes the reaction [LDLR protein results in increased uptake of Cholesterol]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; LDLR gene mutant form results in increased susceptibility to [25-hydroxycholesterol co-treated with Cholesterol]

PMID:12477733 PMID:16271152 PMID:16317514 PMID:16477808 PMID:16937255 More...

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

leptin receptor

multiple interactions
increases abundance

ISO

Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Cholesterol]

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

lipoprotein lipase

increases expression
multiple interactions

ISO
EXP

Cholesterol results in increased expression of LPL mRNA
[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]

PMID:26296894 PMID:30273964

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

LDL receptor related protein 1

multiple interactions

ISO

[Capsaicin results in decreased expression of LRP1 protein] which results in decreased uptake of Cholesterol; [Capsaicin results in decreased expression of LRP1 protein] which results in increased secretion of Cholesterol

NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910

G

lymphocyte antigen 6 family member A

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of LY6A mRNA

NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981

G

lymphocyte antigen 6 family member E

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of LY6E mRNA

NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689

G

microtubule-associated protein 1 light chain 3 beta

increases expression
multiple interactions

ISO

Cholesterol results in increased expression of MAP1LC3B protein modified form
Cholesterol inhibits the reaction [Cadmium Chloride results in increased cleavage of MAP1LC3B protein]

PMID:28275691 PMID:29486218

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase 14

multiple interactions

EXP

[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA]

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

microtubule-associated protein tau

multiple interactions

EXP

[Dietary Fats co-treated with Cholesterol] results in increased expression of MAPT protein modified form; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of MAPT protein modified form]

NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129

G

membrane associated ring-CH-type finger 6

increases stability
multiple interactions

ISO

Cholesterol results in increased stability of MARCHF6 protein
Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein]; Cholesterol inhibits the reaction [Glycerol results in decreased stability of MARCHF6 protein]; Cholesterol inhibits the reaction [MARCHF6 protein results in increased ubiquitination of and results in increased degradation of MARCHF6 protein]; MARCHF6 promotes the reaction [Cholesterol results in increased degradation of SQLE protein]

NCBI chr 2:84,166,570...84,243,817
Ensembl chr 2:82,455,689...82,532,910

G

macrophage receptor with collagenous structure

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MARCO mRNA

NCBI chr13:31,616,278...31,648,521
Ensembl chr13:31,616,278...31,648,521

G

MIA SH3 domain ER export factor 2

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MIA2 mRNA

NCBI chr 6:76,787,508...76,885,246
Ensembl chr 6:76,787,508...76,885,211

G

microRNA 125a

decreases export

ISO

MIR125A mRNA results in decreased export of Cholesterol

NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710

G

marker of proliferation Ki-67

multiple interactions

ISO

[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of MKI67 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of MKI67 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased expression of MKI67 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of MKI67 protein; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in decreased expression of MKI67 protein]

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762

G

MLX interacting protein-like

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA]

NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112

G

macrophage expressed 1

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MPEG1 mRNA

NCBI chr 1:209,452,176...209,456,692
Ensembl chr 1:209,452,133...209,458,855

G

macrophage scavenger receptor 1

multiple interactions

ISO

[resveratrol results in decreased expression of MSR1 protein] which results in decreased uptake of Cholesterol

NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676

G

metallothionein 1

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MT1 mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

metallothionein 2

multiple interactions
increases expression

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MT2 mRNA
Cholesterol results in increased expression of MT2 protein

PMID:22129739 PMID:29486218

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

mechanistic target of rapamycin kinase

increases phosphorylation

ISO

Cholesterol results in increased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mevalonate kinase

decreases chemical synthesis

ISO

MVK protein mutant form results in decreased chemical synthesis of Cholesterol

NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882

G

Ngfi-A binding protein 2

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of NAB2 mRNA

NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989

G

N-acetyl-alpha-glucosaminidase

multiple interactions

EXP

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of NAGLU protein

NCBI chr10:86,001,545...86,009,049
Ensembl chr10:86,001,566...86,008,972

G

nibrin

multiple interactions

ISO

[Cholesterol co-treated with Resveratrol] inhibits the reaction [bisphenol A results in decreased expression of NBN protein]; NBN protein inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]

NCBI chr 5:34,256,678...34,291,163
Ensembl chr 5:29,459,457...29,494,150

G

neutrophil cytosolic factor 1

multiple interactions
increases expression

ISO

Cholesterol inhibits the reaction [irbesartan results in increased expression of NCF1 mRNA]; Cholesterol inhibits the reaction [irbesartan results in increased expression of NCF1 protein]
Cholesterol results in increased expression of NCF1 mRNA; Cholesterol results in increased expression of NCF1 protein

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

nuclear receptor coactivator 2

affects metabolic processing

ISO

NCOA2 protein affects the metabolism of Cholesterol

NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:5,835,706...6,067,451

G

nectin cell adhesion molecule 2

affects expression

ISO

Cholesterol affects the expression of NECTIN2

NCBI chr 1:88,500,086...88,535,474
Ensembl chr 1:79,372,119...79,407,360

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions

EXP

Cholesterol results in increased expression of NFE2L2 mRNA
alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

increases expression
multiple interactions

ISO

Cholesterol results in increased expression of NFKB1 protein
Cholesterol inhibits the reaction [irbesartan results in increased expression of NFKB1 protein]

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor beta

multiple interactions
increases phosphorylation

ISO

Cholesterol inhibits the reaction [irbesartan results in increased phosphorylation of NFKBIB protein]
Cholesterol results in increased phosphorylation of NFKBIB protein

NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862

G

NLR family, pyrin domain containing 3

multiple interactions
affects localization

EXP
ISO

[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein]
Cholesterol analog affects the localization of NLRP3 protein
[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of NLRP3 protein]; NBN protein inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of NLRP3 protein]

PMID:25833014 PMID:28633109 PMID:33239236

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

NPC intracellular cholesterol transporter 1

increases secretion
affects localization
affects abundance
multiple interactions

ISO

NPC1 protein results in increased secretion of Cholesterol
NPC1 affects the localization of Cholesterol
NPC1 protein affects the abundance of Cholesterol
Progesterone inhibits the reaction [NPC1 protein results in increased secretion of Cholesterol]

PMID:12183525 PMID:16174794 PMID:18483620

NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049

G

NPC1 like intracellular cholesterol transporter 1

multiple interactions

ISO

[Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of NPC1L1 mRNA

NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113

G

NPHS1 adhesion molecule, nephrin

multiple interactions

EXP

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in decreased expression of NPHS1 mRNA

NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

EXP

Cholesterol results in increased expression of NQO1 mRNA
alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NQO1 mRNA]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of NQO1 protein]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of NQO1 mRNA]

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group H, member 2

multiple interactions
increases activity

ISO

[RXRB protein binds to NR1H2 protein] which affects the metabolism of Cholesterol; NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H2 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol]
Cholesterol results in increased activity of NR1H2 protein

PMID:14993927 PMID:16415093 PMID:21543282

NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions
increases expression
decreases expression

ISO
EXP

[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Cholesterol co-treated with Ozone] results in increased lipidation of NR1H3 protein
Cholesterol increases expression of NR1H3 mRNA in epithelial cells
cholesterol decreases expression of LXR mRNA in liver
NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H3 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol]

CTD
RGD

PMID:12595494 PMID:16415093 PMID:27703007 PMID:37061692 PMID:25263431

RGD:401842388, RGD:15045610

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
decreases expression
increases export

ISO
EXP

[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol; Dasatinib inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; NR1H4 protein mutant form inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]
cholesterol decreases expression of Nr1h4 mRNA in liver
NR1H4 protein results in increased export of Cholesterol

CTD
RGD

PMID:30996006 PMID:25263431

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

affects metabolic processing
multiple interactions

ISO

NR1I2 protein affects the metabolism of Cholesterol
[NR1I2 protein affects the susceptibility to Pregnenolone Carbonitrile] which affects the abundance of Cholesterol

PMID:15684063 PMID:38971454

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

affects metabolic processing
multiple interactions
affects binding

ISO

NR1I3 protein affects the metabolism of Cholesterol
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased activity of NR1I3 protein] which results in increased abundance of Cholesterol
Cholesterol metabolite binds to NR1I3 protein

PMID:15684063 PMID:16051528 PMID:22101211

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 5, group A, member 2

affects abundance

ISO

NR5A2 gene mutant form affects the abundance of Cholesterol

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

2'-5'-oligoadenylate synthetase 3

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of OAS3 mRNA

NCBI chr12:35,779,028...35,802,781
Ensembl chr12:35,779,022...35,802,781

G

osteoclast stimulatory transmembrane protein

increases expression

ISO

Cholesterol results in increased expression of OCSTAMP mRNA

NCBI chr 3:154,131,113...154,141,611
Ensembl chr 3:154,132,328...154,136,991

G

oxidized low density lipoprotein receptor 1

multiple interactions

EXP

[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein]

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

olfactory receptor family 52 subfamily R member 1C

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of OR52R1 mRNA

NCBI chr 1:157,475,119...157,476,063
Ensembl chr 1:157,471,250...157,476,301

G

otoferlin

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of OTOF mRNA

NCBI chr 6:25,928,018...26,024,631
Ensembl chr 6:25,928,055...26,024,631

G

purinergic receptor P2X 1

decreases activity
multiple interactions

ISO

Cholesterol deficiency results in decreased activity of P2RX1 protein
jasplakinolide inhibits the reaction [Cholesterol deficiency results in decreased activity of P2RX1 protein]

NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

ISO

bisphenol A promotes the reaction [Cholesterol results in increased cleavage of PARP1 protein]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of PARP1 protein]]

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

poly(rC) binding protein 1

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PCBP1 mRNA

NCBI chr 4:118,972,698...118,974,705
Ensembl chr 4:118,972,661...118,976,500

G

proliferating cell nuclear antigen

multiple interactions

ISO

[2,4-Dichlorophenoxyacetic Acid co-treated with Glyphosate] promotes the reaction [[lard co-treated with Cholesterol co-treated with Glucose co-treated with Sucrose co-treated with Fructose] results in decreased expression of PCNA protein]; [2,4-Dichlorophenoxyacetic Acid co-treated with lard co-treated with Cholesterol co-treated with Glucose co-treated with Sucrose co-treated with Fructose] results in decreased expression of PCNA protein; [Glyphosate co-treated with lard co-treated with Cholesterol co-treated with Glucose co-treated with Sucrose co-treated with Fructose] results in decreased expression of PCNA protein; [lard co-treated with Cholesterol co-treated with Glucose co-treated with Sucrose co-treated with Fructose] results in decreased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995

G

pyruvate kinase L/R

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of PKLR mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of PKLR mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of PKLR mRNA

NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870

G

phospholipase D2

multiple interactions

ISO

PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]

NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808

G

paraoxonase 1

decreases chemical synthesis
multiple interactions
increases export
decreases activity

ISO
EXP

PON1 protein results in decreased chemical synthesis of Cholesterol
[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]
PON1 protein results in increased export of Cholesterol
Cholesterol results in decreased activity of PON1 protein

PMID:12615663 PMID:16115471 PMID:16229851 PMID:16331452 PMID:30273964

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

multiple interactions
decreases expression

ISO

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; PPARA affects the reaction [Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]]
Cholesterol results in decreased expression of PPARA mRNA
[Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [pirinixic acid binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Cholesterol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]

PMID:11779144 PMID:12595494 PMID:21088444 PMID:24440342 PMID:25689681

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [resveratrol results in decreased abundance of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [[troglitazone binds to and results in increased activity of PPARG protein] which results in decreased expression of SREBF2 protein] which results in decreased abundance of Cholesterol; [troglitazone binds to and results in increased activity of PPARG protein] which results in decreased abundance of Cholesterol; [troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol; Pravastatin inhibits the reaction [[troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol]
[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA; [lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARG mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARG mRNA]; Losartan inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA]

PMID:12044893 PMID:12595494 PMID:16946405 PMID:18302760 PMID:19797938 More...

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1, regulatory subunit 3G

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PPP1R3G mRNA

NCBI chr17:28,874,956...28,878,288
Ensembl chr17:28,876,482...28,877,525

G

phosphoserine aminotransferase 1

increases expression

ISO

Cholesterol results in increased expression of PSAT1 mRNA

NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682

G

proline and serine rich coiled-coil 1

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PSRC1 mRNA

NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874

G

PYD and CARD domain containing

increases expression
affects localization
multiple interactions

EXP
ISO

Cholesterol analog results in increased expression of PYCARD mRNA
Cholesterol analog affects the localization of PYCARD protein
[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein]
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PYCARD mRNA; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of PYCARD protein]

PMID:19477266 PMID:22129739 PMID:25833014 PMID:28633109

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

Rac family small GTPase 1

multiple interactions
increases expression

ISO

Cholesterol inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RAC1 protein]
Cholesterol results in increased expression of RAC1 mRNA; Cholesterol results in increased expression of RAC1 protein
Cholesterol inhibits the reaction [irbesartan results in increased expression of RAC1 mRNA]

PMID:19028402 PMID:21334995

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases expression

ISO
EXP

Cholesterol inhibits the reaction [irbesartan results in increased expression of RELA protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein]
[methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein affects the localization of RELA protein]]
Cholesterol results in increased expression of RELA protein

PMID:19028402 PMID:23274767 PMID:25833014

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

regulator of cell cycle

increases expression

ISO

Cholesterol results in increased expression of RGCC mRNA

NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141

G

regulator of G-protein signaling 2

increases degradation

ISO

Cholesterol results in increased degradation of RGS2 protein

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

receptor-interacting serine-threonine kinase 2

multiple interactions
increases expression

EXP

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of RIPK2 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of RIPK2 mRNA]

NCBI chr 5:29,630,806...29,662,804
Ensembl chr 5:29,631,570...29,662,657

G

ribosomal protein S21, pseudogene 1

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of RPS21 mRNA

NCBI chr 5:153,387,133...153,387,476
Ensembl chr 5:153,387,176...153,387,427

G

ribosomal protein S6

multiple interactions
increases phosphorylation

ISO

CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6 protein]
Cholesterol inhibits the reaction [Nicotine results in increased phosphorylation of RPS6 protein]

PMID:28275691 PMID:31629012

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

ribosomal protein S6 kinase B1

multiple interactions
increases phosphorylation

ISO

Trehalose inhibits the reaction [Cholesterol inhibits the reaction [Cadmium Chloride results in increased cleavage of RPS6KB1 protein]]; Trehalose inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6KB1 protein]

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908

G

regulatory associated protein of MTOR, complex 1

increases expression

ISO

Cholesterol results in increased expression of RPTOR protein

NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983

G

retinoid X receptor alpha

multiple interactions

ISO

Cholesterol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

retinoid X receptor beta

multiple interactions

ISO

[RXRB protein binds to NR1H2 protein] which affects the metabolism of Cholesterol

NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773

G

S100 calcium binding protein A8

multiple interactions

EXP

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

scavenger receptor class B, member 1

multiple interactions
affects transport

ISO

[Dietary Fats co-treated with Cholesterol] results in decreased expression of SCARB1 mRNA; Losartan inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of SCARB1 mRNA]
SCARB1 protein affects the transport of Cholesterol

PMID:18302760 PMID:26651060

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

stearoyl-CoA desaturase

increases expression
multiple interactions

ISO

Cholesterol results in increased expression of SCD1 mRNA
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of SCD1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of SCD1 mRNA
Cholesterol inhibits the reaction [FGF7 protein results in increased expression of SCD mRNA]

PMID:16162944 PMID:19260826 PMID:24440342

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

shisa family member 5

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SHISA5 mRNA

NCBI chr 8:109,691,504...109,706,411
Ensembl chr 8:109,691,522...109,706,408

G

sirtuin 1

multiple interactions

EXP
ISO

[6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA]
[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased expression of SIRT1 protein; Resveratrol inhibits the reaction [[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased expression of SIRT1 protein]

PMID:21212096 PMID:25833014 PMID:33239236

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 1 member 3

increases expression

ISO

Cholesterol results in increased expression of SLC1A3 mRNA

NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605

G

solute carrier family 28 member 3

increases expression

ISO

Cholesterol results in increased expression of SLC28A3 mRNA

NCBI chr17:6,062,563...6,112,965
Ensembl chr17:6,062,549...6,114,038

G

solute carrier family 2 member 2

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]

NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933

G

solute carrier family 4 member 1 (Diego blood group)

multiple interactions

EXP

[Hydrogen Peroxide co-treated with Cholesterol] affects the localization of SLC4A1 protein; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] affects the localization of SLC4A1 protein]

NCBI chr10:87,306,865...87,323,132
Ensembl chr10:87,306,872...87,323,117

G

solute carrier family 7 member 5

increases expression

ISO

Cholesterol results in increased expression of SLC7A5 mRNA

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

SMAD family member 3

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SMAD3 mRNA

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

sphingomyelin phosphodiesterase 1

multiple interactions

ISO

SMPD1 protein affects the reaction [Cholesterol analog affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of NLRP3 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased expression of IL1B protein]

NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794

G

sphingomyelin phosphodiesterase 3

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SMPD3 mRNA

NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749

G

superoxide dismutase 2

multiple interactions

ISO

[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of SOD2 mRNA]

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189

G

sortilin 1

decreases abundance
multiple interactions

ISO

SORT1 protein results in decreased abundance of Cholesterol
Chloroquine affects the reaction [SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]]; SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]

PMID:25805502 PMID:30950489

NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354

G

squalene epoxidase

increases degradation
multiple interactions

ISO

Cholesterol results in increased degradation of SQLE protein
Cholesterol inhibits the reaction [Hydroxymethylglutaryl-CoA Reductase Inhibitors results in decreased degradation of SQLE protein]; MARCHF6 promotes the reaction [Cholesterol results in increased degradation of SQLE protein]

NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618

G

sequestosome 1

increases expression
multiple interactions

ISO

Cholesterol results in increased expression of SQSTM1 protein
Cholesterol inhibits the reaction [Cadmium Chloride results in decreased expression of SQSTM1 protein]

PMID:28275691 PMID:29486218

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

ISO

SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

sterol regulatory element binding transcription factor 1

multiple interactions

ISO

[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of SREBF1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of SREBF1 mRNA
[25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF1 protein

PMID:24440342 PMID:27324795

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

sterol regulatory element binding transcription factor 2

multiple interactions
increases abundance

ISO
EXP

[25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF2 protein; [[Troglitazone binds to and results in increased activity of PPARG protein] which results in decreased expression of SREBF2 protein] which results in decreased abundance of Cholesterol; betadex inhibits the reaction [SREBF2 protein results in increased abundance of Cholesterol]; SREBF2 promotes the reaction [bisphenol A results in increased import of Cholesterol]; SREBF2 protein affects the reaction [Lipopolysaccharides results in increased abundance of Cholesterol]
[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein]

PMID:16946405 PMID:20578043 PMID:27324795 PMID:28057006 PMID:33677747

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

steroidogenic acute regulatory protein

affects transport
increases transport
increases export
multiple interactions

ISO
EXP

STAR protein affects the transport of Cholesterol
STAR protein results in increased transport of Cholesterol
STAR protein results in increased export of Cholesterol
[[Niacin co-treated with Chromium] results in increased expression of STAR protein] which results in increased export of Cholesterol; Cholesterol inhibits the reaction [bisphenol A results in increased expression of STAR mRNA]; Cholesterol inhibits the reaction [bisphenol A results in increased expression of STAR protein]
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]

PMID:14630719 PMID:15819722 PMID:17934701 PMID:19900470 PMID:20083572 More...

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 1

increases expression

ISO

Cholesterol results in increased expression of STAT1 protein

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 5A

multiple interactions

ISO

Cholesterol inhibits the reaction [Nicotine results in decreased phosphorylation of STAT5 protein]

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

synaptic vesicle glycoprotein 2a

multiple interactions

ISO

[methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] promotes the reaction [SV2A protein binds to Botulinum Toxins, Type A]

NCBI chr 2:183,741,489...183,757,290
Ensembl chr 2:183,741,547...183,756,927

G

synaptopodin

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SYNPO mRNA

NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126

G

TAFA chemokine like family member 2

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of TAFA2 mRNA

NCBI chr 7:58,942,598...59,418,640
Ensembl chr 7:58,942,610...59,417,299

G

transcription factor AP-2 epsilon

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of TFAP2E mRNA

NCBI chr 5:139,009,447...139,030,695
Ensembl chr 5:139,009,453...139,031,108

G

trefoil factor 3

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of TFF3 mRNA

NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054

G

transforming growth factor, beta 1

increases expression
multiple interactions

ISO
EXP

Cholesterol results in increased expression of TGFB1 mRNA
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TGFB1 mRNA

PMID:19110552 PMID:26606054

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 3

multiple interactions
increases expression

ISO

CLEC4E protein inhibits the reaction [Cholesterol results in increased expression of TIMP3 mRNA]

NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839

G

toll-like receptor 4

multiple interactions

EXP

[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TLR4 mRNA

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

transmembrane 4 L six family member 19

increases expression

ISO

Cholesterol results in increased expression of TM4SF19 mRNA

NCBI chr11:68,372,945...68,386,192
Ensembl chr11:68,371,647...68,384,591

G

transmembrane protein 97

affects metabolic processing

ISO

TMEM97 protein affects the metabolism of Cholesterol

NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730

G

tumor necrosis factor

multiple interactions
increases expression

ISO
EXP

[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of TNF protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of TNF mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of TNF protein]
[Cholesterol co-treated with CLEC4E] results in increased expression of TNF protein; [methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein affects the localization of RELA protein]]; [methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]
Cholesterol analog results in increased expression of TNF mRNA
[Cholesterol co-treated with Particulate Matter] results in increased expression of TNF mRNA; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of TNF mRNA]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein]
Cholesterol results in increased expression of TNF mRNA; Cholesterol results in increased expression of TNF protein

PMID:19028402 PMID:19477266 PMID:23274767 PMID:26296894 PMID:26606054 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 1A

increases expression

EXP

Cholesterol analog results in increased expression of TNFRSF1A protein

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

TNF superfamily member 10

increases expression

EXP

Cholesterol analog results in increased expression of TNFSF10 mRNA; Cholesterol analog results in increased expression of TNFSF10 protein

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

tumor protein p53

multiple interactions

ISO

[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of TP53 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of TP53 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of TP53 mRNA

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

TNF receptor-associated factor 1

increases expression

EXP

Cholesterol analog results in increased expression of TRAF1 mRNA

NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807

G

tribbles pseudokinase 3

multiple interactions

ISO

TRIB3 protein results in increased abundance of and results in increased secretion of Cholesterol

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

ubiquitin D

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of UBD mRNA

NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639
Ensembl chr20:1,385,864...1,408,639

G

ubiquitin-conjugating enzyme E2I

multiple interactions

ISO

UBE2I protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Cholesterol]

NCBI chr10:14,782,245...14,802,911
Ensembl chr10:69,701,618...69,702,443
Ensembl chr10:69,701,618...69,702,443

G

vascular cell adhesion molecule 1

increases expression
multiple interactions

ISO
EXP

Cholesterol results in increased expression of VCAM1 mRNA; Cholesterol results in increased expression of VCAM1 protein
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of VCAM1 mRNA
Cholesterol inhibits the reaction [irbesartan results in increased expression of VCAM1 mRNA]; Cholesterol inhibits the reaction [irbesartan results in increased expression of VCAM1 protein]

PMID:19028402 PMID:26606054

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vitamin D receptor

affects binding
affects abundance

ISO

Cholesterol metabolite binds to VDR protein
VDR gene SNP affects the abundance of Cholesterol

PMID:16051528 PMID:25498546

NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:128,987,981...129,037,677

G

vascular endothelial growth factor A

multiple interactions

EXP

[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

multiple interactions

ISO

Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of VIM mRNA]

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187

G

von Willebrand factor

multiple interactions

EXP

[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein]

NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539

G

Z-DNA binding protein 1

multiple interactions

ISO

[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ZBP1 mRNA

NCBI chr 3:182,411,665...182,427,604
Ensembl chr 3:161,993,351...162,003,870

G

zinc finger E-box binding homeobox 1

multiple interactions

ISO

Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of ZEB1 mRNA]

NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214

G

zinc finger E-box binding homeobox 2

multiple interactions

ISO

Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of ZEB2 mRNA]

NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157

cholesterol sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

ISO

cholesteryl sulfate results in decreased expression of CYP11A1 mRNA

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

steroidogenic acute regulatory protein

decreases expression

ISO

cholesteryl sulfate results in decreased expression of STAR mRNA; cholesteryl sulfate results in decreased expression of STAR protein

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

sulfotransferase family 2B member 1

increases abundance

ISO

SULT2B1 protein results in increased abundance of cholesteryl sulfate

NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295

cholesteryl arachidonate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

multiple interactions
decreases abundance

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate
LIPG gene mutant form results in decreased abundance of cholesteryl arachidonate

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

cholesteryl linoleate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

multiple interactions
affects abundance

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate
LIPG gene mutant form affects the abundance of cholesteryl linoleate

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

cholesteryl linolenate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

multiple interactions
increases abundance

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate
LIPG gene mutant form results in increased abundance of cholesteryl linolenate

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

cholesteryl myristate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl myristate

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

affects abundance
multiple interactions

ISO

LIPG gene mutant form affects the abundance of cholesteryl myristate
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl myristate

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

cholesteryl oleate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

multiple interactions
increases abundance

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate
LIPG gene mutant form results in increased abundance of cholesteryl oleate

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

cholesteryl palmitate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl palmitate

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

multiple interactions
increases abundance

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl palmitate
LIPG gene mutant form results in increased abundance of cholesteryl palmitate

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

cholesteryl stearate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase G, endothelial type

decreases abundance

ISO

LIPG gene mutant form results in decreased abundance of cholesterol stearate

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 8

affects expression

EXP

Corn Oil affects the expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA carboxylase alpha

increases expression

EXP

Corn Oil results in increased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

ATP citrate lyase

affects expression

EXP

Corn Oil affects the expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,412,049...85,463,320

G

acyl-CoA thioesterase 2

affects expression

EXP

Corn Oil affects the expression of ACOT2 mRNA

NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245

G

adiponectin, C1Q and collagen domain containing

multiple interactions

EXP

Corn Oil promotes the reaction [Glucose results in increased expression of ADIPOQ protein]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

aldo-keto reductase family 1, member B7

affects expression

EXP

Corn Oil affects the expression of AKR1B7 mRNA

NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502

G

aldehyde dehydrogenase 1 family, member A1

affects expression

EXP

Corn Oil affects the expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

angiopoietin-like 4

affects expression

EXP

Corn Oil affects the expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

amphiregulin

multiple interactions

ISO

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

BCL2-associated agonist of cell death

increases expression

EXP

Corn Oil results in increased expression of BAD mRNA

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

bradykinin receptor B1

multiple interactions

EXP

Corn Oil inhibits the reaction [Glucose results in increased expression of BDKRB1 protein]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

basic helix-loop-helix family, member e40

affects expression

EXP

Corn Oil affects the expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

betaine-homocysteine S-methyltransferase

affects expression

EXP

Corn Oil affects the expression of BHMT mRNA

NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742

G

baculoviral IAP repeat-containing 3

increases expression

ISO

Corn Oil results in increased expression of BIRC3 mRNA

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:5,000,845...5,015,802

G

bone morphogenetic protein 1

affects expression

EXP

Corn Oil affects the expression of BMP1 mRNA

NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776

G

bone morphogenetic protein 2

multiple interactions

ISO

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

cell adhesion molecule 1

affects expression

EXP

Corn Oil affects the expression of CADM1 mRNA

NCBI chr 8:56,744,374...57,075,264
Ensembl chr 8:47,847,325...48,182,833

G

calcitonin-related polypeptide alpha

multiple interactions

ISO

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of CALCA mRNA

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

carbonic anhydrase 6

increases expression

ISO

Corn Oil results in increased expression of CAR6 mRNA

NCBI chr 5:160,658,104...160,676,644
Ensembl chr 5:160,658,105...160,676,644

G

caspase recruitment domain family, member 9

increases expression

ISO

Corn Oil results in increased expression of CARD9 mRNA

NCBI chr 3:9,171,814...9,180,310
Ensembl chr 3:9,171,815...9,180,237

G

catalase

multiple interactions
decreases expression

ISO

[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in decreased expression of CAT protein
Corn Oil results in decreased expression of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 3

decreases expression

ISO

Corn Oil results in decreased expression of CAV3 mRNA

NCBI chr 4:145,582,168...145,598,142
Ensembl chr 4:145,582,060...145,598,137

G

C-C motif chemokine ligand 3

increases expression
decreases expression

ISO
EXP

Corn Oil results in increased expression of CCL3 mRNA
Corn Oil results in decreased expression of CCL3 mRNA

PMID:22760963 PMID:23409006

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

cyclin D1

affects expression

EXP

Corn Oil affects the expression of CCND1 mRNA

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602

G

CD36 molecule

decreases expression

EXP

Corn Oil results in decreased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cadherin-related family member 1

increases expression

EXP

Corn Oil results in increased expression of CDHR1 mRNA

NCBI chr16:12,843,436...12,863,321
Ensembl chr16:12,843,437...12,863,396

G

cyclin-dependent kinase inhibitor 1A

affects expression
increases expression

EXP

Corn Oil affects the expression of CDKN1A mRNA
Corn Oil results in increased expression of CDKN1A mRNA

PMID:16360708 PMID:22760963

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

centromere protein T

increases expression

EXP

Corn Oil results in increased expression of CENPT mRNA

NCBI chr19:33,734,684...33,741,159
Ensembl chr19:33,734,685...33,741,142

G

complement factor B

increases expression

EXP

Corn Oil results in increased expression of CFB mRNA

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

claudin 1

decreases expression
multiple interactions

ISO
EXP

Corn Oil results in decreased expression of CLDN1 mRNA
[(5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid co-treated with Corn Oil] results in decreased expression of CLDN1 mRNA

PMID:33263755 PMID:39096942

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 9

increases expression

ISO

Corn Oil results in increased expression of CLDN9 mRNA

NCBI chr10:12,714,137...12,715,568

G

cytochrome c oxidase subunit 7A1

decreases expression

ISO

Corn Oil results in decreased expression of COX7A1 mRNA

NCBI chr 1:85,422,162...85,447,530
Ensembl chr 1:85,441,871...85,445,151

G

carnitine palmitoyltransferase 1A

increases expression
multiple interactions
affects expression

EXP
ISO

Corn Oil results in increased expression of CPT1A mRNA
[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of CPT1A mRNA
Corn Oil affects the expression of CPT1A mRNA

PMID:16360708 PMID:22760963 PMID:36432690

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055

G

carnitine palmitoyltransferase 2

multiple interactions

ISO

[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of CPT2 mRNA

NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:122,664,677...122,682,095

G

carnitine O-octanoyltransferase

affects expression
multiple interactions

EXP
ISO

Corn Oil affects the expression of CROT mRNA
[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of CROT mRNA

PMID:16360708 PMID:36432690

NCBI chr 4:26,031,729...26,088,057
Ensembl chr 4:25,080,587...25,133,109

G

cathepsin G

increases expression

EXP

Corn Oil results in increased expression of CTSG mRNA

NCBI chr15:29,930,988...29,937,353
Ensembl chr15:29,931,003...29,937,353

G

cytochrome P450, family 17, subfamily a, polypeptide 1

affects expression

EXP

Corn Oil affects the expression of CYP17A1 mRNA

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450 family 7 subfamily A member 1

affects expression

EXP

Corn Oil affects the expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

affects expression

EXP

Corn Oil affects the expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

epoxide hydrolase 2

affects expression

EXP

Corn Oil affects the expression of EPHX2 mRNA

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

ETS proto-oncogene 1, transcription factor

decreases expression

EXP

Corn Oil results in decreased expression of ETS1 mRNA

NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010

G

fatty acid binding protein 1

multiple interactions

EXP

[Ethanol co-treated with Corn Oil] results in decreased expression of FABP1 mRNA

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 2

affects expression

EXP

Corn Oil affects the expression of FABP2 mRNA

NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089

G

fatty acid binding protein 7

affects expression

EXP

Corn Oil affects the expression of FABP7 mRNA

NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880

G

fatty acid synthase

affects expression

EXP

Corn Oil affects the expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

Fc gamma receptor and transporter

decreases expression

EXP

Corn Oil results in decreased expression of FCGRT mRNA

NCBI chr 1:95,574,436...95,584,171
Ensembl chr 1:95,567,175...95,584,084

G

fibrinogen beta chain

affects expression

EXP

Corn Oil affects the expression of FGB mRNA

NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979

G

fibroblast growth factor 21

affects expression

EXP

Corn Oil affects the expression of FGF21 mRNA

NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454

G

follistatin

multiple interactions

ISO

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of FST mRNA

NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571

G

G0/G1switch 2

affects expression

EXP

Corn Oil affects the expression of G0S2 mRNA

NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451

G

growth arrest and DNA-damage-inducible, alpha

affects expression

EXP

Corn Oil affects the expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:96,154,789...96,157,115

G

galanin and GMAP prepropeptide

increases expression

EXP

Corn Oil results in increased expression of GAL mRNA

NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959

G

glucokinase

affects expression

EXP

Corn Oil affects the expression of GCK mRNA

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

gap junction protein, delta 2

increases expression

ISO

Corn Oil results in increased expression of GJD2 mRNA

NCBI chr 3:100,771,450...100,776,134
Ensembl chr 3:100,772,062...100,775,061

G

glutamic-oxaloacetic transaminase 1

affects expression

EXP

Corn Oil affects the expression of GOT1 mRNA

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic-oxaloacetic transaminase 2

decreases expression

EXP

Corn Oil results in decreased expression of GOT2 mRNA

NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994

G

glycerol-3-phosphate dehydrogenase 2

affects expression

EXP

Corn Oil affects the expression of GPD2 mRNA

NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901

G

glutamic--pyruvic transaminase

multiple interactions

EXP

[(5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid co-treated with Corn Oil] results in increased activity of GPT protein; [Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein; Dactinomycin inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]; Orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]

PMID:29479035 PMID:39096942

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

H2A clustered histone 25

affects expression

EXP

Corn Oil affects the expression of H2A mRNA

NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874

G

histidine ammonia lyase

affects expression

EXP

Corn Oil affects the expression of HAL mRNA

NCBI chr 7:28,007,449...28,037,701
Ensembl chr 7:28,006,972...28,037,701

G

hepcidin antimicrobial peptide

affects expression

EXP

Corn Oil affects the expression of HAMP mRNA

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

3-hydroxy-3-methylglutaryl-CoA reductase

affects expression

EXP

Corn Oil affects the expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

homeobox A11

multiple interactions

ISO

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of HOXA11 mRNA

NCBI chr 4:81,342,527...81,346,189
Ensembl chr 4:81,342,528...81,346,232

G

haptoglobin

increases expression

EXP

Corn Oil results in increased expression of HP mRNA

NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523

G

heat shock protein 90 alpha family class A member 1

increases expression

ISO

Corn Oil results in increased expression of HSP90AA1 mRNA

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

isopentenyl-diphosphate delta isomerase 1

affects expression

EXP

Corn Oil affects the expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

insulin-like growth factor 2 mRNA binding protein 2

affects expression
increases expression

EXP

Corn Oil affects the expression of IGF2BP2 mRNA
Corn Oil results in increased expression of IGF2BP2 mRNA

NCBI chr11:78,874,402...78,974,392
Ensembl chr11:78,874,414...78,974,377

G

insulin-like growth factor binding protein 1

affects expression

EXP

Corn Oil affects the expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interferon gamma induced GTPase

affects expression

EXP

Corn Oil affects the expression of IGTP mRNA

NCBI chr10:42,374,590...42,382,410
Ensembl chr10:42,357,400...42,408,247

G

Indian hedgehog signaling molecule

multiple interactions

ISO

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of IHH mRNA

NCBI chr 9:76,504,315...76,510,532
Ensembl chr 9:76,504,315...76,510,532

G

interleukin 12B

increases secretion

EXP

Corn Oil results in increased secretion of IL12B protein

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 18

increases expression

ISO

Corn Oil results in increased expression of IL18 mRNA

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 alpha

increases secretion

EXP

Corn Oil results in increased secretion of IL1A protein

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases secretion

EXP

Corn Oil results in increased secretion of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

increases expression

EXP

Corn Oil results in increased expression of IL1RN mRNA

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 4

increases expression
increases secretion
decreases expression

ISO
EXP

Corn Oil results in increased expression of IL4 mRNA
Corn Oil results in increased secretion of IL4 protein
Corn Oil results in decreased expression of IL4 mRNA

PMID:23409006 PMID:33263755

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6 receptor

increases expression

EXP

Corn Oil results in increased expression of IL6R mRNA

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

interleukin 9

increases secretion

EXP

Corn Oil results in increased secretion of IL9 protein

NCBI chr17:8,111,772...8,114,895
Ensembl chr17:8,111,772...8,114,895

G

inhibin subunit beta E

affects expression

EXP

Corn Oil affects the expression of INHBE mRNA

NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172

G

insulin 1

multiple interactions

EXP

Corn Oil inhibits the reaction [Glucose results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

interleukin-1 receptor-associated kinase 1

increases expression

ISO

Corn Oil results in increased expression of IRAK1 mRNA

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

interferon regulatory factor 5

increases expression

ISO

Corn Oil results in increased expression of IRF5 mRNA

NCBI chr 4:58,127,577...58,140,665
Ensembl chr 4:58,127,640...58,139,267

G

interferon regulatory factor 7

increases expression

ISO

Corn Oil results in increased expression of IRF7 mRNA

NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Corn Oil results in increased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656

G

KLF transcription factor 2

affects expression

EXP

Corn Oil affects the expression of KLF2 mRNA

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

lecithin cholesterol acyltransferase

multiple interactions

ISO

[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of LCAT mRNA

NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231

G

lipocalin 2

increases expression

EXP

Corn Oil results in increased expression of LCN2 mRNA

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

leptin

multiple interactions

EXP

Corn Oil inhibits the reaction [Glucose results in increased expression of LEP protein]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

galectin 1

increases expression

EXP

Corn Oil results in increased expression of LGALS1 mRNA

NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345

G

lysyl oxidase

multiple interactions

ISO

Corn Oil results in increased activity of and results in increased cleavage of LOX protein

NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477

G

lymphocyte antigen 75

increases expression

EXP

Corn Oil results in increased expression of LY75 mRNA

NCBI chr 3:44,764,702...44,852,219
Ensembl chr 3:44,765,122...44,852,374

G

mitogen activated protein kinase kinase 1

increases expression

ISO

Corn Oil results in increased expression of MAP2K1 mRNA

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 3

increases expression

ISO

Corn Oil results in increased expression of MAP2K3 mRNA

NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492

G

mitogen-activated protein kinase kinase 6

affects expression

EXP

Corn Oil affects the expression of MAP2K6 mRNA

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

mitogen activated protein kinase kinase kinase 7

increases expression

ISO

Corn Oil results in increased expression of MAP3K7 mRNA

NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597

G

mitogen activated protein kinase 1

increases expression

ISO

Corn Oil results in increased expression of MAPK1 mRNA

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

increases expression

ISO

Corn Oil results in increased expression of MAPK14 mRNA

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

increases expression

ISO

Corn Oil results in increased expression of MAPK3 mRNA

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

MDM2 proto-oncogene

decreases expression

EXP

Corn Oil results in decreased expression of MDM2 mRNA

NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:53,290,664...53,314,915

G

O-6-methylguanine-DNA methyltransferase

increases expression

EXP

Corn Oil results in increased expression of MGMT mRNA

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

microsomal glutathione S-transferase 2

increases expression

EXP

Corn Oil results in increased expression of MGST2 mRNA

NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828

G

malonyl-CoA decarboxylase

decreases expression

EXP

Corn Oil results in decreased expression of MLYCD mRNA

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

methylsterol monooxygenase 1

affects expression

EXP

Corn Oil affects the expression of MSMO1 mRNA

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

5-methyltetrahydrofolate-homocysteine methyltransferase

multiple interactions

ISO

[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of MTR mRNA

NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822

G

MX dynamin like GTPase 2

affects expression

EXP

Corn Oil affects the expression of MX2 mRNA

NCBI chr11:36,905,698...36,936,308
Ensembl chr11:36,906,111...36,930,342

G

MYD88, innate immune signal transduction adaptor

increases expression

ISO

Corn Oil results in increased expression of MYD88 mRNA

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:119,074,437...119,079,415

G

NFE2 like bZIP transcription factor 2

decreases activity

ISO

Corn Oil results in decreased activity of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

increases expression

ISO

Corn Oil results in increased expression of NFKBIA mRNA

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941

G

NLR family, CARD domain containing 4

increases expression

ISO

Corn Oil results in increased expression of NLRC4 mRNA

NCBI chr 6:20,991,785...21,018,254
Ensembl chr 6:20,995,266...21,018,248

G

nuclear receptor subfamily 1, group H, member 4

affects expression

EXP

Corn Oil affects the expression of NR1H4 mRNA

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 4, group A, member 2

increases expression

EXP

Corn Oil results in increased expression of NR4A2 mRNA

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

NSE3 homolog, SMC5-SMC6 complex component

affects expression

EXP

Corn Oil affects the expression of NSMCE3 mRNA

NCBI chr 1:118,401,302...118,402,629

G

ornithine aminotransferase

affects expression

EXP

Corn Oil affects the expression of OAT mRNA

NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:187,347,865...187,367,682

G

occludin

multiple interactions

EXP

[(5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid co-treated with Corn Oil] results in decreased expression of OCLN mRNA

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

oxidative stress induced growth inhibitor 1

affects expression

EXP

Corn Oil affects the expression of OSGIN1 mRNA

NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516

G

purinergic receptor P2X 5

affects expression

EXP

Corn Oil affects the expression of P2RX5 mRNA

NCBI chr10:57,777,737...57,789,426
Ensembl chr10:57,777,819...57,789,423

G

paired box 8

affects expression

EXP

Corn Oil affects the expression of PAX8 mRNA

NCBI chr 3:7,185,721...7,242,363
Ensembl chr 3:7,185,723...7,242,363

G

platelet derived growth factor subunit A

affects expression

EXP

Corn Oil affects the expression of PDGFA mRNA

NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497

G

platelet derived growth factor receptor beta

increases expression

EXP

Corn Oil results in increased expression of PDGFRB mRNA

NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843

G

PDZ and LIM domain 1

affects expression

EXP

Corn Oil affects the expression of PDLIM1 mRNA

NCBI chr 1:239,042,372...239,091,074
Ensembl chr 1:239,042,385...239,091,076

G

PDZ and LIM domain 2

affects expression

EXP

Corn Oil affects the expression of PDLIM2 mRNA

NCBI chr15:45,235,421...45,250,187
Ensembl chr15:45,237,477...45,249,242

G

placental growth factor

increases expression

EXP

Corn Oil results in increased expression of PGF mRNA

NCBI chr 6:104,816,102...104,826,685
Ensembl chr 6:104,816,104...104,826,685

G

progesterone receptor membrane component 2

affects expression

EXP

Corn Oil affects the expression of PGRMC2 mRNA

NCBI chr 2:124,068,257...124,084,155
Ensembl chr 2:124,068,260...124,084,155

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

increases expression

ISO

Corn Oil results in increased expression of PIK3CA mRNA

NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:115,174,984...115,249,032

G

perilipin 2

affects expression

EXP

Corn Oil affects the expression of PLIN2 mRNA

NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319

G

prolactin receptor

affects expression

EXP

Corn Oil affects the expression of PRLR mRNA

NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine phosphatase, receptor type, F

affects expression

EXP

Corn Oil affects the expression of PTPRF mRNA

NCBI chr 5:131,741,959...131,824,000
Ensembl chr 5:131,742,754...131,810,023

G

PYD and CARD domain containing

increases expression

ISO

Corn Oil results in increased expression of PYCARD mRNA

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

Rac family small GTPase 1

increases expression

ISO

Corn Oil results in increased expression of RAC1 mRNA

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

receptor interacting serine/threonine kinase 1

increases expression

ISO

Corn Oil results in increased expression of RIPK1 mRNA

NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824

G

receptor-interacting serine-threonine kinase 2

increases expression

ISO

Corn Oil results in increased expression of RIPK2 mRNA

NCBI chr 5:29,630,806...29,662,804
Ensembl chr 5:29,631,570...29,662,657

G

RT1 class I, locus A

increases expression

EXP

Corn Oil results in increased expression of RT1-A mRNA

G

RT1 class II, locus Bb

increases expression

EXP

Corn Oil results in increased expression of RT1-BB mRNA

NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597

G

RT1 class I, locus CE11

decreases expression

EXP

Corn Oil results in decreased expression of RT1-CE11 mRNA

NCBI chr20:3,355,393...3,358,520
Ensembl chr20:3,350,937...3,380,362

G

RT1 class I, locus CE14

increases expression

EXP

Corn Oil results in increased expression of RT1-CE14 mRNA

NCBI chr20:3,296,654...3,300,795
Ensembl chr20:3,297,196...3,305,134

G

RT1 class I, locus CE15

decreases expression

EXP

Corn Oil results in decreased expression of RT1-CE15 mRNA

NCBI chr20:3,275,575...3,279,074
Ensembl chr20:3,264,172...3,279,563
Ensembl chr20:3,264,172...3,279,563

G

RT1 class I, locus CE16

increases expression

EXP

Corn Oil results in increased expression of RT1-CE16 mRNA

NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563

G

RT1 class I, locus CE2

increases expression

EXP

Corn Oil results in increased expression of RT1-CE2 mRNA

NCBI chr20:3,538,452...3,541,841
Ensembl chr20:3,537,809...3,541,790

G

RT1 class I, locus CE3

increases expression

EXP

Corn Oil results in increased expression of RT1-CE3 mRNA

NCBI chr20:3,516,647...3,520,938
Ensembl chr20:2,623,953...2,692,081

G

RT1 class I, locus CE4

increases expression

EXP

Corn Oil results in increased expression of RT1-CE4 mRNA

NCBI chr20:3,431,509...3,504,535

G

RT1 class I, locus CE5

increases expression

EXP

Corn Oil results in increased expression of RT1-CE5 mRNA

NCBI chr20:3,403,418...3,479,476

G

RT1 class Ib, locus N1

decreases expression

EXP

Corn Oil results in decreased expression of RT1-N1 mRNA

G

S100 calcium binding protein A8

increases expression

EXP

Corn Oil results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

increases expression

EXP

Corn Oil results in increased expression of S100A9 mRNA

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

stearoyl-CoA desaturase

affects expression

EXP

Corn Oil affects the expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

sodium voltage-gated channel beta subunit 1

affects expression

EXP

Corn Oil affects the expression of SCN1B mRNA

NCBI chr 1:86,353,917...86,363,820
Ensembl chr 1:86,353,917...86,363,739

G

serine dehydratase

affects expression

EXP

Corn Oil affects the expression of SDS mRNA

NCBI chr12:36,083,226...36,090,540
Ensembl chr12:36,083,229...36,088,203

G

secreted frizzled-related protein 2

decreases expression

EXP

Corn Oil results in decreased expression of SFRP2 mRNA

NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063

G

solute carrier family 25 member 20

multiple interactions

ISO

[bisphenol A co-treated with Resveratrol co-treated with Corn Oil] results in increased expression of SLC25A20 mRNA

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

solute carrier family 25 member 25

affects expression

EXP

Corn Oil affects the expression of SLC25A25 mRNA

NCBI chr 3:15,708,702...15,742,195
Ensembl chr 3:15,708,703...15,742,216

G

superoxide dismutase 1

decreases activity
multiple interactions

ISO

Corn Oil results in decreased activity of SOD1 protein
[Corn Oil co-treated with Iron, Dietary] results in decreased activity of SOD1 protein; [Corn Oil co-treated with Iron] results in decreased activity of SOD1 protein; Iron promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]; Iron, Dietary promotes the reaction [Corn Oil results in decreased activity of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

secreted protein acidic and cysteine rich

increases expression

EXP

Corn Oil results in increased expression of SPARC mRNA

NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396

G

squalene epoxidase

affects expression

EXP

Corn Oil affects the expression of SQLE mRNA

NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618

G

sterol regulatory element binding transcription factor 1

affects expression

EXP

Corn Oil affects the expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

somatostatin receptor 3

decreases expression

EXP

Corn Oil results in decreased expression of SSTR3 mRNA

NCBI chr 7:110,092,563...110,109,043
Ensembl chr 7:110,092,575...110,099,769

G

SGT1 homolog, MIS12 kinetochore complex assembly cochaperone

increases expression

ISO

Corn Oil results in increased expression of SUGT1 mRNA

NCBI chr15:54,991,419...55,032,244
Ensembl chr15:54,990,672...55,069,150

G

spleen associated tyrosine kinase

increases expression

ISO

Corn Oil results in increased expression of SYK mRNA

NCBI chr17:12,756,493...12,830,927
Ensembl chr17:12,604,619...12,661,410

G

tachykinin, precursor 1

decreases expression

EXP

Corn Oil results in decreased expression of TAC1 mRNA

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

tyrosine aminotransferase

affects expression

EXP

Corn Oil affects the expression of TAT mRNA

NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031

G

TBC1 domain family, member 14

affects expression

EXP

Corn Oil affects the expression of TBC1D14 mRNA

NCBI chr14:74,172,652...74,272,182
Ensembl chr14:74,172,664...74,272,183

G

transforming growth factor alpha

decreases expression

EXP

Corn Oil results in decreased expression of TGFA mRNA

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

TIR domain containing adaptor molecule 1

increases expression

ISO

Corn Oil results in increased expression of TICAM1 mRNA

NCBI chr 9:1,102,559...1,111,023
Ensembl chr 9:1,102,366...1,123,147

G

tight junction protein 1

multiple interactions

EXP

[(5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid co-treated with Corn Oil] results in decreased expression of TJP1 mRNA

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tight junction protein 2

increases expression

ISO

Corn Oil results in increased expression of TJP2 mRNA

NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295

G

tight junction protein 3

increases expression

ISO

Corn Oil results in increased expression of TJP3 mRNA

NCBI chr 7:8,427,650...8,446,279
Ensembl chr 7:8,432,811...8,446,279

G

TNF receptor superfamily member 1A

increases expression

ISO

Corn Oil results in increased expression of TNFRSF1A mRNA

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

toll interacting protein

increases expression

ISO

Corn Oil results in increased expression of TOLLIP mRNA

NCBI chr 1:196,961,585...196,984,252
Ensembl chr 1:196,950,771...196,983,625

G

two pore segment channel 2

affects expression

EXP

Corn Oil affects the expression of TPCN2 mRNA

NCBI chr 1:200,416,538...200,446,252
Ensembl chr 1:200,416,540...200,446,236

G

tumor protein, translationally-controlled 1

increases expression

EXP

Corn Oil results in increased expression of TPT1 mRNA

NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625

G

vascular endothelial growth factor B

decreases expression

EXP

Corn Oil results in decreased expression of VEGFB mRNA

NCBI chr 1:204,172,297...204,178,046
Ensembl chr 1:204,172,225...204,177,944

G

vanin 1

affects expression

EXP

Corn Oil affects the expression of VNN1 mRNA

NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395

G

WAP four-disulfide core domain 21

increases expression

EXP

Corn Oil results in increased expression of WFDC21 mRNA

NCBI chr10:68,627,836...68,633,705
Ensembl chr10:68,627,820...68,633,701

G

X-linked inhibitor of apoptosis

decreases expression

ISO

Corn Oil results in decreased expression of XIAP mRNA

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:120,897,907...120,934,700

G

X-prolyl aminopeptidase 2

affects expression

EXP

Corn Oil affects the expression of XPNPEP2 mRNA

NCBI chr X:127,287,765...127,317,036
Ensembl chr X:127,287,979...127,317,223

G

zinc finger DHHC-type palmitoyltransferase 23

affects expression

EXP

Corn Oil affects the expression of ZDHHC23 mRNA

NCBI chr11:70,224,581...70,240,971
Ensembl chr11:56,718,826...56,734,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

peroxisome proliferator-activated receptor gamma

increases activity

ISO

linoleamide analog results in increased activity of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
decreases expression
increases expression
increases phosphorylation
increases degradation

ISO

1-Butanol inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]]; Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Phospholipids]]; triacsin C inhibits the reaction [Linoleic Acid results in increased degradation of ABCA1 protein]
Linoleic Acid analog results in decreased expression of ABCA1 mRNA
Linoleic Acid results in increased expression of ABCA1 mRNA
Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]
Linoleic Acid results in increased phosphorylation of ABCA1 protein

PMID:16118212 PMID:18356535 PMID:27939595

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily G member 1

decreases expression

ISO

Linoleic Acid results in decreased expression of ABCG1 mRNA; Linoleic Acid results in decreased expression of ABCG1 protein

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

acetyl-CoA carboxylase alpha

decreases expression

EXP

Linoleic Acid results in decreased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acyl-CoA dehydrogenase medium chain

increases expression

EXP

Linoleic Acid results in increased expression of ACADM mRNA

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

ATP citrate lyase

decreases expression

EXP

Linoleic Acid results in decreased expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,412,049...85,463,320

G

aminocarboxymuconate semialdehyde decarboxylase

decreases expression

EXP

Linoleic Acid results in decreased expression of ACMSD mRNA

NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209

G

acyl-CoA oxidase 1

increases expression

EXP

Linoleic Acid results in increased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

adiponectin, C1Q and collagen domain containing

decreases expression

ISO

Linoleic Acid results in decreased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adiponectin receptor 1

increases expression

ISO

Linoleic Acid analog results in increased expression of ADIPOR1 mRNA

NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241

G

advanced glycosylation end product-specific receptor

multiple interactions

EXP

AGER protein results in increased susceptibility to [Azoxymethane co-treated with Glucose co-treated with Linoleic Acid]; Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]; Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Losartan inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Losartan inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]

NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078

G

aryl hydrocarbon receptor

multiple interactions

ISO

Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

arachidonate 15-lipoxygenase

increases oxidation

ISO

ALOX15 protein results in increased oxidation of Linoleic Acid

NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874

G

apolipoprotein A1

multiple interactions

ISO

Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

amyloid beta precursor protein

multiple interactions

ISO

[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

achaete-scute family bHLH transcription factor 2

decreases expression

ISO

Linoleic Acid results in decreased expression of ASCL2 mRNA

NCBI chr 1:198,148,999...198,151,406
Ensembl chr 1:198,148,999...198,151,406

G

butyrylcholinesterase

increases expression

ISO

Linoleic Acid results in increased expression of BCHE mRNA

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

BCL2, apoptosis regulator

multiple interactions

EXP

[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of BCL2 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

catalase

increases expression
multiple interactions

ISO
EXP

Linoleic Acid results in increased expression of CAT protein
Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased activity of CAT protein]

PMID:10946007 PMID:34111468

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

increases expression

ISO

Linoleic Acid results in increased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

CD36 molecule

multiple interactions

EXP

[Oleic Acid co-treated with Linoleic Acid] results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

EXP

Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of CHRNA7 mRNA]

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

cannabinoid receptor 1

multiple interactions
affects response to substance

ISO

CNR1 protein affects the reaction [Linoleic Acid results in increased secretion of GCG protein]
CNR1 protein affects the susceptibility to Linoleic Acid

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

collagen type I alpha 1 chain

increases expression

ISO

Linoleic Acid results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type III alpha 1 chain

decreases expression

ISO

Linoleic Acid results in decreased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

carnitine palmitoyltransferase 1A

increases expression

EXP

Linoleic Acid results in increased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055

G

CREB binding protein

multiple interactions

ISO

Linoleic Acid affects the reaction [PPARA protein binds to CREBBP protein]

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,335,953...11,461,888

G

cytochrome c, somatic

multiple interactions

ISO

[Oleic Acid co-treated with Linoleic Acid] results in increased expression of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

ISO

Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 promoter]]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity

ISO

Linoleic Acid results in decreased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions
decreases activity

ISO

CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]
Linoleic Acid results in decreased activity of CYP2C19 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity

ISO

Linoleic Acid results in decreased activity of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

ISO

Linoleic Acid results in decreased activity of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

DNA-damage inducible transcript 3

increases expression

ISO

Linoleic Acid analog results in increased expression of DDIT3 protein

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

iodothyronine deiodinase 1

decreases activity

ISO

Linoleic Acid results in decreased activity of DIO1 protein

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 2

decreases activity

ISO

Linoleic Acid results in decreased activity of DIO2 protein

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

decreases activity

ISO

Linoleic Acid results in decreased activity of DIO3 protein

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

endothelin 1

decreases expression

ISO

Linoleic Acid results in decreased expression of EDN1 mRNA; Linoleic Acid results in decreased expression of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

fatty acid binding protein 1

decreases expression

ISO

Linoleic Acid results in decreased expression of FABP1 mRNA

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 3

decreases expression

ISO

Linoleic Acid results in decreased expression of FABP3 mRNA

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

fatty acid binding protein 4

affects localization

ISO

Linoleic Acid analog affects the localization of FABP4 protein

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

fatty acid desaturase 2

multiple interactions
increases expression

ISO

[Linoleic Acid co-treated with Testosterone] results in increased expression of FADS2 mRNA
FADS2 protein inhibits the reaction [Linoleic Acid results in increased activity of LOX protein]
Linoleic Acid results in increased expression of FADS2 mRNA; Linoleic Acid results in increased expression of FADS2 protein

PMID:21457203 PMID:26240151

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

fatty acid synthase

decreases expression

EXP

Linoleic Acid results in decreased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

free fatty acid receptor 3

increases expression

ISO

Linoleic Acid analog results in increased expression of FFAR3 mRNA

NCBI chr 1:86,105,388...86,106,728
Ensembl chr 1:86,104,920...86,106,849

G

forkhead box O1

decreases expression

ISO

Linoleic Acid results in decreased expression of FOXO1 protein

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790

G

glucagon

multiple interactions

ISO

CNR1 protein affects the reaction [Linoleic Acid results in increased secretion of GCG protein]

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

glutamate cysteine ligase, modifier subunit

increases expression

ISO

Linoleic Acid metabolite results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

gap junction protein, beta 1

increases abundance

ISO

GJB1 protein results in increased abundance of Linoleic Acid

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

glutamate ionotropic receptor NMDA type subunit 2A

multiple interactions

EXP

Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of GRIN2A mRNA]

NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

EXP

Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of GRIN2B mRNA]

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

glutathione S-transferase alpha 1

increases expression
multiple interactions

ISO

Linoleic Acid results in increased expression of GSTA1 mRNA
NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of GSTA1 mRNA]

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 4

increases expression

ISO

Linoleic Acid metabolite results in increased expression of GSTA4 mRNA

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

hepatitis A virus cellular receptor 1

increases secretion

ISO

Linoleic Acid results in increased secretion of HAVCR1 protein

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

heme oxygenase 1

multiple interactions
increases expression

ISO

NFE2L2 mRNA promotes the reaction [Linoleic Acid metabolite results in increased expression of HMOX1 mRNA]
Linoleic Acid metabolite results in increased expression of HMOX1 mRNA; Linoleic Acid metabolite results in increased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 5

increases expression

ISO

Linoleic Acid analog results in increased expression of HSPA5 protein

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891

G

interferon gamma

increases expression

ISO

Linoleic Acid results in increased expression of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

increases expression

ISO

Linoleic Acid results in increased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

increases expression
multiple interactions

ISO
EXP

Linoleic Acid results in increased expression of IL1B protein
Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of IL1B mRNA]

PMID:16305726 PMID:34111468

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

decreases expression

ISO

Linoleic Acid results in decreased expression of IL2 protein

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 4

decreases expression

ISO

Linoleic Acid results in decreased expression of IL4 protein

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

decreases expression

ISO

Linoleic Acid results in decreased expression of IL5 protein

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

affects expression
multiple interactions
increases expression
increases secretion

ISO
EXP

Linoleic Acid affects the expression of IL6 protein
Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of IL6 mRNA]
Linoleic Acid results in increased expression of IL6 mRNA
Linoleic Acid results in increased secretion of IL6 protein

PMID:16305726 PMID:17374693 PMID:21457203 PMID:34111468

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin receptor

increases expression

ISO

Linoleic Acid analog results in increased expression of INSR mRNA

NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883

G

iodotyrosine deiodinase

multiple interactions

ISO

Linoleic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

G

lecithin cholesterol acyltransferase

increases expression

ISO

Linoleic Acid analog results in increased expression of LCAT mRNA

NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231

G

lipase C, hepatic type

multiple interactions

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Linoleic Acid

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

multiple interactions

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Linoleic Acid

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

G

lysyl oxidase

multiple interactions
increases activity

ISO

FADS2 protein inhibits the reaction [Linoleic Acid results in increased activity of LOX protein]; TGFB1 protein promotes the reaction [Linoleic Acid results in increased activity of LOX protein]

NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477

G

lipin 1

decreases expression

ISO

Linoleic Acid analog results in decreased expression of LPIN1 mRNA

NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097

G

lecithin retinol acyltransferase

increases expression

EXP

Linoleic Acid results in increased expression of LRAT mRNA

NCBI chr 2:170,562,148...170,571,212
Ensembl chr 2:168,266,877...168,273,619

G

mitogen activated protein kinase 3

multiple interactions

ISO

Linoleic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

multiple interactions
decreases expression

ISO
EXP

Linoleic Acid results in decreased expression of and results in decreased activity of MMP9 protein
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of MMP9 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of MMP9 protein]
Linoleic Acid results in decreased expression of MMP9 mRNA

PMID:22467055 PMID:23288142

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

neutrophil cytosolic factor 1

multiple interactions

ISO

Linoleic Acid affects the reaction [Zymosan analog affects the localization of NCF1 protein]

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

neutrophil cytosolic factor 2

multiple interactions

ISO

Linoleic Acid affects the reaction [Zymosan analog affects the localization of NCF2 protein]

NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277

G

nuclear receptor coactivator 1

multiple interactions

ISO

Linoleic Acid promotes the reaction [PPARA protein binds to NCOA1 protein]

NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:27,232,611...27,475,664

G

nuclear receptor coactivator 2

multiple interactions

ISO

Linoleic Acid promotes the reaction [PPARA protein binds to NCOA2 protein]

NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:5,835,706...6,067,451

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions

ISO

Linoleic Acid metabolite results in increased expression of NFE2L2 protein; Linoleic Acid results in increased expression of NFE2L2 mRNA; Linoleic Acid results in increased expression of NFE2L2 protein
NFE2L2 mRNA promotes the reaction [Linoleic Acid metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 mRNA]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of CYP2A6 protein]; NFE2L2 protein promotes the reaction [Linoleic Acid results in increased expression of GSTA1 mRNA]

PMID:26879219 PMID:28555106

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

EXP

Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of NFKB1 mRNA]

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions

EXP

[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of NOS2 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

decreases expression

ISO

Linoleic Acid results in decreased expression of NOS3 mRNA

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

NAD(P)H quinone dehydrogenase 1

increases expression

ISO

Linoleic Acid metabolite results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

ISO

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Linoleic Acid analog

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

ISO

[Glucose deficiency co-treated with Linoleic Acid] results in increased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

pyruvate dehydrogenase kinase 4

increases expression

EXP

Linoleic Acid results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

phospholipase D2

multiple interactions

ISO

PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]

NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808

G

perilipin 1

increases expression

ISO

Linoleic Acid analog results in increased expression of PLIN1 mRNA

NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828

G

paraoxonase 1

multiple interactions
decreases activity

ISO

Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Linoleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid]
Linoleic Acid results in decreased activity of PON1 protein

PMID:12871208 PMID:15375178

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

multiple interactions
increases expression
affects abundance
increases activity
affects binding

ISO
EXP

[Bezafibrate binds to and results in increased activity of PPARA protein] which results in increased oxidation of Linoleic Acid; Linoleic Acid affects the reaction [PPARA protein binds to CREBBP protein]; Linoleic Acid binds to and results in increased activity of PPARA protein; Linoleic Acid promotes the reaction [PPARA protein binds to NCOA1 protein]; Linoleic Acid promotes the reaction [PPARA protein binds to NCOA2 protein]
Linoleic Acid results in increased expression of PPARA mRNA
PPARA protein affects the abundance of Linoleic Acid
Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of Linoleic Acid]; Linoleic Acid binds to and results in increased activity of PPARA protein
Linoleic Acid results in increased expression of PPARA mRNA; Linoleic Acid results in increased expression of PPARA protein
Linoleic Acid results in increased activity of PPARA protein
Linoleic Acid binds to PPARA protein

PMID:10403814 PMID:11172467 PMID:15491415 PMID:16731579 PMID:18154422 More...

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor delta

multiple interactions
decreases expression
increases expression
increases activity
affects binding

ISO
EXP

Linoleic Acid binds to and results in increased activity of PPARB protein
Linoleic Acid results in decreased expression of PPARD mRNA
Linoleic Acid results in increased expression of PPARD mRNA
Linoleic Acid results in increased activity of PPARD protein
Linoleic Acid binds to PPARB protein

PMID:11172467 PMID:15708366 PMID:16731579 PMID:23843199 PMID:25786526

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

peroxisome proliferator-activated receptor gamma

affects binding
multiple interactions
increases expression
increases activity
decreases expression

ISO
EXP

Linoleic Acid binds to PPARG protein
Linoleic Acid binds to and results in increased activity of PPARG protein
Linoleic Acid results in increased expression of PPARG mRNA
resveratrol inhibits the reaction [Linoleic Acid results in increased expression of PPARG protein]
Linoleic Acid results in increased activity of PPARG protein
Linoleic Acid results in decreased expression of PPARG mRNA; Linoleic Acid results in decreased expression of PPARG protein

PMID:11172467 PMID:12021203 PMID:15708366 PMID:16731579 PMID:18154422 More...

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

increases expression

EXP
ISO

Linoleic Acid results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

PPARG coactivator 1 beta

increases expression

EXP

Linoleic Acid results in increased expression of PPARGC1B mRNA

NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194

G

presenilin 1

multiple interactions

ISO

[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Linoleic Acid]

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

EXP
ISO

Linoleic Acid results in increased expression of PTGS2 mRNA
Linoleic Acid inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 mRNA]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PTGS2 promoter]]; Linoleic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]

PMID:14563831 PMID:18001219

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

retinoid X receptor alpha

affects binding
multiple interactions

ISO

Linoleic Acid binds to RXRA protein
Linoleic Acid binds to and results in increased activity of RXRA protein

PMID:16258897 PMID:16731579

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

stearoyl-CoA desaturase

multiple interactions
increases expression

ISO

[Linoleic Acid co-treated with Testosterone] results in increased expression of SCD mRNA
Linoleic Acid results in increased expression of SCD mRNA; Linoleic Acid results in increased expression of SCD protein

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

serpin family E member 1

increases expression

ISO

Linoleic Acid results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

solute carrier family 22 member 6

decreases activity

ISO

Linoleic Acid results in decreased activity of SLC22A6 protein

NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173

G

solute carrier family 22 member 8

decreases activity

ISO

Linoleic Acid results in decreased activity of SLC22A8 protein

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

SMAD family member 3

decreases abundance

ISO

SMAD3 protein results in decreased abundance of Linoleic Acid

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

sterol regulatory element binding transcription factor 1

decreases expression

EXP

Linoleic Acid results in decreased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

transforming growth factor, beta 1

multiple interactions

ISO

TGFB1 protein promotes the reaction [Linoleic Acid results in increased activity of LOX protein]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

decreases response to substance
multiple interactions

ISO
EXP

Linoleic Acid results in decreased susceptibility to TNF protein
Linoleic Acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TNF mRNA]

PMID:22683933 PMID:34111468

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

ISO

TRPV1 results in increased susceptibility to [Linoleic Acid co-treated with Freund's Adjuvant]

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

uncoupling protein 2

increases expression

EXP

Linoleic Acid results in increased expression of UCP2 mRNA

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

vascular endothelial growth factor A

multiple interactions

EXP

[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

Wnt family member 10B

decreases expression

ISO

Linoleic Acid results in decreased expression of WNT10B mRNA

NCBI chr 7:129,922,088...129,927,892
Ensembl chr 7:129,922,088...129,927,892

linoleic acid hydroperoxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions
increases lipidation

ISO

Ascorbic Acid promotes the reaction [linoleic acid hydroperoxide results in increased lipidation of AGT protein modified form]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

cytoglobin

increases metabolic processing

EXP

CYGB protein results in increased metabolism of linoleic acid hydroperoxide

NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442

G

glutathione peroxidase 1

increases reduction

ISO

GPX1 protein results in increased reduction of linoleic acid hydroperoxide

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 2

increases reduction

ISO

GPX2 protein results in increased reduction of linoleic acid hydroperoxide

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 mRNA]; lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

angiotensinogen

multiple interactions

ISO

2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aryl hydrocarbon receptor

multiple interactions

ISO

AHR affects the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

arachidonate 5-lipoxygenase

multiple interactions
affects abundance

EXP

zileuton inhibits the reaction [ALOX5 protein affects the abundance of lipoxin A4]

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases expression

EXP

Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

collagen type I alpha 1 chain

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of COL1A2 protein]

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

C-X-C motif chemokine ligand 2

multiple interactions

ISO

lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of CXCL2 protein]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

formyl peptide receptor 2

multiple interactions
increases activity

ISO
EXP

[Aspirin results in increased abundance of lipoxin A4] which results in increased expression of FPR2; lipoxin A4 analog binds to and results in decreased activity of FPR2 protein
lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FPR2 mRNA]
lipoxin A4 results in increased activity of FPR2

PMID:12594298 PMID:19597002 PMID:21765620

NCBI chr 1:58,776,592...58,785,227
Ensembl chr 1:58,776,752...58,786,019

G

heme oxygenase 1

increases expression
multiple interactions

EXP

lipoxin A4 results in increased expression of HMOX1 mRNA; lipoxin A4 results in increased expression of HMOX1 protein
lipoxin A4 promotes the reaction [NFE2L2 protein binds to HMOX1 enhancer]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

intercellular adhesion molecule 1

affects response to substance
increases expression
multiple interactions

ISO
EXP

ICAM1 protein affects the susceptibility to lipoxin A4
lipoxin A4 results in increased expression of ICAM1 protein
Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of ICAM1 protein]

PMID:7602232 PMID:36057361

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 10

multiple interactions

ISO

2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]]; lipoxin A4 promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of IL13 protein]

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 1 beta

decreases expression
multiple interactions
decreases secretion

ISO

lipoxin A4 analog results in decreased expression of IL1B protein
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
lipoxin A4 analog results in decreased secretion of IL1B protein
lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein]

PMID:10377187 PMID:21659618 PMID:21831303 PMID:29969931

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

increases secretion
multiple interactions

ISO

lipoxin A4 analog results in increased secretion of IL4 protein
lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of IL4 protein]

PMID:10377187 PMID:34537180

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of IL5 protein]

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions

ISO

lipoxin A4 inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

mitogen activated protein kinase 1

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 9

multiple interactions
increases phosphorylation

EXP

Gentamicins inhibits the reaction [lipoxin A4 results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

ISO

2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; [lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MAS1 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of MAS1 protein]

NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709

G

myeloperoxidase

multiple interactions

ISO

2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFE2 like bZIP transcription factor 2

affects localization
multiple interactions

EXP

lipoxin A4 affects the localization of NFE2L2 protein
lipoxin A4 promotes the reaction [NFE2L2 protein binds to HMOX1 enhancer]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

multiple interactions

ISO

2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased degradation of NFKBIA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]

PMID:21831303 PMID:29969931

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

ISO

butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

platelet derived growth factor subunit B

multiple interactions

ISO

lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein]

PMID:12223454 PMID:20709806

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

platelet derived growth factor receptor beta

multiple interactions
decreases phosphorylation

ISO

lipoxin A4 affects the reaction [PDGFB protein results in increased phosphorylation of PDGFRB protein]; lipoxin A4 inhibits the reaction [Leukotriene D4 results in increased activity of PDGFRB protein]; PDGFB protein promotes the reaction [lipoxin A4 results in decreased phosphorylation of PDGFRB protein]

PMID:12223454 PMID:20709806

NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843

G

peroxisome proliferator-activated receptor gamma

multiple interactions

EXP

lipoxin A4 binds to and results in increased activity of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

platelet-activating factor receptor

multiple interactions

ISO

[WEB 2086 binds to and results in decreased activity of PTAFR protein] which results in decreased susceptibility to lipoxin A4

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 2

multiple interactions
affects abundance

EXP

[lipoxin A4 co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of PTGS2 protein; Celecoxib inhibits the reaction [PTGS2 protein affects the abundance of lipoxin A4]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]

PMID:15326064 PMID:21765620

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of RELA protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]

PMID:21831303 PMID:23063943 PMID:29969931

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

selectin P

affects response to substance

ISO

SELP protein affects the susceptibility to lipoxin A4

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

suppressor of cytokine signaling 2

multiple interactions
increases expression

ISO

AHR affects the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA]
lipoxin A4 results in increased expression of SOCS2 mRNA; lipoxin A4 results in increased expression of SOCS2 protein

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

signal transducer and activator of transcription 3

multiple interactions

ISO

lipoxin A4 inhibits the reaction [Ovalbumin results in increased phosphorylation of STAT3 protein]

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057

G

transforming growth factor, beta 1

increases expression
multiple interactions

EXP

lipoxin A4 results in increased expression of TGFB1 protein
Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of TGFB1 protein]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

ISO
EXP

lipoxin A4 analog inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; lipoxin A4 inhibits the reaction [TNF protein results in increased secretion of IL1B protein]
Gentamicins inhibits the reaction [lipoxin A4 results in increased expression of TNF protein]
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of CXCL2 protein]; lipoxin A4 analog inhibits the reaction [TNF protein results in increased secretion of IL1B protein]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

PMID:10377187 PMID:21575454 PMID:21831303 PMID:23063943 PMID:29969931 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

methyl linoleate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

iodotyrosine deiodinase

multiple interactions

ISO

methyl linoleate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

ISO

methyl oleate binds to and results in increased activity of AHR protein

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

estrogen receptor 1

multiple interactions

ISO

methyl oleate binds to and results in increased activity of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

methyl oleate binds to and results in increased activity of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

N-oleoyldopamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cannabinoid receptor 1

multiple interactions

EXP

N-oleoyldopamine binds to and results in increased activity of CNR1 protein

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

collagen type I alpha 1 chain

multiple interactions

ISO

N-oleoyldopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

transforming growth factor, beta 1

multiple interactions

ISO

N-oleoyldopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions
increases activity

ISO
EXP

3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [N-oleoyldopamine results in increased activity of TRPV1 protein]

PMID:12569099 PMID:15615864

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression
increases phosphorylation
increases degradation

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ABCA1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ABCA1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ABCA1 mRNA; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]
Oleic Acid results in increased expression of ABCA1 mRNA
Oleic Acid results in increased phosphorylation of ABCA1 protein
Oleic Acid results in increased degradation of ABCA1 protein
Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]

PMID:16118212 PMID:18356535 PMID:30547786 PMID:38953992

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

increases expression

EXP

Oleic Acid results in increased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily D member 3

multiple interactions

ISO

PPARA protein promotes the reaction [Oleic Acid results in increased expression of ABCD3 mRNA]

NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020

G

ATP binding cassette subfamily G member 1

decreases expression

ISO

Oleic Acid results in decreased expression of ABCG1 mRNA; Oleic Acid results in decreased expression of ABCG1 protein

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 2

increases expression

ISO

Oleic Acid results in increased expression of ABCG2 mRNA

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409

G

acetyl-CoA acyltransferase 1A

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACAA1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACAA1 mRNA

NCBI chr 8:127,956,126...127,966,348
Ensembl chr 8:119,079,775...119,088,624

G

acetyl-CoA acyltransferase 2

multiple interactions
increases expression

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAA2 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACAA2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACAA2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACAA2 mRNA
Oleic Acid results in increased expression of ACAA2 mRNA

NCBI chr18:70,620,310...70,648,417
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA carboxylase alpha

multiple interactions
increases expression

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACACA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACACA mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ACACA mRNA; cyhalothrin promotes the reaction [Oleic Acid results in increased expression of ACACA protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ACACA mRNA]

PMID:30611723 PMID:36529352 PMID:36905866

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACACB mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

acyl-CoA dehydrogenase family, member 9

multiple interactions
increases expression

ISO

[Vehicle Emissions results in increased abundance of Particulate Matter] inhibits the reaction [Oleic Acid results in increased expression of ACAD9 mRNA]

NCBI chr 2:118,943,170...118,966,150
Ensembl chr 2:118,943,174...118,966,547

G

acyl-CoA dehydrogenase, long chain

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADL mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of ACADL mRNA

NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220

G

acyl-CoA dehydrogenase medium chain

multiple interactions

EXP
ISO

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of ACADM mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of ACADM mRNA]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of ACADM mRNA]
[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACADM mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADM mRNA

PMID:26190035 PMID:30611723

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

acyl-CoA dehydrogenase short chain

multiple interactions
increases expression

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACADS mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACADS mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADS mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACADS mRNA
Oleic Acid results in increased expression of ACADS mRNA

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898

G

acyl-CoA dehydrogenase, very long chain

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACADVL mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACADVL mRNA

NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075

G

acetyl-CoA acetyltransferase 1

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACAT1 mRNA

NCBI chr 8:62,876,003...62,905,080
Ensembl chr 8:53,979,813...54,008,855

G

acetyl-CoA acetyltransferase 2

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACAT2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACAT2 mRNA

NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:47,695,788...47,752,821

G

angiotensin I converting enzyme

affects activity

EXP

Oleic Acid affects the activity of ACE protein

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

ATP citrate lyase

multiple interactions
decreases expression

ISO

[[Vehicle Emissions results in increased abundance of Particulate Matter] which co-treated with Oleic Acid] results in decreased expression of ACLY mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACLY mRNA
Oleic Acid results in decreased expression of ACLY mRNA

PMID:30611723 PMID:31340670

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,412,049...85,463,320

G

acyl-CoA thioesterase 1

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACOT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT1 mRNA

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

acyl-CoA thioesterase 12

multiple interactions
increases expression

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT12 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACOT12 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT12 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACOT12 mRNA
Oleic Acid results in increased expression of ACOT12 mRNA

NCBI chr 2:22,986,867...23,027,538
Ensembl chr 2:22,986,626...23,027,536

G

acyl-CoA thioesterase 4

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT4 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACOT4 mRNA

NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917

G

acyl-CoA thioesterase 6

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT6 mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of ACOT6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT6 mRNA

NCBI chr 6:103,732,372...103,741,446
Ensembl chr 6:103,732,372...103,741,446

G

acyl-CoA thioesterase 7

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACOT7 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT7 mRNA

NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309

G

acyl-CoA thioesterase 8

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of ACOT8 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOT8 mRNA

NCBI chr 3:153,531,192...153,542,851
Ensembl chr 3:153,531,193...153,542,851

G

acyl-CoA oxidase 1

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [Fenofibrate co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [muraglitazar co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA; [Rosiglitazone co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; [tesaglitazar co-treated with Oleic Acid] results in increased expression of ACOX1 mRNA; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA]

PMID:24534255 PMID:30611723 PMID:36905866

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA oxidase 2

multiple interactions
decreases expression

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACOX2 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of ACOX2 mRNA
Oleic Acid results in decreased expression of ACOX2 mRNA

NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160

G

acyl-CoA synthetase long-chain family member 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ACSL1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

acyl-CoA synthetase long-chain family member 3

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ACSL3 mRNA

NCBI chr 9:87,563,601...87,613,078
Ensembl chr 9:80,115,112...80,164,627

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in increased expression of ACSL4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ACSL4 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACSL4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ACSL4 mRNA

PMID:30547786 PMID:30611723

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

acyl-CoA synthetase long-chain family member 5

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of ACSL5 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of ACSL5 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of ACSL5 mRNA

NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

ISO

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of ACTA2 mRNA
Oleic Acid results in increased expression of ACTA2 mRNA

PMID:26187275 PMID:32918399

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554

G

ADAM metallopeptidase domain 17

multiple interactions

ISO

[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in increased expression of ADAM17 mRNA; lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in increased expression of ADAM17 mRNA]

NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639

G

adiponectin, C1Q and collagen domain containing

decreases expression
multiple interactions

EXP

Oleic Acid results in decreased expression of ADIPOQ mRNA
sophocarpine inhibits the reaction [Oleic Acid results in decreased expression of ADIPOQ mRNA]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adiponectin receptor 2

decreases expression

EXP

oleic acid cotreated with ethanol decreases expression of adipor2 mRNA in rat primary hepatocytes

RGD

NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355

G

1-acylglycerol-3-phosphate O-acyltransferase 1

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in decreased expression of AGPAT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of AGPAT1 mRNA

NCBI chr20:4,140,565...4,149,531
Ensembl chr20:4,135,957...4,145,278

G

1-acylglycerol-3-phosphate O-acyltransferase 2

increases expression
multiple interactions

ISO

Oleic Acid results in increased expression of AGPAT2 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of AGPAT2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of AGPAT2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT2 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of AGPAT2 mRNA

PMID:30547786 PMID:30611723

NCBI chr 3:29,814,924...29,826,569
Ensembl chr 3:9,416,843...9,428,371

G

1-acylglycerol-3-phosphate O-acyltransferase 5

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT5 mRNA

NCBI chr16:77,641,887...77,688,148
Ensembl chr16:70,943,135...70,985,560

G

aryl hydrocarbon receptor

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AHR mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of AHR mRNA; Oleic Acid inhibits the reaction [Particulate Matter affects the localization of AHR protein]

PMID:30547786 PMID:38456238

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation
decreases phosphorylation

EXP
ISO

Oleic Acid inhibits the reaction [IRS2 results in increased phosphorylation of and results in increased activity of AKT1 protein]
Oleic acid increases phosphorylation of AKT1 protein in hepatocellular carcinoma cells
[Oleic Acid co-treated with Palmitic Acid] results in decreased phosphorylation of AKT1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]

CTD
RGD

PMID:14604813 PMID:25536389 PMID:26847930 PMID:37460115

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921

G

albumin

multiple interactions
affects binding
decreases secretion

ISO

[ALB protein binds to Oleic Acid] promotes the reaction [ALB protein results in increased reduction of Dithionitrobenzoic Acid]; [ALB protein binds to Oleic Acid] promotes the reaction [Pyruvaldehyde results in increased oxidation of ALB protein]; [ALB protein modified form binds to Oleic Acid] which results in decreased reduction of Dithionitrobenzoic Acid; [Oleic Acid co-treated with muraglitazar] results in increased expression of ALB mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of ALB protein; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of ALB mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of ALB mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of ALB protein]; Quercetin inhibits the reaction [Oleic Acid results in decreased secretion of ALB protein]; Silymarin inhibits the reaction [Oleic Acid results in decreased secretion of ALB protein]; Vitamin E inhibits the reaction [Oleic Acid results in decreased secretion of ALB protein]

PMID:23348005 PMID:24534255 PMID:25451573 PMID:38103844

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 1 family, member A1

decreases expression

ISO

Oleic Acid results in decreased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

angiopoietin-like 4

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANGPTL4 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

annexin A2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANXA2 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

apolipoprotein A1

multiple interactions

ISO

Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A4

increases expression

ISO

Oleic Acid results in increased expression of APOA4 mRNA

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein A5

increases expression
multiple interactions

ISO

Oleic Acid results in increased expression of APOA5 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of APOA5 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of APOA5 mRNA; [GW 4064 co-treated with Oleic Acid] results in increased expression of APOA5 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of APOA5 mRNA

NCBI chr 8:46,561,180...46,563,818
Ensembl chr 8:46,561,229...46,563,816

G

apolipoprotein B

multiple interactions
decreases expression
increases expression

ISO
EXP

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of APOB mRNA; [Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Oleic Acid co-treated with Folic Acid co-treated with Vitamin B 6 co-treated with Vitamin E] results in decreased expression of APOB protein; [GW 4064 co-treated with Oleic Acid] results in decreased expression of APOB mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of APOB mRNA; Bezafibrate inhibits the reaction [Oleic Acid results in increased expression of APOB protein]; Oleic Acid inhibits the reaction [Glucosamine results in decreased secretion of APOB protein]; Oleic Acid results in increased expression of and results in increased secretion of APOB protein
Oleic Acid results in decreased expression of APOB mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of APOB mRNA; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of APOB mRNA]; Oleic Acid inhibits the reaction [Glucosamine results in increased degradation of APOB protein]

PMID:12048068 PMID:15618547 PMID:17237316 PMID:19383982 PMID:26854922 More...

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C3

multiple interactions

ISO

[Oleic Acid co-treated with muraglitazar] results in increased expression of APOC3 mRNA; [Oleic Acid co-treated with rosiglitazone] results in increased expression of APOC3 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of APOC3 mRNA

NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583

G

apolipoprotein C4

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of APOC4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of APOC4 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of APOC4 mRNA

NCBI chr 1:79,335,745...79,339,942
Ensembl chr 1:79,335,745...79,339,981

G

apolipoprotein E

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of APOE mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of APOE mRNA

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

multiple interactions

ISO

[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Oleic Acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Oleic Acid]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arginase 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ARG1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ARG1 mRNA

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

activating transcription factor 6

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ATF6 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ATF6 mRNA
Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of ATF6 mRNA]

PMID:32369900 PMID:32976987

NCBI chr13:85,460,312...85,639,959
Ensembl chr13:82,930,034...83,107,177

G

autophagy related 5

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG5 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG5 protein]

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG7 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG7 protein]

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

beta-1,4-galactosyltransferase 5

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of B4GALT5 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of B4GALT5 mRNA

NCBI chr 3:156,018,056...156,033,983
Ensembl chr 3:156,018,053...156,070,074

G

beta-secretase 1

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of BAX mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of BAX mRNA

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of BCL2 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of BCL2 mRNA

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases cleavage

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP3 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP3 mRNA
Oleic Acid results in increased cleavage of CASP3 protein
Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased cleavage of CASP3 protein]

PMID:32369900 PMID:32976987 PMID:36273635

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions
increases cleavage

EXP
ISO

IRS2 inhibits the reaction [Oleic Acid results in increased cleavage of CASP9 protein]
3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP9 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CASP9 mRNA

PMID:14604813 PMID:32369900

Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions
increases activity
decreases activity

ISO
EXP

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CAT mRNA; Quercetin inhibits the reaction [Oleic Acid results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Oleic Acid results in decreased activity of CAT protein]; Vitamin E inhibits the reaction [Oleic Acid results in decreased activity of CAT protein]
Oleic Acid results in increased activity of CAT protein
[Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in increased activity of CAT protein; [Oleic Acid co-treated with Palmitic Acid] results in increased activity of CAT protein; Dexamethasone inhibits the reaction [Oleic Acid results in increased activity of CAT protein]; gossypin inhibits the reaction [Oleic Acid results in increased activity of CAT protein]

PMID:23348005 PMID:26854922 PMID:30547786 PMID:37696682

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] affects the expression of CAV2 mRNA

NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244

G

CD36 molecule

multiple interactions
increases expression

ISO
EXP

GW 4064 inhibits the reaction [Oleic Acid results in increased expression of CD36 protein]
Oleic Acid results in increased expression of CD36 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CD36 mRNA; [GW 4064 co-treated with Oleic Acid] results in increased expression of CD36 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of CD36 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CD36 mRNA; [Tamoxifen co-treated with Oleic Acid] results in increased expression of CD36 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CD36 mRNA]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CD36 mRNA]
[Oleic Acid co-treated with Linoleic Acid] results in increased expression of CD36 mRNA

PMID:23371517 PMID:28552552 PMID:30611723 PMID:36347319 PMID:38092172 More...

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CDKN1A mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CDKN1A mRNA

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585

G

cell death-inducing DFFA-like effector c

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CIDEC protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CIDEC mRNA

NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173

G

collagen type I alpha 1 chain

multiple interactions
increases expression

ISO

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of COL1A1 mRNA; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of COL1A1 mRNA]

PMID:26187275 PMID:32918399

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

cytochrome c oxidase assembly factor heme A:farnesyltransferase COX10

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of COX10 mRNA

NCBI chr10:48,630,993...48,742,805
Ensembl chr10:48,630,676...48,746,667

G

carnitine palmitoyltransferase 1A

increases expression
decreases expression
multiple interactions

EXP
ISO

Oleic Acid results in increased expression of CPT1A mRNA
Oleic Acid results in decreased expression of CPT1A mRNA
[Starch co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; [Sucrose co-treated with Oleic Acid] results in increased expression of CPT1A mRNA
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of CPT1A mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A protein; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of CPT1A mRNA]; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A protein]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of CPT1A mRNA]; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA]
[Farnesol analog co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CPT1A mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of CPT1A protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CPT1A mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT1A protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CPT1A mRNA; Bezafibrate promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; Fenofibrate promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; isosilybin promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA]; muraglitazar promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; Rosiglitazone promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]; Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of CPT1A mRNA]; tesaglitazar promotes the reaction [Oleic Acid results in increased expression of CPT1A mRNA]

PMID:11171094 PMID:24534255 PMID:25048947 PMID:26190035 PMID:26854922 More...

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055

G

carnitine palmitoyltransferase 2

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of CPT2 mRNA; [muraglitazar co-treated with Oleic Acid] results in increased expression of CPT2 mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of CPT2 mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of CPT2 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of CPT2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA; [Rosiglitazone co-treated with Oleic Acid] results in increased expression of CPT2 mRNA; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA]

PMID:24534255 PMID:30611723 PMID:36905866

NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:122,664,677...122,682,095

G

CREB binding protein

decreases expression

EXP

Oleic Acid results in decreased expression of CREBBP mRNA

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,335,953...11,461,888

G

C-reactive protein

multiple interactions

ISO

[Eicosapentaenoic Acid co-treated with Docosahexaenoic Acids co-treated with Oleic Acid co-treated with Folic Acid co-treated with Vitamin B 6 co-treated with Vitamin E] results in decreased expression of CRP protein

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

C-X-C motif chemokine ligand 10

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] affects the expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CXCL2 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of CXCL2 mRNA

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

cytochrome c, somatic

multiple interactions

ISO

[Oleic Acid co-treated with anastrozole] affects the localization of CYCS protein; [Oleic Acid co-treated with letrozole] affects the localization of CYCS protein; [Oleic Acid co-treated with Linoleic Acid] results in increased expression of CYCS protein

PMID:24161488 PMID:27016407

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

ISO

Oleic Acid results in increased expression of CYP1A1 mRNA; Oleic Acid results in increased expression of CYP1A1 protein
[Estradiol co-treated with Benzo(a)pyrene] promotes the reaction [Oleic Acid results in increased expression of CYP1A1 mRNA]; [Estradiol co-treated with Benzo(a)pyrene] promotes the reaction [Oleic Acid results in increased expression of CYP1A1 protein]; Oleic Acid inhibits the reaction [Particulate Matter results in increased expression of CYP1A1 mRNA]; Oleic Acid inhibits the reaction [Particulate Matter results in increased expression of CYP1A1 protein]

PMID:31730885 PMID:38456238

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases expression
multiple interactions

ISO

Oleic Acid results in decreased expression of CYP1A2 mRNA
Farnesol analog inhibits the reaction [Oleic Acid results in decreased expression of CYP1A2 mRNA]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 24, subfamily a, polypeptide 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP24A1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CYP24A1 mRNA

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, family 26, subfamily a, polypeptide 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP26A1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of CYP26A1 mRNA

NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204

G

cytochrome P450, family 26, subfamily b, polypeptide 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in increased expression of CYP26B1 mRNA

NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions
decreases expression

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CYP2B6 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of CYP2B6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CYP2B6 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of CYP2B6 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of CYP2B6 mRNA; [Oleic Acid co-treated with Troglitazone] results in increased expression of CYP2B6 mRNA; Farnesol analog inhibits the reaction [Oleic Acid results in decreased expression of CYP2B6 mRNA]

PMID:24534255 PMID:30611723

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
increases expression

EXP
ISO

[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [Ethanol results in increased expression of CYP2E1 mRNA]; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP2E1 mRNA; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP2E1 mRNA]
Oleic Acid results in increased expression of CYP2E1 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of CYP2E1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of CYP2E1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of CYP2E1 mRNA; Farnesol analog inhibits the reaction [Oleic Acid results in increased expression of CYP2E1 mRNA]

PMID:26854922 PMID:30611723

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
decreases expression

ISO

Farnesol analog inhibits the reaction [Oleic Acid results in decreased expression of CYP3A4 mRNA]
Oleic Acid results in decreased expression of CYP3A4 mRNA; Oleic Acid results in decreased expression of CYP3A4 protein

PMID:26739624 PMID:30611723

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 4, subfamily a, polypeptide 1

multiple interactions

EXP

[Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in decreased expression of CYP4A1 mRNA

NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464

G

cytochrome P450, family 4, subfamily f, polypeptide 6

multiple interactions

ISO

PPARA protein promotes the reaction [Oleic Acid results in increased expression of CYP4F16 mRNA]

NCBI chr 7:12,030,276...12,058,020
Ensembl chr 7:12,030,301...12,057,782

G

cytochrome P450 family 7 subfamily A member 1

decreases expression
multiple interactions

EXP
ISO

Oleic Acid results in decreased expression of CYP7A1 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP7A1 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CYP7A1 mRNA]

PMID:32738331 PMID:38103844

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

DNA-damage inducible transcript 3

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of DDIT3 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of DDIT3 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of DDIT3 mRNA]; Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of DDIT3 protein]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]

PMID:32369900 PMID:32976987 PMID:37009739

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201

G

2,4-dienoyl-CoA reductase 1

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of DECR1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of DECR1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of DECR1 mRNA

NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018

G

derlin 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] affects the expression of DERL1 mRNA

NCBI chr 7:89,404,413...89,427,095
Ensembl chr 7:89,404,417...89,427,145

G

diacylglycerol O-acyltransferase 1

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of DGAT1 mRNA

NCBI chr 7:110,104,514...110,119,091
Ensembl chr 7:108,218,524...108,234,299

G

diacylglycerol O-acyltransferase 2

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in increased expression of DGAT2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of DGAT2 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DGAT2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of DGAT2 mRNA

PMID:30611723 PMID:38092172

NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:153,454,080...153,484,428

G

dehydrodolichyl diphosphate synthase subunit

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of DHDDS mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of DHDDS mRNA

NCBI chr 5:146,198,359...146,224,479
Ensembl chr 5:146,197,457...146,224,454

G

dynamin 1-like

affects phosphorylation

ISO

Oleic Acid affects the phosphorylation of DNM1L protein

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

dystonin

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of DST mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of DST mRNA

NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615

G

dynein cytoplasmic 1 heavy chain 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1H1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of DYNC1H1 mRNA

NCBI chr 6:129,615,208...129,680,888
Ensembl chr 6:129,609,397...129,680,883

G

dynein cytoplasmic 1 intermediate chain 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1I1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of DYNC1I1 mRNA

NCBI chr 4:34,819,313...35,132,647
Ensembl chr 4:33,852,927...34,166,149

G

E2F transcription factor 1

decreases expression

ISO

Oleic Acid results in decreased expression of E2F1 protein

NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:143,049,478...143,075,361

G

enoyl-CoA hydratase 1

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ECH1 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of ECH1 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of ECH1 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of ECH1 mRNA; [Oleic Acid co-treated with Troglitazone] results in increased expression of ECH1 mRNA

PMID:24534255 PMID:30611723

NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795

G

enoyl-CoA hydratase, short chain 1

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ECHS1 mRNA

NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884

G

endothelin 1

decreases expression

ISO

Oleic Acid results in decreased expression of EDN1 mRNA; Oleic Acid results in decreased expression of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

epidermal growth factor receptor

multiple interactions
increases phosphorylation

ISO

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of EGFR protein; [Palmitic Acid co-treated with Oleic Acid] affects the expression of EGFR mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of EGFR protein]
Oleic Acid results in increased phosphorylation of EGFR protein

PMID:27447558 PMID:30547786 PMID:38103844

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of EIF2AK3 mRNA]; [Palmitic Acid co-treated with Oleic Acid] affects the expression of EIF2AK3 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of EIF2AK3 mRNA

PMID:30547786 PMID:32369900

NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:102,805,510...102,866,911

G

ELOVL fatty acid elongase 5

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of ELOVL5 mRNA

NCBI chr 8:87,671,164...87,737,618
Ensembl chr 8:78,790,846...78,857,284

G

ELOVL fatty acid elongase 6

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in increased expression of ELOVL6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of ELOVL6 mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of ELOVL6 mRNA; [Oleic Acid co-treated with Fenofibrate] affects the expression of ELOVL6 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of ELOVL6 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of ELOVL6 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of ELOVL6 mRNA

PMID:24534255 PMID:30547786 PMID:30611723

NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:218,063,804...218,171,186

G

enolase 3

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ENO3 mRNA

NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921

G

ER lipid raft associated 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ERLIN1 mRNA

NCBI chr 1:242,921,147...242,956,472
Ensembl chr 1:242,921,152...242,956,394

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ERN1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ERN1 mRNA

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

fatty acid binding protein 1

affects binding
multiple interactions
decreases expression

EXP
ISO

Oleic Acid binds to FABP1 protein
Oleic acid binds to Fabp1 protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of FABP1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FABP1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of FABP1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of FABP1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of FABP1 mRNA; Dibutyl Phthalate inhibits the reaction [Oleic Acid results in decreased expression of FABP1 mRNA]; Diethylhexyl Phthalate inhibits the reaction [Oleic Acid results in decreased expression of FABP1 mRNA]; Oleic Acid inhibits the reaction [11-(dansylamino)undecanoic acid binds to FABP1 protein]
Bezafibrate inhibits the reaction [Oleic Acid binds to FABP1 protein]

CTD
RGD

PMID:2328261 PMID:30547786 PMID:30611723 PMID:31110286 PMID:38092172 More...

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 2

affects binding

EXP

FABP2 protein modified form binds to Oleic Acid

NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089

G

fatty acid binding protein 4

multiple interactions
affects localization
increases expression

ISO

[Glucose deficiency co-treated with Clofibrate co-treated with Oleic Acid] results in increased expression of FABP4 mRNA; [Glucose deficiency co-treated with Oleic Acid] results in increased expression of FABP4 mRNA
Oleic Acid analog affects the localization of FABP4 protein
Oleic Acid results in increased expression of FABP4 mRNA

PMID:8536680 PMID:26739624 PMID:27939595

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

Fas cell surface death receptor

multiple interactions
increases expression

EXP
ISO

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS mRNA; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS mRNA]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FAS mRNA; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FAS protein]
Oleic Acid results in increased expression of FAS mRNA

PMID:26190035 PMID:32918399 PMID:36347319 PMID:36905866

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591

G

fatty acid synthase

multiple interactions

ISO
EXP

[cyhalothrin co-treated with Oleic Acid] results in increased expression of FASN protein; [Farnesol analog co-treated with Oleic Acid] results in increased expression of FASN mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FASN mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of FASN mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of FASN mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of FASN protein; [Oleic Acid co-treated with Fenofibrate] affects the expression of FASN mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of FASN mRNA; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of FASN mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of FASN mRNA]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of FASN protein]; Metformin inhibits the reaction [[cyhalothrin co-treated with Oleic Acid] results in increased expression of FASN protein]
[Sucrose co-treated with Oleic Acid] results in increased expression of FASN mRNA
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [Ethanol results in increased expression of FASN mRNA]; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of FASN mRNA

PMID:24534255 PMID:26854922 PMID:26895660 PMID:30611723 PMID:33508418 More...

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

farnesyl diphosphate farnesyl transferase 1

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of FDFT1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

free fatty acid receptor 1

decreases expression

EXP

Oleic Acid results in decreased expression of FFAR1 mRNA

NCBI chr 1:86,111,368...86,112,272
Ensembl chr 1:86,111,368...86,112,272

G

fibroblast growth factor 21

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FGF21 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FGF21 mRNA

NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454

G

fission, mitochondrial 1

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of FIS1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FIS1 mRNA

NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377

G

flotillin 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FLOT1 mRNA

NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978

G

farnesyltransferase, CAAX box, subunit alpha

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in increased expression of FNTA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of FNTA mRNA

NCBI chr16:66,065,131...66,083,460
Ensembl chr16:66,065,132...66,083,460

G

farnesyltransferase, CAAX box, subunit beta

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of FNTB mRNA

NCBI chr 6:95,536,540...95,619,587
Ensembl chr 6:95,470,683...95,619,586

G

forkhead box A1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of FOXA1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of FOXA1 mRNA

NCBI chr 6:80,838,380...80,871,195
Ensembl chr 6:75,103,503...75,136,188

G

forkhead box O1

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] results in decreased phosphorylation of FOXO1 protein; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of TFAM mRNA]

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790

G

ferritin heavy chain 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of FTH1 protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of FTH1 protein]

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glucosylceramidase beta 1

multiple interactions

ISO

[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in increased expression of GBA1 mRNA; intybin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in increased expression of GBA1 mRNA]

NCBI chr 2:174,609,437...174,615,457
Ensembl chr 2:174,609,403...174,618,263

G

glucagon

multiple interactions
increases secretion

ISO

GNAT3 protein promotes the reaction [Oleic Acid results in increased secretion of GCG protein]

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLC protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLC protein]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLM protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLM protein]

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

geranylgeranyl diphosphate synthase 1

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of GGPS1 mRNA

NCBI chr17:51,263,262...51,282,471
Ensembl chr17:51,263,263...51,276,220

G

gamma-glutamyltransferase 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] affects the expression of GGT1 mRNA

NCBI chr20:13,074,141...13,103,551
Ensembl chr20:13,074,700...13,108,442

G

glucagon-like peptide 1 receptor

multiple interactions
affects localization

EXP

[Glucose co-treated with Oleic Acid] results in decreased expression of GLP1R protein; Acetylcysteine inhibits the reaction [Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein]; Chloroquine inhibits the reaction [Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein]; exenatide inhibits the reaction [[Glucose co-treated with Oleic Acid] results in decreased expression of GLP1R protein]; Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein; wortmannin inhibits the reaction [Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein]
Oleic Acid affects the localization of GLP1R protein

NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241

G

glutamate dehydrogenase 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of GLUD1 mRNA

NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957

G

G protein subunit alpha 11

increases expression

EXP

Oleic Acid results in increased expression of GNA11 protein

NCBI chr 7:8,163,520...8,177,863
Ensembl chr 7:8,162,750...8,179,812

G

G protein subunit alpha q

increases expression

EXP

Oleic Acid results in increased expression of GNAQ protein

NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672

G

G protein subunit alpha transducin 3

multiple interactions

ISO

GNAT3 protein promotes the reaction [Oleic Acid results in increased secretion of GCG protein]

NCBI chr 4:17,162,500...17,212,283
Ensembl chr 4:17,162,490...17,212,283

G

glycerol-3-phosphate acyltransferase, mitochondrial

multiple interactions

ISO

[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of GPAM protein; acadesine inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of GPAM protein]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of GPAM protein]

NCBI chr 1:264,111,599...264,176,112
Ensembl chr 1:254,106,331...254,142,639

G

glycerol-3-phosphate acyltransferase 3

increases expression
multiple interactions

ISO

Oleic Acid results in increased expression of GPAT3 mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of GPAT3 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of GPAT3 mRNA

NCBI chr14:9,018,762...9,072,552
Ensembl chr14:8,714,373...8,766,490

G

glycerol-3-phosphate acyltransferase 4

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in increased expression of GPAT4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of GPAT4 mRNA

NCBI chr16:75,515,935...75,555,431
Ensembl chr16:68,819,079...68,852,901

G

glutamic--pyruvic transaminase

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in increased activity of GPT protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 4

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

growth regulating estrogen receptor binding 1

increases expression
multiple interactions

ISO

Oleic Acid results in increased expression of GREB1 mRNA
Tamoxifen inhibits the reaction [Oleic Acid results in increased expression of GREB1 mRNA]

NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633

G

glycogen synthase kinase 3 beta

multiple interactions
decreases phosphorylation

ISO

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione S-transferase alpha 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] affects the expression of GSTA1 mRNA

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

hydroxyacyl-CoA dehydrogenase

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADH mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

increases expression
multiple interactions

ISO

Oleic Acid results in increased expression of HADHA mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADHA mRNA; [[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in decreased expression of HADHA mRNA; [[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in decreased expression of HADHA protein; [Farnesol analog co-treated with Oleic Acid] results in increased expression of HADHA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of HADHA mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of HADHA mRNA; GW 7647 promotes the reaction [Oleic Acid results in increased expression of HADHA mRNA]; intybin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in decreased expression of HADHA mRNA]; intybin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in decreased expression of HADHA protein]; lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in decreased expression of HADHA mRNA]; lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in decreased expression of HADHA protein]

PMID:30611723 PMID:36055749

NCBI chr 6:31,907,801...31,947,434
Ensembl chr 6:26,187,956...26,227,869

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

multiple interactions
increases expression

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HADHB mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of HADHB mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of HADHB mRNA; GW 7647 promotes the reaction [Oleic Acid results in increased expression of HADHB mRNA]; Oleic Acid promotes the reaction [GW 7647 results in increased expression of HADHB mRNA]

NCBI chr 6:31,873,404...31,907,557
Ensembl chr 6:26,153,578...26,184,869

G

hepatitis A virus cellular receptor 1

increases secretion

ISO

Oleic Acid results in increased secretion of HAVCR1 protein

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HIF1A protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HIF1A protein

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

hypoxia inducible lipid droplet-associated

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HILPDA protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HILPDA protein

NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of HMGCR mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of HMGCR mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of HMGCR mRNA
[[Palmitic Acid co-treated with Oleic Acid] co-treated with IFNA2 protein alternative form] results in decreased expression of HMGCR protein

PMID:30611723 PMID:31299271

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

multiple interactions

ISO

[perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of HMGCS1 mRNA

NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:51,649,497...51,667,100

G

heme oxygenase 1

multiple interactions

ISO

[gastrodin co-treated with Oleic Acid] results in increased expression of HMOX1 protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein; dorsomorphin inhibits the reaction [[gastrodin co-treated with Oleic Acid] results in increased expression of HMOX1 protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]

PMID:26634892 PMID:32976958 PMID:36905866

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hepatocyte nuclear factor 4, alpha

multiple interactions
increases expression

EXP
ISO

sophocarpine inhibits the reaction [Oleic Acid results in increased expression of HNF4A protein]
[Palmitic Acid co-treated with Oleic Acid] affects the expression of HNF4A mRNA

PMID:23395669 PMID:30547786

NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320

G

hydroxysteroid dehydrogenase like 2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of HSDL2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HSDL2 mRNA

NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839

G

heat shock protein family A (Hsp70) member 5

increases expression
multiple interactions

EXP
ISO

Oleic Acid results in increased expression of HSPA5 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased expression of HSPA5 mRNA]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]
[Palmitic Acid co-treated with Oleic Acid] affects the expression of HSPA5 mRNA

PMID:24349266 PMID:30547786 PMID:32976987 PMID:37009739

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891

G

interleukin 18

multiple interactions

ISO

[perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of IL18 mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased secretion of IL18 protein

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 alpha

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of IL1A mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
increases expression

EXP
ISO

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of IL1B mRNA]; gossypin inhibits the reaction [Oleic Acid results in increased expression of IL1B mRNA]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of IL1B mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased secretion of IL1B protein; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B mRNA]

PMID:26190035 PMID:36423729 PMID:37009739 PMID:37696682 PMID:38103844

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases expression
decreases expression

EXP
ISO

3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; [Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein; Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]; gossypin inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]; Resveratrol inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; Resveratrol inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]
Oleic Acid results in decreased expression of IL6 mRNA
Oleic Acid results in increased expression of IL6 mRNA; Oleic Acid results in increased expression of IL6 protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of IL6 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of IL6 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of IL6 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 mRNA]; dorsomorphin inhibits the reaction [gastrodin inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]]; gastrodin inhibits the reaction [Oleic Acid results in increased expression of IL6 mRNA]; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of IL6 protein]

PMID:25348860 PMID:26634892 PMID:30611723 PMID:32918399 PMID:37009739 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions
increases secretion

ISO
EXP

[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
Oleic Acid results in increased secretion of INS1 protein
Oleic Acid promotes the reaction [Glucose results in increased secretion of INS1 protein]

PMID:24349266 PMID:26847930

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

ISO

[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA; [Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]; troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]
[[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with alitretinoin] results in increased uptake of Oleic Acid

PMID:10777552 PMID:11292061

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

insulin receptor

decreases phosphorylation
multiple interactions

ISO

Oleic Acid results in decreased phosphorylation of INSR protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]

NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883

G

insulin receptor substrate 2

multiple interactions
decreases expression

EXP
ISO

IRS2 inhibits the reaction [Oleic Acid results in increased cleavage of CASP9 protein]; Oleic Acid inhibits the reaction [IRS2 results in increased phosphorylation of and results in increased activity of AKT1 protein]
Oleic Acid results in decreased expression of IRS2 protein
Metformin inhibits the reaction [Oleic Acid results in decreased expression of IRS2 protein]; qidan inhibits the reaction [Oleic Acid results in decreased expression of IRS2 protein]

PMID:14604813 PMID:36592823

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

iodotyrosine deiodinase

multiple interactions

ISO

Oleic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

G

Janus kinase 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of JAK1 protein; [Palmitic Acid co-treated with Oleic Acid] affects the expression of JAK1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of JAK1 protein

NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:115,780,248...115,888,926

G

Janus kinase 2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] affects the expression of JAK2 mRNA

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Kelch-like ECH-associated protein 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in increased expression of KEAP1 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of KEAP1 protein]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

laminin subunit beta 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of LAMB1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of LAMB1 mRNA

NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585

G

low density lipoprotein receptor

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

leptin

decreases expression
increases expression
multiple interactions

ISO
EXP

Oleic Acid results in decreased expression of LEP mRNA
Oleic Acid results in increased expression of LEP mRNA
sophocarpine inhibits the reaction [Oleic Acid results in increased expression of LEP mRNA]

PMID:9002984 PMID:23395669

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipase C, hepatic type

multiple interactions
decreases expression

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Oleic Acid
Oleic Acid results in decreased expression of LIPC mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of LIPC mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LIPC mRNA; Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of LIPC mRNA]

PMID:24777581 PMID:30611723 PMID:32918399

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

multiple interactions

ISO

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Oleic Acid

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

G

lysyl oxidase

increases activity

ISO

Oleic Acid results in increased activity of LOX protein

NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477

G

lipin 1

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in increased expression of LPIN1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LPIN1 mRNA

NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097

G

lipin 2

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of LPIN2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LPIN2 mRNA

NCBI chr 9:111,083,378...111,158,193
Ensembl chr 9:111,083,745...111,158,193

G

lipin 3

decreases expression
multiple interactions

ISO

Oleic Acid results in decreased expression of LPIN3 mRNA
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of LPIN3 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of LPIN3 mRNA

NCBI chr 3:149,533,719...149,558,494
Ensembl chr 3:149,534,051...149,558,327

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] affects the expression of MAP1LC3B mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased lipidation of MAP1LC3B protein

PMID:30547786 PMID:36905866

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase kinase 8

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP3K8 mRNA

NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216

G

mitogen-activated protein kinase kinase kinase kinase 4

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP4K4 mRNA

NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698

G

mitogen activated protein kinase 1

multiple interactions

ISO

Oleic Acid inhibits the reaction [Particulate Matter results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions

ISO

Oleic Acid inhibits the reaction [Particulate Matter results in increased phosphorylation of MAPK14 protein]

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions

ISO

Oleic Acid inhibits the reaction [Particulate Matter results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

ISO

Oleic Acid inhibits the reaction [Particulate Matter results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981

G

malonyl-CoA-acyl carrier protein transacylase

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of MCAT mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of MCAT mRNA

NCBI chr 7:116,573,632...116,585,767
Ensembl chr 7:114,693,612...114,704,542

G

mitochondrial trans-2-enoyl-CoA reductase

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of MECR mRNA

NCBI chr 5:144,029,684...144,056,373
Ensembl chr 5:144,029,731...144,055,863

G

mitochondrial fission factor

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of MFF mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of MFF mRNA

NCBI chr 9:84,007,798...84,036,039
Ensembl chr 9:84,007,798...84,036,039

G

mitofusin 1

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of MFN1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of MFN1 mRNA

NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640

G

monoglyceride lipase

multiple interactions

EXP

[Oleic Acid co-treated with Palmitic Acid] affects the reaction [Chlorpyrifos results in decreased activity of MGLL protein]

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

microRNA 30a

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MIR30A mRNA

NCBI chr 9:25,737,600...25,737,670
Ensembl chr 9:25,737,600...25,737,670

G

microRNA 497

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MIR497 mRNA; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of BACE1 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of DDIT3 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of HSPA5 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL1B protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of IL6 protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MIR497 mRNA]

NCBI chr10:54,951,514...54,951,582
Ensembl chr10:54,951,505...54,951,584

G

microRNA 675

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MIR675 mRNA

NCBI chr 1:197,732,275...197,732,358
Ensembl chr 1:197,732,275...197,732,358

G

mixed lineage kinase domain like pseudokinase

multiple interactions
increases phosphorylation

ISO

necrostatin-1 inhibits the reaction [Oleic Acid results in increased phosphorylation of MLKL protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of MLKL protein]

NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502

G

MLX interacting protein-like

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of MLXIPL mRNA

NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112

G

matrix metallopeptidase 2

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of MMP9 protein; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of MMP9 protein]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

metallothionein 1

multiple interactions

EXP

[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [Ethanol results in increased expression of MT1 mRNA]; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of MT1 mRNA; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of MT1 mRNA]

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

metallothionein 2

multiple interactions

EXP

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of MT2A mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

microsomal triglyceride transfer protein

multiple interactions
decreases expression

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of MTTP mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of MTTP mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MTTP mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MTTP mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of MTTP mRNA; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of MTTP mRNA]; Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of MTTP mRNA]

PMID:30547786 PMID:30611723 PMID:32918399 PMID:36347319 PMID:38092172

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases expression

ISO

[gastrodin co-treated with Oleic Acid] results in increased phosphorylation of and affects the localization of NFE2L2 protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of and affects the localization of NFE2L2 protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NFE2L2 protein; dorsomorphin inhibits the reaction [[gastrodin co-treated with Oleic Acid] results in increased phosphorylation of and affects the localization of NFE2L2 protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NFE2L2 protein]; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of and affects the localization of NFE2L2 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GPX4 protein]; NFE2L2 protein affects the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein]
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NFE2L2 mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NFE2L2 mRNA]
Oleic Acid results in increased expression of NFE2L2 mRNA; Oleic Acid results in increased expression of NFE2L2 protein

PMID:26634892 PMID:26847930 PMID:28555106 PMID:32976958 PMID:36905866

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nitric oxide synthase 3

decreases expression

ISO

Oleic Acid results in decreased expression of NOS3 mRNA

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

NPC1 like intracellular cholesterol transporter 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NPC1L1 mRNA

NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NQO1 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NQO1 protein]

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 0, group B, member 2

decreases expression
increases expression
multiple interactions

ISO
EXP

Oleic Acid results in decreased expression of NR0B2 mRNA
Oleic Acid results in increased expression of NR0B2 mRNA
[Farnesol analog co-treated with Oleic Acid] results in decreased expression of NR0B2 mRNA; [GW 4064 co-treated with Oleic Acid] results in increased expression of NR0B2 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of NR0B2 mRNA

PMID:30611723 PMID:32738331

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

ISO
EXP

[Oleic Acid co-treated with Fenofibrate] affects the expression of NR1H3 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of NR1H3 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in increased expression of NR1H3 mRNA; [Oleic Acid co-treated with tesaglitazar] affects the expression of NR1H3 mRNA; [Oleic Acid co-treated with Troglitazone] affects the expression of NR1H3 mRNA
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of NR1H3 mRNA

PMID:24534255 PMID:26190035

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
decreases expression

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of NR1H4 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of NR1H4 mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of NR1H4 mRNA; [Oleic Acid co-treated with Fenofibrate] results in decreased expression of NR1H4 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of NR1H4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of NR1H4 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of NR1H4 mRNA
Oleic Acid results in decreased expression of NR1H4 mRNA

PMID:24534255 PMID:30547786 PMID:30611723

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NR1I2 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of NR1I3 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of NR1I3 mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of NR1I3 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of NR1I3 mRNA; [Oleic Acid co-treated with Rosiglitazone] results in decreased expression of NR1I3 mRNA; [Oleic Acid co-treated with Troglitazone] affects the expression of NR1I3 mRNA

PMID:24534255 PMID:30611723

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear respiratory factor 1

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NRF1 mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of NRF1 mRNA]

NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328

G

purinergic receptor P2X 7

multiple interactions

EXP

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 protein; Resveratrol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 mRNA]; Resveratrol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of P2RX7 protein]

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

poly (ADP-ribose) polymerase 1

increases cleavage
increases activity
multiple interactions

ISO

Oleic Acid results in increased cleavage of PARP1 protein
Oleic Acid results in increased activity of PARP1 protein
[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; PARP1 protein affects the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]

PMID:21132278 PMID:25536389 PMID:30165350

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404

G

pyruvate carboxylase

decreases expression

EXP

Oleic Acid results in decreased expression of PC mRNA

NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380

G

phosphoenolpyruvate carboxykinase 1

multiple interactions
increases expression

ISO

[Glucose deficiency co-treated with Clofibrate co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Glucose deficiency co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of PCK1 mRNA]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PCK1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PCK1 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of PCK1 mRNA

PMID:8536680 PMID:9518257 PMID:26847930 PMID:30611723

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

platelet derived growth factor subunit B

multiple interactions
increases expression

ISO

Sorafenib inhibits the reaction [Oleic Acid results in increased expression of PDGFB mRNA]

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

pyruvate dehydrogenase kinase 4

increases expression
multiple interactions

ISO

Oleic Acid results in increased expression of PDK4 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PDK4 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PDK4 protein

PMID:26739624 PMID:30547786

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

decaprenyl diphosphate synthase subunit 1

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PDSS1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PDSS1 mRNA

NCBI chr17:85,059,953...85,098,739
Ensembl chr17:85,060,106...85,098,730

G

phosphatidylethanolamine binding protein 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PEBP1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PEBP1 mRNA

NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862

G

peroxisomal trans-2-enoyl-CoA reductase

decreases expression
multiple interactions

ISO

Oleic Acid results in decreased expression of PECR mRNA
[GW 4064 co-treated with Oleic Acid] results in decreased expression of PECR mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of PECR mRNA

NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511

G

PGAM family member 5, mitochondrial serine/threonine protein phosphatase

multiple interactions

ISO

PGAM5 protein promotes the reaction [Oleic Acid results in increased expression of SQSTM1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of MLKL protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK3 protein]

NCBI chr12:46,409,324...46,416,410
Ensembl chr12:46,409,369...46,416,420

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] affects the expression of PIK3C2A mRNA

NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472

G

PTEN induced kinase 1

multiple interactions
decreases expression

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PINK1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PINK1 mRNA; Metformin inhibits the reaction [Oleic Acid results in decreased expression of PINK1 protein]; qidan inhibits the reaction [Oleic Acid results in decreased expression of PINK1 protein]

PMID:32369900 PMID:36592823

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

pyruvate kinase L/R

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PKLR mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PKLR mRNA

NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870

G

phospholipase D1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PLD1 mRNA

NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692

G

pleckstrin

multiple interactions

ISO

Oleic Acid promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein]

NCBI chr14:91,397,015...91,429,693
Ensembl chr14:91,397,019...91,454,131

G

perilipin 1

increases expression

ISO

Oleic Acid results in increased expression of PLIN1 mRNA

NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828

G

perilipin 2

multiple interactions
increases expression

EXP
ISO

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PLIN2 mRNA; Oleic Acid promotes the reaction [LG 100268 results in increased expression of PLIN2 protein]; Oleic Acid promotes the reaction [pirinixic acid results in increased expression of PLIN2 protein]
Rimonabant inhibits the reaction [Oleic Acid results in increased expression of PLIN2 protein]
Oleic Acid results in increased expression of PLIN2 mRNA; Oleic Acid results in increased expression of PLIN2 protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of PLIN2 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of PLIN2 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PLIN2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PLIN2 protein; Bezafibrate promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; Dichlorodiphenyl Dichloroethylene promotes the reaction [Oleic Acid results in increased expression of PLIN2 protein]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased expression of PLIN2 protein]; Fenofibrate promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; muraglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; Rosiglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; tesaglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]; Troglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN2 mRNA]

PMID:16489205 PMID:24534255 PMID:25048947 PMID:26739624 PMID:30547786 More...

NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319

G

perilipin 3

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in increased expression of PLIN3 mRNA

NCBI chr 9:1,111,178...1,123,057
Ensembl chr 9:1,102,366...1,123,147

G

perilipin 4

multiple interactions
increases expression

ISO

Bezafibrate promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; muraglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; rosiglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; tesaglitazar promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]; troglitazone promotes the reaction [Oleic Acid results in increased expression of PLIN4 mRNA]

NCBI chr 9:929,168...938,062
Ensembl chr 9:929,176...938,056

G

perilipin 5

multiple interactions

EXP

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PLIN5 mRNA; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PLIN5 mRNA]

NCBI chr 9:939,745...946,188
Ensembl chr 9:939,747...946,120

G

phospholipid phosphatase 6

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of PLPP6 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of PLPP6 mRNA

NCBI chr 1:226,679,100...226,681,952
Ensembl chr 1:226,679,100...226,681,949

G

patatin-like phospholipase domain containing 3

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PNPLA3 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PNPLA3 mRNA

NCBI chr 7:117,173,485...117,194,065
Ensembl chr 7:115,293,538...115,314,077

G

paraoxonase 1

multiple interactions
decreases activity

ISO

[Calcium co-treated with Oleic Acid] results in increased stability of PON1 protein; Calcium promotes the reaction [Oleic Acid inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of PON1 protein]]; Oleic Acid inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of PON1 protein]; Oleic Acid inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein]; Oleic Acid inhibits the reaction [Copper promotes the reaction [Ascorbic Acid results in decreased activity of PON1 protein]]; Oleic Acid inhibits the reaction [Hydrogen Peroxide results in decreased activity of PON1 protein]; Oleic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]
Oleic Acid results in decreased activity of PON1 protein

PMID:12871208 PMID:15104111 PMID:15375178

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

multiple interactions
affects binding
increases expression
affects abundance
decreases expression
increases activity

ISO
EXP

Diethylhexyl Phthalate inhibits the reaction [PPARA protein affects the abundance of Oleic Acid]; Oleic Acid binds to and results in increased activity of PPARA protein; Oleic Acid inhibits the reaction [troglitazone results in decreased expression of PPARA mRNA]; PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC13A1 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC16A9 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of ABCD3 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of CYP2C65 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of CYP4F16 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of SLC27A4 mRNA]; PPARA protein promotes the reaction [Oleic Acid results in increased expression of SLC6A3 mRNA]
Oleic Acid binds to PPARA protein
Oleic Acid results in increased expression of PPARA mRNA; Oleic Acid results in increased expression of PPARA protein
[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARA mRNA; [tetrabromobisphenol A co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; [Triiodothyronine co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein]; Oleic Acid binds to and results in increased activity of PPARA protein; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein]
Oleic Acid results in decreased expression of PPAR mRNA; Oleic Acid results in decreased expression of PPARA mRNA; Oleic Acid results in decreased expression of PPARA protein
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of PPARA mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PPARA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PPARA mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of PPARA protein; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PPARA mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of PPARA mRNA; [Vehicle Emissions results in increased abundance of Particulate Matter] inhibits the reaction [Oleic Acid results in increased expression of PPARA mRNA]; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA mRNA]]; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA protein]]; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased activity of and results in increased localization of PPARA protein]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased expression of PPARA protein]; Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA mRNA]; Estradiol inhibits the reaction [Oleic Acid results in decreased expression of PPARA protein]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of PPARA protein]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA protein]; Oleic Acid binds to and results in increased activity of PPARA protein; Oleic Acid results in increased activity of and results in increased localization of PPARA protein; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of PPARA mRNA]; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of PPARA protein]
Oleic Acid results in increased activity of PPARA protein

PMID:9688458 PMID:10403814 PMID:11056218 PMID:15491415 PMID:15949695 More...

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor delta

increases expression
multiple interactions
decreases expression

ISO
EXP

Oleic Acid results in increased expression of PPARD mRNA
Oleic Acid binds to and results in increased activity of PPARB protein
[Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in increased expression of PPARD mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARB mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARD mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARB mRNA]; Oleic Acid binds to and results in increased activity of PPARB protein; tetrabromobisphenol A inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARD mRNA]
Oleic Acid results in decreased expression of PPARD mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PPARD mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of PPARD mRNA; Oleic Acid binds to and results in increased activity of PPARB protein

PMID:11172467 PMID:16731579 PMID:24349266 PMID:25048947 PMID:26190035 More...

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

peroxisome proliferator-activated receptor gamma

increases expression
affects binding
multiple interactions

ISO
EXP

Oleic Acid results in increased expression of PPARG mRNA
Oleic Acid binds to PPARG protein
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [Ethanol results in increased expression of PPARG mRNA]; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA; Ethanol inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]; tetrabromobisphenol A inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]; Triiodothyronine inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]
[cyhalothrin co-treated with Oleic Acid] results in increased expression of PPARG protein; [Farnesol analog co-treated with Oleic Acid] results in increased expression of PPARG mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of PPARG mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of PPARG mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG protein; [Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PPARG protein; [Tamoxifen co-treated with Oleic Acid] results in increased expression of PPARG mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PPARG protein]; Metformin inhibits the reaction [[cyhalothrin co-treated with Oleic Acid] results in increased expression of PPARG protein]; Oleic Acid binds to and results in increased activity of PPARG protein
Oleic Acid results in increased expression of PPARG mRNA; Oleic Acid results in increased expression of PPARG protein

PMID:11172467 PMID:18154422 PMID:24534255 PMID:24998974 PMID:25048947 More...

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARGC1A mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARGC1A mRNA]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PRKAA1 mRNA

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

protein kinase AMP-activated catalytic subunit alpha 2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] affects the expression of PRKAA2 mRNA

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

G

parkin RBR E3 ubiquitin protein ligase

decreases expression
multiple interactions

ISO

Oleic Acid results in decreased expression of PRKN protein
Metformin inhibits the reaction [Oleic Acid results in decreased expression of PRKN protein]; qidan inhibits the reaction [Oleic Acid results in decreased expression of PRKN protein]

NCBI chr 1:51,236,410...52,430,242
Ensembl chr 1:48,690,556...49,882,555

G

presenilin 1

multiple interactions

ISO

[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Oleic Acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Oleic Acid]

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

ISO

dorsomorphin inhibits the reaction [gastrodin inhibits the reaction [Oleic Acid results in increased expression of PTGS2 mRNA]]; gastrodin inhibits the reaction [Oleic Acid results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RAB18, member RAS oncogene family

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RAB18 mRNA

NCBI chr17:54,944,099...54,976,093
Ensembl chr17:54,943,955...54,976,043

G

Rab geranylgeranyltransferase subunit alpha

multiple interactions

ISO

[Farnesol analog co-treated with Oleic Acid] results in decreased expression of RABGGTA mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of RABGGTA mRNA

NCBI chr15:29,206,328...29,213,398
Ensembl chr15:29,206,157...29,213,348

G

Rab geranylgeranyltransferase subunit beta

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of RABGGTB mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of RABGGTB mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of RABGGTB mRNA

NCBI chr 2:242,844,758...242,850,951
Ensembl chr 2:242,844,762...242,851,050

G

RB transcriptional corepressor 1

decreases phosphorylation

ISO

Oleic Acid results in decreased phosphorylation of RB1 protein

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:48,371,296...48,502,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

Oleic Acid inhibits the reaction [Particulate Matter results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

Ras homolog, mTORC1 binding

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHEB mRNA

NCBI chr 4:10,278,970...10,320,160
Ensembl chr 4:10,279,370...10,320,160

G

ras homolog family member B

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHOB mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of RHOB mRNA

NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:31,363,548...31,366,108

G

receptor interacting serine/threonine kinase 1

multiple interactions
increases phosphorylation

ISO

necrostatin-1 inhibits the reaction [Oleic Acid results in increased phosphorylation of RIPK1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK1 protein]

NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824

G

receptor-interacting serine-threonine kinase 3

increases phosphorylation
multiple interactions

ISO

Oleic Acid results in increased phosphorylation of RIPK3 protein
necrostatin-1 inhibits the reaction [Oleic Acid results in increased phosphorylation of RIPK3 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased phosphorylation of RIPK3 protein]

NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ROCK2 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of ROCK2 protein

NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031

G

retinoid X receptor alpha

multiple interactions

ISO

Oleic Acid binds to and results in increased activity of RXRA protein

PMID:16731579 PMID:27131391

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

scavenger receptor class B, member 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of SCARB1 mRNA

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

stearoyl-CoA desaturase

multiple interactions
decreases expression

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [Farnesol analog co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SCD mRNA; [Oleic Acid co-treated with Bezafibrate] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SCD mRNA; [Oleic Acid co-treated with Fenofibrate] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with muraglitazar] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SCD1 mRNA; [Oleic Acid co-treated with tesaglitazar] results in increased expression of SCD1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SCD mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SCD mRNA; [perfluorodecanoic acid co-treated with Oleic Acid] results in increased expression of SCD mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SCD1 mRNA]
Oleic Acid results in decreased expression of SCD mRNA
[Starch co-treated with Oleic Acid] results in increased expression of SCD1 mRNA; [Sucrose co-treated with Oleic Acid] results in increased expression of SCD1 mRNA

PMID:24534255 PMID:26895660 PMID:30547786 PMID:30611723 PMID:36423729 More...

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

sterol carrier protein 2

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of SCP2 mRNA

NCBI chr 5:128,035,714...128,110,015
Ensembl chr 5:122,776,549...122,881,287

G

serpin family E member 1

multiple interactions

ISO

[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA; [Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SERPINE1 mRNA; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; Bezafibrate inhibits the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]; Troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 mRNA]; Troglitazone promotes the reaction [[Oleic Acid co-treated with INS protein] results in increased expression of SERPINE1 protein]

PMID:11292061 PMID:30547786

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

sirtuin 1

increases expression
multiple interactions
decreases activity

EXP
ISO

Oleic Acid results in increased expression of SIRT1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Oleic Acid results in decreased activity of SIRT1 protein]; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]
[Ethanol co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of SIRT1 protein

PMID:24349266 PMID:25536389 PMID:26854922

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260

G

sirtuin 4

decreases expression

EXP

Oleic Acid results in decreased expression of SIRT4 mRNA

NCBI chr12:46,785,852...46,800,179
Ensembl chr12:41,131,262...41,139,439

G

solute carrier family 13 member 1

multiple interactions

ISO

PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC13A1 mRNA]

NCBI chr 4:52,569,179...52,647,126
Ensembl chr 4:52,569,375...52,647,099

G

solute carrier family 16, member 9

multiple interactions

ISO

PPARA protein promotes the reaction [Oleic Acid results in decreased expression of SLC16A9 mRNA]

NCBI chr20:18,335,862...18,377,125
Ensembl chr20:18,335,862...18,377,022

G

solute carrier family 25 member 11

decreases expression

EXP

Oleic Acid results in decreased expression of SLC25A11 mRNA

NCBI chr10:55,357,590...55,360,441
Ensembl chr10:55,357,597...55,360,410

G

solute carrier family 25 member 20

increases expression
multiple interactions

EXP
ISO

Oleic Acid results in increased expression of SLC25A20 protein
[Farnesol analog co-treated with Oleic Acid] results in increased expression of SLC25A20 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SLC25A20 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of SLC25A20 mRNA

PMID:24349266 PMID:30611723

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

solute carrier family 25 member 22

decreases expression

EXP

Oleic Acid results in decreased expression of SLC25A22 mRNA

NCBI chr 1:196,528,471...196,536,398
Ensembl chr 1:196,528,472...196,536,331

G

solute carrier family 27 member 1

multiple interactions

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SLC27A1 mRNA; [Farnesol analog co-treated with Oleic Acid] results in increased expression of SLC27A1 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SLC27A1 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SLC27A1 mRNA

NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063

G

solute carrier family 27 member 2

multiple interactions
increases expression

ISO

[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in increased expression of SLC27A2 mRNA; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SLC27A2 mRNA; [GW 7647 co-treated with Oleic Acid] results in increased expression of SLC27A2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of SLC27A2 mRNA; Tamoxifen promotes the reaction [Oleic Acid results in increased expression of SLC27A2 mRNA]

PMID:30611723 PMID:38092172 PMID:38191086

NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208

G

solute carrier family 27 member 4

multiple interactions

ISO

PPARA protein promotes the reaction [Oleic Acid results in increased expression of SLC27A4 mRNA]

NCBI chr 3:13,075,022...13,087,943
Ensembl chr 3:13,075,022...13,087,943

G

solute carrier family 2 member 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SLC2A1 mRNA

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

solute carrier family 2 member 2

increases expression
multiple interactions

ISO

Oleic Acid results in increased expression of SLC2A2 mRNA
[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of SLC2A2 mRNA; Bezafibrate inhibits the reaction [Oleic Acid results in increased expression of SLC2A2 mRNA]

PMID:12048068 PMID:30547786

NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933

G

solute carrier family 6 member 3

multiple interactions

ISO

PPARA protein promotes the reaction [Oleic Acid results in increased expression of SLC6A3 mRNA]

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

small integral membrane protein 20

increases expression

ISO

Oleic Acid results in increased expression of SMIM20 mRNA

NCBI chr14:57,711,304...57,722,681
Ensembl chr14:57,711,307...57,722,681

G

synaptosome associated protein 23

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SNAP23 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SNAP23 mRNA

NCBI chr 3:107,514,088...107,546,177
Ensembl chr 3:107,514,131...107,544,320

G

suppressor of cytokine signaling 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOCS1 mRNA

NCBI chr10:5,389,574...5,391,265
Ensembl chr10:4,882,560...4,884,383

G

suppressor of cytokine signaling 2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS2 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SOCS2 mRNA

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

suppressor of cytokine signaling 3

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

superoxide dismutase 1

multiple interactions
decreases secretion
decreases expression

ISO

Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in decreased secretion of SOD1 protein]; gastrodin inhibits the reaction [Oleic Acid results in decreased expression of SOD1 mRNA]

PMID:26634892 PMID:27996362

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

increases expression
multiple interactions

EXP
ISO

Oleic Acid results in increased expression of SOD2 mRNA
[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOD2 mRNA

PMID:24349266 PMID:30547786

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189

G

sequestosome 1

increases expression
multiple interactions

ISO

Oleic Acid results in increased expression of SQSTM1 protein
[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in increased expression of SQSTM1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SQSTM1 protein; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SQSTM1 protein]; lactucin inhibits the reaction [[[Palmitic Acid co-treated with Oleic Acid] results in increased abundance of Fatty Acids, Nonesterified] which results in increased expression of SQSTM1 mRNA]; Metformin inhibits the reaction [Oleic Acid results in increased expression of SQSTM1 protein]; necrostatin-1 inhibits the reaction [Oleic Acid results in increased expression of SQSTM1 protein]; PGAM5 protein promotes the reaction [Oleic Acid results in increased expression of SQSTM1 protein]; qidan inhibits the reaction [Oleic Acid results in increased expression of SQSTM1 protein]

PMID:36055749 PMID:36273635 PMID:36592823 PMID:36905866

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

increases expression
multiple interactions
decreases expression

EXP
ISO

Oleic Acid results in increased expression of SREBF1 mRNA
Oleic Acid results in increased expression of SREBF1 mRNA; Oleic Acid results in increased expression of SREBF1 protein
[N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA
[Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in increased expression of SREBF1 protein; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA]; sophocarpine inhibits the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]
[6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime co-treated with Oleic Acid] results in decreased expression of SREBF1 mRNA; [cyhalothrin co-treated with Oleic Acid] results in increased expression of SREBF1 protein; [GW 4064 co-treated with Oleic Acid] results in decreased expression of SREBF1 mRNA; [GW 7647 co-treated with Oleic Acid] results in decreased expression of SREBF1 mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of SREBF1 mRNA; [Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of SREBF1 protein; [Oleic Acid co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SREBF1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 protein; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 protein; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]]; Benzo(a)pyrene inhibits the reaction [Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 protein]]; Cholecalciferol inhibits the reaction [Tamoxifen promotes the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]]; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA]; Dibutyl Phthalate inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 mRNA]; Diethylhexyl Phthalate promotes the reaction [Oleic Acid results in increased expression of SREBF1 protein]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 protein]; Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]; Estradiol inhibits the reaction [Oleic Acid results in increased expression of SREBF1 protein]; GW 6471 inhibits the reaction [[Oleic Acid co-treated with Dibutyl Phthalate] results in increased expression of SREBF1 protein]; isosilybin inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of SREBF1 protein]; Metformin inhibits the reaction [[cyhalothrin co-treated with Oleic Acid] results in increased expression of SREBF1 protein]; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of SREBF1 mRNA]; Plant Extracts inhibits the reaction [Oleic Acid results in decreased expression of SREBF1 protein]; Tamoxifen promotes the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]; VDR protein affects the reaction [Tamoxifen promotes the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]]
Oleic Acid results in decreased expression of SREBF1 mRNA; Oleic Acid results in decreased expression of SREBF1 protein

PMID:15949695 PMID:23395669 PMID:23603006 PMID:26190035 PMID:26854922 More...

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

sulfotransferase family 2A member 1

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

thromboxane A2 receptor

multiple interactions

EXP

Phenolsulfonphthalein inhibits the reaction [Oleic Acid results in increased expression of TBXA2R mRNA]

NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176

G

trans-2,3-enoyl-CoA reductase

multiple interactions

ISO

[GW 4064 co-treated with Oleic Acid] results in decreased expression of TECR mRNA

NCBI chr19:24,526,700...24,568,168
Ensembl chr19:24,541,615...24,568,168

G

transcription factor A, mitochondrial

multiple interactions

ISO

[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of TFAM mRNA; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in decreased expression of TFAM mRNA]

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

transferrin receptor

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] results in increased expression of TFRC protein; ginkgolide B inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of TFRC protein]

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor, beta 1

multiple interactions
increases expression

ISO

Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TGFB1 protein]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta 2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TGFB2 mRNA

NCBI chr13:100,691,540...100,793,227
Ensembl chr13:98,160,087...98,261,405

G

thyroid hormone responsive

multiple interactions
decreases expression

ISO

Bezafibrate promotes the reaction [Oleic Acid results in decreased expression of THRSP mRNA]; Fenofibrate promotes the reaction [Oleic Acid results in decreased expression of THRSP mRNA]

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

TIMP metallopeptidase inhibitor 1

multiple interactions
increases expression

ISO

[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TIMP1 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of TIMP1 mRNA; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TIMP1 mRNA]

PMID:26187275 PMID:30547786 PMID:32918399

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

decreases response to substance
increases expression
multiple interactions

ISO
EXP

Oleic Acid results in decreased susceptibility to TNF protein
Oleic Acid results in increased expression of TNF mRNA; Oleic Acid results in increased expression of TNF protein
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein; BACE1 protein affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; MIR497 affects the reaction [SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]]; SNHG14 affects the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Dexamethasone inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; gossypin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; gossypin inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; quercetin 3-O-glucuronide inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF protein]
[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ABCA1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ACSL1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AGPAT5 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of AHR mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ARG1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of B4GALT5 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CAT mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CXCL2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of CXCL3 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1H1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of DYNC1I1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ENO3 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of ERLIN1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of FOXA1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of GLUD1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of GLUD2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of HSDL2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of IL1A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of LAMB1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of NR1H4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PEBP1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PKLR mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PLD1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PNPLA3 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PPARD mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of PRKAA1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RAB18 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHEB mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of RHOB mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SCD mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SERPINE1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SLC2A1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOCS1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of SOD2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TGFB2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TNFAIP2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TUBB2A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of UGCG mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VAMP4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VCAN mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of CPT1A protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in decreased expression of DST mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ACSL4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANGPTL4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ANXA2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CIDEC protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CPT1A mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CXCL8 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP24A1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of CYP26A1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FGF21 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of FLOT1 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HIF1A protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of HILPDA protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of JAK1 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of LDLR mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP3K8 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MAP4K4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of MTTP mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PDK4 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PLIN2 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of PPARA mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of ROCK2 protein; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SNAP23 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS2 mRNA; [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] results in increased expression of SOCS3 mRNA; Coptidis rhizoma extract inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of TNF mRNA]; dorsomorphin inhibits the reaction [gastrodin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]]; gastrodin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Quercetin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Quercetin inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; Silymarin inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TNF protein]; Vitamin E inhibits the reaction [Oleic Acid results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Oleic Acid results in increased expression of TNF protein]

PMID:22683933 PMID:23348005 PMID:26190035 PMID:26634892 PMID:30547786 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 2

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TNFAIP2 mRNA

NCBI chr 6:130,476,832...130,489,914
Ensembl chr 6:130,476,889...130,489,914

G

tumor protein p53

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of TP53 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased expression of TP53 mRNA

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

ISO

Oleic Acid inhibits the reaction [Particulate Matter results in increased expression of and results in increased phosphorylation of TRPV1 protein]

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

tubulin, beta 2A class IIa

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TUBB2A mRNA

NCBI chr17:30,796,842...30,800,713
Ensembl chr17:30,747,503...30,800,714

G

Tu translation elongation factor, mitochondrial

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid] affects the expression of TUFM mRNA

NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395

G

uncoupling protein 2

increases expression
multiple interactions
decreases expression

EXP

Oleic Acid results in increased expression of UCP2 mRNA
[Oleic Acid co-treated with Palmitic Acid co-treated with Ethanol] results in decreased expression of UCP2 protein; [Oleic Acid co-treated with Palmitic Acid] results in decreased expression of UCP2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA; [Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; tetrabromobisphenol A promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein]
Oleic Acid results in decreased expression of UCP2 mRNA

PMID:11341955 PMID:12588052 PMID:24349266 PMID:25048947 PMID:26854922

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

uncoupling protein 3

increases expression
multiple interactions

EXP
ISO

Oleic Acid results in increased expression of UCP3 mRNA
Oleic Acid inhibits the reaction [troglitazone results in decreased expression of UCP3 mRNA]

PMID:11056218 PMID:12630940

NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762

G

UDP-glucose ceramide glucosyltransferase

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of UGCG mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of UGCG mRNA

NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393

G

vesicle-associated membrane protein 4

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VAMP4 mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of VAMP4 mRNA

NCBI chr13:74,919,872...74,942,791
Ensembl chr13:74,919,880...74,933,686

G

versican

multiple interactions

ISO

[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VCAN mRNA; [Palmitic Acid co-treated with Oleic Acid] affects the expression of VCAN mRNA

NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637

G

vitamin D receptor

multiple interactions

ISO

VDR protein affects the reaction [Tamoxifen promotes the reaction [Oleic Acid results in increased expression of SREBF1 mRNA]]

NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:128,987,981...129,037,677

G

vanin 1

multiple interactions

ISO

Oleic Acid promotes the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of VNN1 mRNA]

NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395

G

X-box binding protein 1

multiple interactions

ISO

3-N-1(spermine)-7, 24-dihydroxy-5-cholestane 24-sulfate inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased splicing of XBP1 mRNA]; [Palmitic Acid co-treated with Oleic Acid] results in increased splicing of XBP1 mRNA
Oleic Acid inhibits the reaction [[Palmitates co-treated with bisphenol A] results in increased splicing of XBP1 mRNA]

PMID:32369900 PMID:32976987

NCBI chr14:84,604,623...84,609,707
Ensembl chr14:80,390,643...80,395,693

G

Yes1 associated transcriptional regulator

affects localization

ISO

Oleic Acid affects the localization of YAP1 protein

NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010

oleoyl ethanolamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases export

ISO

ABCB1 protein results in increased export of N-oleoylethanolamine

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709

G

peroxisome proliferator activated receptor alpha

increases response to substance
multiple interactions

ISO

PPARA results in increased susceptibility to N-oleoylethanolamine
N-oleoylethanolamine binds to and results in increased activity of PPARA protein

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

prostaglandin-endoperoxide synthase 2

decreases expression

ISO

N-oleoylethanolamine results in decreased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

palmitoleic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases degradation
multiple interactions
increases phosphorylation

ISO

palmitoleic acid results in increased degradation of ABCA1 protein
palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]
palmitoleic acid results in increased phosphorylation of ABCA1 protein

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

apolipoprotein A1

multiple interactions

ISO

palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]]

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

amyloid beta precursor protein

multiple interactions

ISO

[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of palmitoleic acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of palmitoleic acid]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

interleukin 6

increases expression

ISO

palmitoleic acid results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

multiple interactions

ISO

[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased abundance of palmitoleic acid analog

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

ISO

[Glucose deficiency co-treated with palmitoleic acid] results in increased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

paraoxonase 1

multiple interactions
decreases activity

ISO

palmitoleic acid inhibits the reaction [[Ascorbic Acid co-treated with Copper Sulfate] results in decreased activity of PON1 protein]; palmitoleic acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]
palmitoleic acid results in decreased activity of PON1 protein

PMID:12871208 PMID:15375178

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

presenilin 1

multiple interactions

ISO

[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of palmitoleic acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of palmitoleic acid]

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

ricinoleic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cannabinoid receptor 1

affects binding

ISO

ricinoleic acid analog binds to CNR1 protein

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor 2

multiple interactions

ISO

ricinoleic acid analog binds to and affects the activity of CNR2 protein

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

interleukin 4

multiple interactions

ISO

ricinoleic acid inhibits the reaction [IL4 protein results in increased expression of VCAM1 protein]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

prostaglandin D2 synthase

affects binding

ISO

ricinoleic acid binds to PTGDS protein

NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

ISO

ricinoleic acid analog binds to and affects the activity of TRPV1 protein

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

vascular cell adhesion molecule 1

multiple interactions

ISO

ricinoleic acid inhibits the reaction [IL4 protein results in increased expression of VCAM1 protein]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

affects expression

EXP

Soybean Oil affects the expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP-binding cassette, sub-family B member 1B

affects expression

EXP

Soybean Oil affects the expression of ABCB1B mRNA

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily B member 4

affects expression

EXP

Soybean Oil affects the expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 1

affects expression

EXP

Soybean Oil affects the expression of ABCC1 mRNA

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

affects expression

EXP

Soybean Oil affects the expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 5

affects expression

EXP

Soybean Oil affects the expression of ABCC5 mRNA

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily C member 6

affects expression

EXP

Soybean Oil affects the expression of ABCC6 mRNA

NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464

G

acetyl-CoA acetyltransferase 1

decreases activity

EXP

Soybean Oil results in decreased activity of ACAT1 protein

NCBI chr 8:62,876,003...62,905,080
Ensembl chr 8:53,979,813...54,008,855

G

BCL2, apoptosis regulator

increases expression

EXP

Soybean Oil results in increased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

catalase

increases activity

EXP

Soybean Oil results in increased activity of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

cyclin D1

increases expression

EXP

Soybean Oil results in increased expression of CCND1 mRNA

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602

G

cytochrome P450, family 4, subfamily a, polypeptide 1

affects expression

EXP

Soybean Oil affects the expression of CYP4A1 mRNA

NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464

G

cytochrome P450 family 7 subfamily A member 1

increases activity

EXP

Soybean Oil results in increased activity of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

glutathione S-transferase pi 1

multiple interactions

EXP

Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein]

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases activity

EXP

Soybean Oil results in increased activity of HMGCR protein

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

interleukin 12B

decreases expression

ISO

Soybean Oil results in decreased expression of IL12B mRNA

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

solute carrier family 22 member 1

affects expression

EXP

Soybean Oil affects the expression of SLC22A1 mRNA

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 7

affects expression

EXP

Soybean Oil affects the expression of SLC22A7 mRNA

NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

decreases expression

ISO

Triolein results in decreased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily G member 5

decreases expression

ISO

Triolein results in decreased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

decreases expression

ISO

Triolein results in decreased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA carboxylase alpha

multiple interactions

ISO

Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of ACACA mRNA]]; Triolein promotes the reaction [Fructose results in increased expression of ACACA mRNA]

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

apolipoprotein A4

multiple interactions

EXP

[Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in increased expression of APOA4 protein

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein E

multiple interactions

EXP

[Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in decreased expression of APOE protein

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

multiple interactions

EXP

Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein alternative form]; Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

catalase

multiple interactions

EXP

Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of CAT mRNA]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

ISO

Triolein results in decreased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

fatty acid synthase

multiple interactions

ISO

Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of FASN mRNA]]; Triolein promotes the reaction [Fructose results in increased expression of FASN mRNA]

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261

G

glutathione peroxidase 1

multiple interactions

EXP

Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of GPX1 mRNA]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

ISO

Triolein results in increased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

microsomal triglyceride transfer protein

increases expression

ISO

Triolein results in increased expression of MTTP mRNA

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

NPC1 like intracellular cholesterol transporter 1

decreases expression

ISO

Triolein results in decreased expression of NPC1L1 mRNA

NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113

G

stearoyl-CoA desaturase

multiple interactions

ISO

Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased abundance of Triglycerides]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of ACACA mRNA]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of FASN mRNA]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of SREBF1 mRNA]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of SREBF1 protein]]

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562

G

superoxide dismutase 1

multiple interactions

EXP

Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD1 mRNA]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

EXP

Triolein inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD2 mRNA]

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189

G

sterol regulatory element binding transcription factor 1

multiple interactions

ISO

Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of SREBF1 mRNA]]; Triolein inhibits the reaction [SCD1 gene mutant form inhibits the reaction [Fructose results in increased expression of SREBF1 protein]]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	20845
role	20805
biological role	20803
biochemical role	20250
metabolite	20231
eukaryotic metabolite	19946
animal metabolite	19790
crustacean metabolite	17176
Daphnia metabolite	17176
Daphnia galeata metabolite	886
(2Z,5Z,8Z,11Z,14Z,17Z)-icosa-2,5,8,11,14,17-hexaenoic acid	0
(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoic acid	0
all-cis-5,8,11,14,17-icosapentaenoic acid +	0
all-cis-octadeca-6,9,12,15-tetraenoic acid +	0
arachidonic acid +	321
cholesterol +	362
linoleic acid +	289
oleic acid +	461
palmitoleic acid +	8

paths to the root